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The TRIB1 gene has been implicated in several human pathologies, including cancer, lipid 
disorders and cardiovascular disease. It is well appreciated that TRIB1 is a critical regulator of 
macrophage polarisation, favouring the activation of an anti-inflammatory phenotype. Recent 
studies also pointed to a role of TRIB1 in the pathogenesis of prostate cancer, although the 
mechanisms behind its overexpression remain elusive.  
TRIB1 protein is produced from a highly unstable mRNA, with a half-life shorter than 1 hour, 
suggesting it may be subject to post-transcriptional regulation. The TRIB1 transcript includes 
a long, conserved 3UTR, potentially enriched with putative miRNA-binding sites and 
polymorphisms. The latter could contribute to the regulation of TRIB1 expression, via either 
creating or abolishing miRNA-binding sites. However, the post-transcriptional regulation of 
TRIB1 by miRNAs has not been comprehensively investigated.  
The work presented in this thesis explored the post-transcriptional regulation of TRIB1 by 
miRNAs, using a combination of bioinformatics and experimental tools, with focus on 
macrophage and prostate cancer biology. We identified multiple miRNAs predicted to target 
the 3’UTR of TRIB1 with good alignment scores and free energy values. We experimentally 
validated the interaction between miR-101-3p and TRIB1 in human macrophages and 
demonstrated that the overexpression of miR-101-3p and TRIB1 caused opposite genetic 
signatures, suggesting the biological importance of their interaction. Similarly, we identified 
21 miRNAs targeting TRIB1, which are either downregulated or silenced in prostate cancer 
and could possibly account for the elevated expression of TRIB1. We focussed on the activity 
of the oncomiR miR-132-3p and observed that it is able to modulate the expression of TRIB1 
and its downstream genes.  
Additionally, a collaborative study on macrophage transcriptomes was performed using 
multiple RNA-seq experiments, leading to the identification of “super regulators” miRNAs and 
their targetome in pro-inflammatory macrophages.  
Lastly, a brief preliminary research was also conducted on genetic variants affecting the 3’UTR 
of TRIB1: we found that TRIB1 SNPs create novel miRNA-binding sites and impairs the 
expression of distant genes, thus acting as potential trans-eQTLs. However, this remains to be 




Chapter 1. General Introduction 
1.1. microRNAs as master regulators of gene expression 
MicroRNAs (miRNAs) are small non-coding, single stranded RNAs (generally 21-25 
nucleotides long) that play a fundamental role in the regulation of gene expression, acting as 
key molecules in RNA-mediated silencing mechanisms. The first miRNA was discovered in 
1993 by Lee and colleagues. They were screening for mutations in the Caenorhabditis elegans 
larval development and found that the gene lin-4 does not code for a protein but for a small 
RNA complementary to multiple sites in the 3’ untranslated region (3’UTR) of the lin-14 
messenger RNA (mRNA) (Lee et al.,1993, Wightman et al.,1993). This complementarity 
resulted in the impairment of the translation of the lin-14 mRNA into the LIN-14 protein. It 
was the first evidence of anti-sense RNA-RNA interaction and since then a large number of 
small non-coding RNAs and their targets have been discovered and characterized. miRNAs 
have been found in both animals and plants, as well as in some viruses and they are highly 
conserved among different species (Bartel et al., 2003, Zhang et al., 2006). There are over 
48,000 mature miRNA products in 271 species recorded in miRBase (version 22, released in 
October 2018), a searchable online database of published miRNAs and annotations (Kozomara 
et al., 2019). Highlighting the importance of miRNAs in human physiology, it has been 
estimated that more than half of the protein coding-genes are negatively regulated by miRNAs 
and that a single miRNA species can target hundreds of different mRNAs (Friedman et al., 
2009). Therefore, it is not surprising that dysregulated miRNA expression is associated with 
multiple human diseases (Calin et al., 2006).  
 
1.1.1. Genomics & biogenesis 
The identification of miRNA coding genes has been largely approached by using the 
complementary DNA (cDNA) cloning method, in which small RNA molecules are first 
separated from the total RNA and then cloned to construct a cDNA library to be sequenced, as 
described in detail by Ambros and colleagues (Ambros et al., 2004). However, this method is 
limited by not being sensitive to discover miRNAs whose expression is not abundant or is 
restricted only to some cell/tissue types. This can be overcome by using computational 
approaches and examining genomic sequences on the basis of phylogenetic conservation 
criteria (Bartel et al., 2004, Kim et al., 2006). Several studies showed that genes encoding for 
miRNAs are located in intergenic regions and they are distant from annotated genes, thus 
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forming independent transcriptional units (Lagos-Quintana et al., 2001, Lau et al., 2001, Lee 
et al., 2001). However, it is also known that some miRNAs are processed from the introns of 
protein coding genes (Ambros et al., 2003), as well as introns and exons of “non-coding” genes 
(Rodriguez et al., 2004). Interestingly, Cai and colleagues found that 9 human miRNAs are 
excised from the 3’UTR of transcripts (Cai et al., 2004). miRNA coding genes are usually 
transcribed by RNA polymerase II (Lee et al., 2004), despite some evidence suggesting that 
the transcription of miRNA genes can be also mediated by the RNA polymerase III (Borchert 
et al., 2006). The canonical mechanism of miRNA biogenesis in mammals is illustrated in 
Figure 1.1. The first maturation step occurs inside the nucleus after the transcription of the 
miRNA coding gene. The product of transcription is a long capped and polyadenylated primary 
miRNA (pri-miRNA) characterized by the presence of stem loop structures. The pri- miRNA 
is processed into a precursor miRNA (pre-miRNA) of approximately 60-70 nucleotides by the 
RNase III endonuclease DROSHA that cleaves both strands at the level of the stem loops. To 
process the pri-miRNA the protein PASHA (DGCR8) is also required (Tomari et al., 2005). 
The pre-miRNAs are then transported to the cytoplasm by Exportin 5 (EXP-5), a GTP-
dependent nucleo/cytoplasmic transporter. The latter recognizes a 2-nucleotide 3’ overhang 
created by DROSHA at the 3’ end of the pre-miRNAs, which therefore defines one end of the 
mature miRNA. Once in the cytoplasm, another RNase III endonuclease, DICER, processes 
the precursors into small double-stranded RNA duplexes containing both the mature sequence 
of the miRNA and its complementary strand (Bartel et al., 2004, He et al., 2004). The dsRNA 
duplex is also referred to as a miRNA: miRNA* duplex, where miRNA is the mature miRNA 
and miRNA* (also known as star-strand) corresponds to the complementary arm. They are 
commonly termed 5p and 3p, depending on which end of the stem loop they derive from. 
Generally, only one strand, probably the most unstable, is incorporated in the RNA-induced 
silencing complex (RISC), whereas the other one is released and degraded (Du et al., 2005). 
However, it has been reported that in some cases both strands can be loaded into the RISC: for 
example, Huang and colleagues have recently demonstrated that both miR-582-3p and miR-
582-5p are functional. They have been shown to repress prostate cancer metastasis to bone by 
targeting and downregulating several components of the TGF- signalling pathway (Huang et 
al., 2019). The RISC complex is composed of different conserved proteins, including 










Figure 1.1. Schematic illustration of miRNAs biogenesis in mammals 
 
miRNA-coding genes are transcribed by RNA pol II into a pri-miRNA. This is further cleaved 
by DROSHA that together with the protein PASHA creates a pre-miRNA of 60-70 nucleotides. 
In turn, this is translocated to the cytoplasm by the GTP-dependent nucleo/cytoplasm cargo 
transporter EXP-5. Once in the cytoplasm, the pre-miRNA is processed by DICER that forms 

























1.1.2. Mechanisms & functions: the RNA-Induced Silencing Complex 
Initially, it was believed that miRNAs do not cause transcript degradation but only repress 
protein translation. In fact, the first miRNA identified in Caenorhabditis elegans, lin-4, was 
only shown to repress LIN-4 protein synthesis and seemed to not affect messenger RNA levels 
(Lee et al.,1993, Wightman et al.,1993). However, it is now well appreciated that via 
association with the effector proteins of the RISC, miRNAs guide and mediate silencing of 
gene expression by either suppressing protein translation and/or promoting target mRNA 
cleavage (Bartel et al., 2004). Both mechanisms are the consequence of “target recognition”, 
the Watson-Crick complementarity between the “seed” sequence, 6-8 nucleotides (typically 
2nd-8th) at the 5' end of the miRNA and the transcript sequence (Lewis et al., 2003, Grimson 
et al., 2007) (shown in Figure 1.2.A). The majority of miRNA-binding sites have been 
identified in the 3’UTR of genes (Bartel et al., 2009). However, functional binding can also 
occur in the 5’ UTR, as well as in the coding region (CDS) (Kloosterman et al., 2004, Lytle et 
al., 2007, Fang et al., 2011). It has been proposed that the balance between mRNA degradation 
and protein synthesis inhibition is determined by the extent of the base-pairing between the 
miRNA and the mRNA. The messenger RNA is cleaved when the miRNA perfectly matches 
its target-sequence, whereas a partial base-pairing is more likely to promote translational 
repression (Hutvagner et al., 2002, Zeng et al., 2002, Zeng et al., 2003, Doench et al., 2003). 
Although they mediate target recognition, which represents the triggering step for gene 
silencing mechanisms, miRNAs do not work alone. Figure 1.2.B schematizes the canonical 
mechanism of action of miRNA-guided gene silencing and its main players. Structural studies 
showed that the mRNA degradation is mediated by Ago proteins which contain two 
characteristic domains: an N-terminal PAZ domain that recognise the 3’ end of the guide-
miRNA (Lingel et al., 2005) and a C-terminal PIWI domain. The latter is similar to the 
ribonuclease H (nuclease activity) and for this reason thought to be responsible for the mRNA 
cleavage (Parker et al., 2004, Song et al., 2004). In mammals, all four Ago proteins (Ago1-4) 
contribute to miRNA- guided gene silencing, while in Drosophila only Ago1 protein plays this 
role (Ipsaro et al., 2015). Further work has also shown that miRNAs promote target 
destabilization prior to degradation by recruiting deadenylases through GW182 protein which 
is also recognized by Ago (Fabian et al., 2011). In fact, GW182 proteins are mainly 
characterized by the presence of an Argonaute-binding domain (ABD) and a silencing domain 
(SD) (Jonas et al., 2015). The molecular mechanisms of miRNA-mediated translational 
suppression in animals are still poorly understood, particularly the step in which translation is 
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blocked. To date, several mechanisms have been proposed; they involve GW182 and the 
recruitment of translational repressors (Iwakawa et al., 2015, Jonas et al., 2015). However, 
even though recent reports have enhanced our understanding of the miRNA-mediated 
mechanisms of silencing, it is still believed that they may exert additional functions. In fact, it 
is beginning to emerge that miRNA activity may oscillate between activation and repression 
of target genes, as previously reported, particularly in cancer (Vasudevan et al., 2007, 
Valinezhad et al., 2014). Therefore, there is no doubt that miRNA-mediated mechanisms in 


















Figure 1.2. miRNA binding site on target sequence and its downstream consequences 
The miRNA binding site on the target mRNA referred as “seed region” (A). Typically, this is 
located between the 2nd and the 8th nucleotide at the 5' end of the miRNA but its length varies 
among different molecules. The most common seed lengths are 6nt, 7nt and 8nt. The process 
of target recognition (1) is followed by the recruitment of the RISC proteins Ago and GW182 
(2) which together with other repressors mediate the cleavage of mRNA and the inhibition of 





1.1.3. Computational tools to predict microRNA-target interaction 
It is thought that genes with longer 3’UTRs have a higher number of miRNA-binding sites, 
compared to genes with shorter 3’UTRs. Moreover, genes with longer 3’UTRs are more 
conserved and often involved in developmental processes (Cheng et al., 2009), whereas 
housekeeping genes contributing to basic cellular mechanisms, although conserved, have 
shorter 3’UTRs, thereby avoiding stringent miRNA-mediated post-transcriptional regulation 
(Stark et al., 2005). However, it is well established that a single miRNA has the potential to 
bind to multiple genes and, conversely, one gene can be targeted by multiple miRNAs. 
Moreover, it is likely that single miRNA binds to different sequences in the same 3’UTR and 
these binding sites might also overlap with each other. As mentioned earlier, miRNAs also 
bind to the 5’UTR and CDS of transcripts. In addition, one must consider the presence of 
Single-Nucleotide-Polymorphisms (SNPs) as well as Multiple-Nucleotide-Polymorphisms 
(MNPs) and small insertions/deletions (INDELs). In fact, mutations in either of the sequences 
(miRNA and target) can affect the miRNA-target interaction by creating and abolishing the 
binding site, as well as modifying the binding affinity (Chen et al., 2008, Wei et al., 2012). For 
this reason, prior to applying experimental approaches it is useful to characterize and predict 
miRNA-target interactions “in silico”, as well as the putative presence of known 
polymorphisms. To this aim, in the last few years, a number of bioinformatics and 
computational tools have been developed. The current databases used to identify and predict 
miRNA-target interactions, including SNPs databases, are briefly listed in Table 1.1. along 
with a short description. They are characterized by intuitive function and a friendly interface 
and can be easily accessed by less experienced users. Mostly, target prediction tools are 
accessible via free web-sources but some of them can also be downloaded as software and 
packages (R, C, Python, Java) for independent external searches (Riffo-Campos et al., 2016). 
All of them rely on the function of different, dedicated algorithms that can be divided into two 
main categories: rule-based algorithms and data-driven algorithms (Yue et al., 2009). Rule 
based algorithms consider biological parameters including the seed region matching (Watson-
Crick complementarity), the conservation status between different species and the 
thermodynamic features of RNA-RNA interaction (Riffo-Campos et al., 2016, Peterson et al., 
2014). The latter refer to the minimization of the free energy or Gibbs free energy (showing 
how strong the miRNA binds to its target) and the site accessibility (the degree of openness of 
the 3’UTR bound to a miRNA, representing how much the binding site is accessible) (Mathews 
et al., 1999, Kertesz et al., 2007) (Figure 1.3.A-B). Indeed, the majority of target prediction 
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tools incorporate the Vienna RNA package and the PITA program, designed to calculate the 
free energy and the accessibility energy (Lorenz et al., 2011, Kertesz et al., 2007). Data-driven 
algorithms follow the same rules but they are further complemented with experimental findings 
(validated interactions) (Yue et al., 2009). Interestingly, several databases contain both 
predicted and validated modules and they also provide users with additional information (e.g. 
miRWalk 2.0 contains tissue specific expression, cell line specific expression, gene-enrichment 





























Table 1.1. List of online repositories for miRNA-target identification and SNP detection 
miRNA-target prediction and SNP/INDEL detection in either target genes and miRNAs is 
achieved by using dedicated tools. In most cases, entries can be retrieved by both miRNA and 
target gene symbols, as well as tissue/cell line/disease of interest. SNP: Single Nucleotide 





Database Description Type of algorithm Reference
miRBase Published miRNA sequences, target interactions and
nomenclature






Predicted and validated target interactions and miRNA tissue
/disease specific expression (based on existing literature)
Rule-based, data-driven Dweep et al., 2011
Sticht et al., 2018
miRDB Target prediction and functional annotations in human,
mouse, rat, dog, chicken
Rule-based, data-driven Chen and Wang
2020
Wong et al., 2015
Liu et al., 2019
TargetScan Prediction of miRNA-target in human, mouse, worm, fly and
fish; conserved and poorly conserved interactions
Rule-based Agarwal et al., 2015
RNA22 Interactive and pre-computed miRNA-target interactions Rule-based, data-
driven
Miranda KC et al.,
2006
miRanda Predicted miRNA-target interaction and miRNA specific
tissue expression
Rule-based Betel et al., 2010
DIANA
TaRBase
Published experimentally validated miRNA-interactions;
alignment details and conservation scores





miRNA-target prediction and functional analysis Data-driven Paraskevopoulou et
al., 2013
miRTarBase Experimentally validated miRNA-target interactions Data-driven Chou et al., 2016
RePTar miRNA-target interactions, including noncanonical seed
pairing (3’ compensatory binding site, full match binding
sites, centered binding site)
Rule-based Elefant et al., 2011
miRTar miRNA-target interactions, biological functions and
regulatory relationship
Data-driven Hsu et al., 2011
miRdSNP Disease-associated SNPs in 3’UTR sequences and miRNA
target sites
Data-driven Bruno et al., 2012
PolymiRTS SNPs and INDELs in miRNAs and their targets also
supported by experimental findings




Open-source platform of miRNA-ncRNA, miRNA-mRNA,
ncRNA-RNA, RNA-RNA, RBP-ncRNA and RBP-mRNA
interactions from CLIP-seq, degradome-seq and RNA-RNA
interactome data









Figure 1.3. Schematic overview of free energy and RNA site accessibility 
RNA secondary structure showing a region of high free energy characterized by the presence 
of a hairpin loop and a region of low free energy corresponding to the stem which increases 
stability (A) (adapted from Peterson et al., 2014); example of an RNA secondary structure 







1.1.4. microRNAs in health and disease 
Being master regulators of gene expression, cell differentiation, proliferation and apoptosis, 
miRNAs are recognised to have a big impact on health and disease. Aberrant expression of 
miRNAs has been implicated in virtually all human diseases, from inherited conditions to 
cancer, autoimmunity, neurodegeneration, cardiovascular disease, metabolic disorders and 
many others (Ardekani et al., 2010, Li et al., 2012). A strong link between miRNAs and human 
diseases is seen in DiGeorge Syndrome, a genetic disorder characterized by a heterogeneous 
group of defects and clinical manifestations, including immunodeficiency, skeletal and cardiac 
anomalies, neuromuscular problems, hypocalcaemia and psychiatric illnesses. This syndrome 
is caused by a deletion in chromosomal region 22q11.2, where the gene encoding Pasha 
(DGCR8, also called DiGeorge Syndrome Chromosomal or Critical Region 8) is located. As 
discussed above (Section 1.1.1. Genomics & biogenesis), Pasha acts as partner of Drosha in 
the biogenesis of miRNAs. Therefore, patients affected by DiGeorge Syndrome show a pattern 
of dysregulated miRNA expression, resulting in aberrant gene expression and multi organ 
disease (de La Morena et al., 2013, Landthaler et al., 2004, Shiohama et al., 2003). miRNAs 
are also required for normal development and organogenesis, as suggested by a multitude of 
studies involving Dicer mutant animals and cell lines. In fact, it has been shown that mice 
lacking Dicer1 die at embryonic stage, because of the lack of proliferation and differentiation 
of embryonic stem cells (Bernstein et al., 2003).  In zebrafish and Drosophila, deletion of 
Dicer1 also results in development arrest and impairment of stem cell proliferation (Hatfield et 
al., 2005, Wienholds et al., 2003). The same effect was observed in human embryonic stem 
cells (hESCs), where the loss of DICER1 induces apoptosis and impairs self-renewal, due to 
deficiency in mature miRNAs. In fact, transfection of selected miRNAs is able to rescue the 
phenotype of DICER1-depleted cells, regulating the expression of apoptotic genes (Teijeiro et 
al., 2018). As the fundamental impact of miRNAs on health and disease became clear, much 
attention has focused on their potential role as biomarkers for disease diagnosis, prognosis and 
responses to therapy. To date, a number of circulating miRNAs have been established as 
diagnostic markers for different types of cancer, as well as in cardiovascular and infectious 
diseases. For example, it has been shown that in HIV-infected patients plasma levels of miR-
29, miR-150 and miR-146b-5p are highly altered compared to healthy individuals (Faruq et 
al., 2015, Monteleone et al., 2015, Munshi et al., 2014). Plasma miR-21-5p, miR-20a-5p, miR-
141-3p, miR-145-5p, miR-155-5p and miR-223-3p have been identified as biomarkers for 
early diagnosis of non-small cell lung cancers (NSCLC) (Geng et al., 2014, Arab et al., 2017, 
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Zhang et al., 2017). Interestingly, miRNAs found in body fluids can also be used as diagnostic 
biomarkers. A number of miRNAs found in the saliva have been shown to be predictive of 
mild-traumatic brain injury and concussion, which is known to be difficult to diagnose (Di 
Pietro et al., 2018). Five serum miRNAs (miR-1, miR-20a, miR-27a, miR-34 and miR-423-
5p) have been identified as strong diagnostic markers for gastric cancer (Liu et al., 2011), while 
miR-125a-5p, targeting HER2, serves as a prognostic marker and could be used as a potential 
therapy against gastric neoplasms (Nishida et al., 2011). Notably, the world’s first miRNA-
based therapeutic, miravirsen, is currently in phase II clinical trials for the treatment of hepatitis 
C liver infection (HCV). It is based on the inhibition of miR-122, the most abundant miRNA 
in the liver, which is known to be an important host factor for HCV pathogenesis (Lindow et 



































1.2. Macrophages, a plastic cell population 
Macrophages are professional phagocytes, first discovered in the late 19th century by Ilya 
Metchnikoff (https://en.wikipedia.org/wiki/%C3%89lie_Metchnikoff). They represent a key 
cell type of the innate immune system and according to environmental cues they can change 
their physiology and become either protective or detrimental in the context of human disease. 
The ability to integrate and respond to a wide range of extracellular signals, both pro- and anti-
inflammatory, makes macrophages one of the most versatile and plastic cell types of the 
haematopoietic system (Wynn et al., 2013, Gordon et al., 2014). Macrophages function in a 
multitude of biological processes such as inflammation (promotion/resolution), 
immunosuppression, phagocytosis, apoptotic cell clearance (efferocytosis), wound healing, 
tumour promotion (tumour-associated macrophages, TAMs) and intercellular communication 
via the release of extracellular vesicles (Mosser et al., 2008, Koh et al., 2011, Quatromoni et 
al., 2012, Ismail et al., 2013, Martin et al., 2014). This section summarises the main features 
of macrophages, focusing on their plasticity and involvement in a variety of human diseases. 
1.2.1. Origin and development 
Macrophages reside in all the tissues of the body and, as for all blood cells, they arise following 
a complex differentiation program. It was initially believed that macrophages only derive from 
circulating monocytes but recently it has become clear that they have a dual origin: a proportion 
of these cells originate from haematopoietic stem cells (HSCs) but most adult tissue resident 
macrophage populations are established during embryonic development and before definitive 
haematopoiesis (Epelman et al., 2014, Davies et al., 2015). In fact, through the power of fate-
mapping strategies it has been revealed that tissue macrophages derive from cells existing 
within the yolk sac and the foetal liver (Schulz et al., 2012, Yona et al., 2013). The 
differentiation of macrophages from HSCs strictly depends on the activity of Myb, a 
haematopoietic transcription factor involved in myeloblastosis and leukemia (Sumner et al., 
2000, Lahortiga et al., 2007, Nguyen et al., 2016). However, macrophages derived from 
embryonic and extra-embryonic tissues do not require Myb activity, suggesting that they are 
genetically distinct from the blood precursor (Pattabiraman et al., 2013, Schulz et al., 2012). 
Embryonic and monocyte-derived macrophage lineages are found in the brain (microglia), lung 
(alveolar macrophages), liver (Kupffer cells), spleen (red pulp macrophages), heart (CCR2- 
macrophages), skin (Langerhans cells), peritoneum and kidney. Macrophages populating the 
skin, heart (CCR2+ macrophages) and gut also differentiate from circulating monocytes that 
continuously replace them (Epelman et al., 2014).  
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1.2.2. Function and activation states 
Being leukocytes, macrophages are motile cells. They have the ability to migrate through the 
wall of blood vessels as monocytes into inflamed and damaged tissues, differentiating into 
macrophages. This process is known as chemotaxis and it requires complex cellular signalling 
(Jones et al., 2000, Xuan et al., 2015). More importantly, macrophages are characterized by 
the expression of Toll-Like Receptors (TLRs) through which they detect and internalise 
products of bacteria and pathogens. They also produce nitric oxide (NO) and reactive oxygen 
species (ROS) facilitating the killing of phagocytosed microorganisms and secrete bioactive 
lipids and multiple cytokines (Billack et al., 2006). Cytokines produced by macrophages 
represent the link between innate and adaptive immunity and they can either promote or inhibit 
inflammation, as well as cause tissue damage. The activation of macrophages toward different 
phenotypes is called polarisation and it has been intensively studied in both human and animal 
models. However, this is not a fixed event and classifying macrophage phenotypes still remains 
a big challenge. According to the historical concept of polarisation, M1 macrophages are the 
classically activated cells which exhibit a pro-inflammatory status, whilst M2 macrophages 
display an anti-inflammatory phenotype and are mainly involved in tissue repair and 
homeostasis (Martinez et al., 2008, Wang et al., 2014). M1 macrophages are activated by pro-
inflammatory cytokines such as INF- and LPS which enhance the expression of TLRs thus 
favouring the phagocytic activity of macrophages. Moreover, these cells are characterized by 
high levels of opsonic receptors (CD16) and IL-12 and low levels of IL-10. In addition, by 
secreting high levels of IL-1, TNF-, IL-15, IL-18, IL-23, IL-8 and IL-6, M1 macrophages 
significantly contribute to the activation and polarisation of Th1 cells and mediate pathogen 
killing and tumour resistance. On the contrary, M2 phenotype arises when macrophages are 
activated upon stimulation with anti-inflammatory cytokines, mainly IL-4 and IL-10. M2 
macrophages are characterized by IL-10high and IL-12low expression and abundant levels of 
non-opsonic receptors, such as the mannose receptor and scavenger receptors. They are further 
classified in three subtypes M2a, M2b and M2c activated by different stimuli, including IL-4, 
IL-10, IL-13, TGF-, glucocorticoids (GCs) and immune complexes (ICs). M2 macrophages 
not only exert an anti-inflammatory activity, but they also contribute to wound healing, 
immunoregulation, immunosuppression, tissue remodelling, clearance of apoptotic bodies and 
tumour progression (Mantovani et al., 2004, Mantovani et al., 2005, Martinez et al., 2008, 
Viola et al., 2019). From a metabolic point of view, it has been shown that murine macrophages 
are characterized by the metabolism of arginine, which is a complex amino acid involved in a 
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variety of biological processes, ranging from single cell regulation to the whole organism 
regulation. In M1 cells, arginine is used to produce NO, while in M2 macrophages it is mainly 
catabolised to produce ornithine, urea and polyamines. The production of NO is mediated by 
the inducible nitric oxide synthase (iNos), which is highly expressed by M1 cells and results in 
increased cell death. Instead, ornithine, urea and polyamines are generated by arginase (Arg), 
abundant in M2 cells, which in turn promote proliferation. These two enzymes are among the 
most employed markers enabling the functional characterization of M1 and M2 macrophages 
in mice (Rath et al., 2014). However, in human macrophages the expression and activity of 
iNos and arginase is still under debate. In fact, many groups have been able to detect them but 
others have not. It seems that the presence of arginine-metabolizing enzymes strictly depends 
on cell source (i.e. blood-derived macrophages and tissue resident macrophages), as well as the 
health status of the individual (Thomas et al., 2014). In addition to arginine metabolism, 
different macrophages display different lipid metabolism pathways. M1 macrophages rely on 
fatty acid synthesis (FAS), while M2 cell metabolism is mainly supported by fatty-acids 
oxidation (FAO), which is also thought to promote cellular longevity (Remmerie et al., 2018). 





















Figure 1.4. Overview of macrophage polarisation and function 
Classically or M1-activated macrophages are induced by inflammatory stimuli, such as LPS 
and INF- and they are mediators of inflammation, pathogens killing and tumour resistance. 
Alternatively or M2-activated macrophages mainly respond to anti-inflammatory cytokines, 
glucocorticoids (GCs) and immunocomplexes (ICs). They exert a variety of functions, 












1.2.3. Macrophages in health and disease 
Traditionally considered the first line of defence against infectious diseases, macrophages play 
a crucial role in maintaining all tissues in a healthy condition, for example by directing the 
clearance of dead and dying cells, as well as toxic substances and pathogens. The physiological 
roles of macrophages have been intensively studied in metabolic tissues (adipose tissue and 
liver) where, polarised towards an anti-inflammatory M2 phenotype, they control and maintain 
insulin sensitivity and energy homeostasis, especially after an increased caloric intake 
(Fujisaka et al., 2016). However, in individuals affected by obesity the protective role of 
macrophages is subverted: they switch to the pro-inflammatory M1 phenotype, promoting a 
low-grade chronic inflammation, thus leading to insulin resistance, fibrosis and fatty liver 
disease (Claria et al.,2011, Odegaard et al., 2013). Both M1 and M2 macrophages play a key 
role in the pathogenesis of atherosclerosis, a chronic inflammatory disease caused by lipid 
retention in the arterial wall. Recruited at the site of the lesion, macrophages accumulate in the 
arterial intima where they uptake atherogenic lipoproteins via either scavenger receptors or 
micropinocytosis, promoting the formation of foam “fatty” cells, the hallmark of the 
atherosclerotic plaque. The population of macrophages found in the plaques is highly 
heterogeneous but it is believed that M1 macrophages are present in progressing plaques, at an 
early stage, while M2 macrophages, involved in the mechanisms of repair and stabilization, are 
found in regressing plaques (Moore et al., 2013, Bobryshev et al., 2016).  A dual role for 
macrophages has been also established in cancer, where they take the name of tumour-
associated macrophages (TAMs). Up to 50% of solid tumours are composed of macrophages: 
they have been shown to facilitate angiogenesis, immunosuppression, invasion and metastasis 
and for this reason they have formed a key area of investigation for the development of cell-
based therapies and genetic reprogramming strategies (Yang et al., 2018). Several studies 
reported that either genetic or pharmacological inhibition of macrophage-colony stimulating 
factor (M-CSF) results in a strong reduction in the number of TAMs thus suppressing 
angiogenesis and tumour growth and progression in different cancer models (Kubota et al., 
2009, Pyonteck et al., 2012, Ryder et al., 2013). TAMs derive from both circulating monocytes 
and embryonic tissues and they usually display different activation states, depending on the 
type of cancer, as well as the stage (Zhu et al., 2017, Laviron et al., 2019). Due to the high 
plasticity of TAMs, they cannot be defined by the classical M1/M2 nomenclature. It is, 
however, widely accepted that the population of macrophages found in tumours more closely 
resembles the phenotype of M2-like cells. In fact, TAMs express high levels of arginase, which, 
 41 
as mentioned before, is required for cell proliferation and it is also linked to 
immunosuppression (Bronte et al., 2005, Mantovani et al., 2013, Laviron et al., 2019). Indeed, 
inhibiting arginase expression has a negative effect on tumour growth and has been shown to 
shift TAMs toward a pro-inflammatory phenotype (Sharda et al., 2011, Steggerda et al., 2017). 
Pro-inflammatory M1-macrophages are thought to be protective against cancer, due to their 
cytotoxic activity. It has been reported that M2 cells predominate over M1 in tumour tissue and 
cancer patients with higher infiltration of M1 cells in the tumour show a better overall survival, 
compared to patients with low M1 macrophages infiltration (Ohri et al., 2009, Jackute et al., 
2018). In addition, mice lacking Stat6, a transcription factor required for M2 polarisation, 
produce M1 macrophages with high levels of iNOS and are resistant to metastatic disease 
compared to control mice (Sinha et al., 2005). Similarly, the pharmacological inhibition of 
STAT3, another transcription factor required for M2 activation, induces tumour cell apoptosis 
and enhanced tumour immunogenicity (Xin et al., 2009). Interferon regulatory factor 5 (IRF-
5) in combination with its activating kinase IKKβ has also been tested and was successful in 
generating anti-tumour immunity through M1 induction in models of melanoma, glioblastoma 
and ovarian cancer (Zhang et al., 2019). However, it is important to mention that the tumour 
microenvironment (TME) “educates” macrophages and TAMs often sharing features of both 
M1 and M2 varying among individual stages of tumour development (Qian et al., 2010, Laoui 
et al., 2011, van Dalen et al., 2018). 
In addition to insulin resistance, cardiovascular disease and cancer, the plasticity of 
macrophages has also been implicated in autoimmunity, rheumatoid arthritis, kidney disease 
and neuroimmune disorders (Kinne et al., 2000, Duffield et al., 2010, Fan et al., 2016). The 















Figure 1.5. The contribution of macrophages to health and disease 
Macrophages play a crucial role in maintaining all tissues in a healthy state, acting as 
modulators of immunity, metabolism and tissue homeostasis. However, in the presence of a 
pathological insult their protective role is subverted: closely involved in a multitude of 
biological processes, macrophages can trigger a variety of human diseases including cancer, 






























1.2.4. microRNAs regulating macrophage development and function 
In the past few years, miRNA regulation of macrophage development, function and 
polarisation has been the subject of intense research. It has been shown that murine macrophage 
development from haematopoietic precursor cells requires the expression of a specific subset 
of miRNAs (miR-146a, miR-342, miR-338, miR-155) which are induced by the transcription 
factor PU.1 (Zhang et al., 1994); miR-146, has also been tested in zebrafish, confirming its 
crucial and conserved role in macrophage differentiation (Ghani et al., 2011). However, the 
importance of miR-146 in macrophage differentiation appears to be controversial. 
Starczynowski and colleagues reported that over-expression of miR-146a in mouse 
hematopoietic precursor cells causes a reduced differentiation and survival of these cells, 
mimicking the cytotoxic effect of LPS long exposure (Starczynowski et al., 2011). PU.1 also 
suppresses a specific cluster of miRNAs (miR17-5p, miR-18a, miR-20a, miR-92) which have 
been shown to act in a feedback loop with the transcription factor acute myeloid leukemia-1 
(AML1) during haematopoiesis (Fontana et al., 2007, Ghani et al., 2011). Several studies 
identified specific subsets of miRNAs that are differentially expressed in distinct macrophage 
phenotypes. By using a miRNA microarray analysis in cultured bone marrow derived 
macrophages (BMDMs), Zhang and colleagues identified a total of 109 miRNAs differentially 
expressed between M1 and M2 conditions (Zhang et al., 2013). M1 polarised macrophages are 
characterized by the expression of miR-181a, miR-155-5p, miR-204-5p, miR-451, whereas M2 
macrophages differentially express miR-125-3p, miR-146-3p, miR-143-3p, miR-145-5p 
(Zhang et al., 2013). In particular, miR-155 has been intensively studied in M1 polarised 
macrophages. It has been shown that macrophages derived from miR-155 knockout mice do 
not express M1 related genes, even in response to stimulation with LPS and INF- (Jablonski 
et al., 2016). Moreover, the lack of miR-155 is linked to the dysregulation of approximately 
650 genes previously associated with M1 phenotype (Jablonski et al., 2015). Accordingly, 
myeloid specific knockout of miR-155 enhances tumour growth in a breast cancer mouse 
model, due to the lack of M1 anti-tumoural immunity (Zonari et al., 2013). Macrophage 
polarisation has also been linked to the activity of miR-21, which has been found by several 
groups to suppress M1 cells and favour M2 macrophage polarisation (Caescu et al., 2015, 
Wang et al., 2015). Consistent with these findings, miR-21 expression is associated with poor 
survival in patients with specific cancers. miR-21 knockout mice develop smaller tumours 
compared to controls, suggesting that the lack of miR-21 activates genes able to re-educate 
TAMs towards an M1-like phenotype (Xi et al., 2018). Another M2-specific miRNA is miR-
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124, which has been shown to upregulate CD206, Ym1, Fizz1, Arg1 and TGF- and 
downregulate iNOS, CD86, TNF- (Veremeyko et al., 2013). Furthermore, miR-124 
expression is strongly induced by IL-4 and IL-13 (Veremeyko et al., 2013). Another miRNA 
controlling macrophage function is miR-101-3p, which directly target the 3’UTR of the dual 
specificity phosphatase (DUSP1) and the ATP-binding cassette transporter A1 (ABCA1). By 
negatively modulating these genes, miR-101-3p enhances inflammation and promote 
cholesterol accumulation in macrophages, thus offering a promising target to simultaneously 
antagonize inflammation and improve lipid metabolism (Wei et al., 2015, Zhang et al., 2015). 
Although many other miRNAs have been implicated in macrophages, there is little information 
about miRNA-mRNA networks in human macrophages and there are often opposing data. This 
raises the need for integrated transcriptomic analysis to identify multiple gene networks that 
can be used for both mechanistic investigations and novel drug development.  
 
1.2.5. Limitations of the M1/M2 paradigm 
The M1/M2 classification of functional macrophage phenotypes has been widely used to 
characterize macrophage populations in vitro and so far, has provided useful insights into the 
role of macrophage in health and disease. However, when it comes to complex in vivo 
environments, this model has significant limitations: macrophages generate heterogeneous and 
dynamic responses that are not easy to categorize, especially during some diseases (Martinez 
et al., 2014, Laviron et al., 2019). Martinez and Gordon suggested that M1 and M2 features do 
not exclude each other, but they can coexist, giving rise to a mixed phenotype that only depends 
on the balance of activating and inhibiting environmental signals. For this reason, the role of 
M1 and M2 should be considered beyond the historical, bipolar classification (Martinez et al., 
2014). Mitsi and colleagues have observed that steady state alveolar macrophages are 
characterized by both M1 and M2 signatures and this mixed phenotype can be changed by 
environmental stresses and stimuli, such as HIV infection (Mitsi et al., 2018). Trombetta and 
colleagues also reported the existence of a mixed M1/M2 population in the lung of patients 
affected by systemic sclerosis (Trombetta et al., 2018). Other examples of macrophage 
heterogeneity come from atherosclerosis and cancer (as previously discussed in section 1.2.3. 
Macrophages in health and disease). They are diseases in which both pro- and anti-
inflammatory cells play decisive roles, more often in a stage- and environment-dependent 
manner. Both M1 and M2 makers have been detected in atherosclerotic plaques: M2 cells 
populate the stable region, while M1 cells are more abundant in the unstable plaque (de 
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Gaetano et al., 2016). Similarly, TAMs found in non-small cell lung cancer (NSCLC) consist 
of a mixed M1/M2 populations: Jackute and colleagues observed that the tumour tissue and 
stroma are mostly populated by M2 cells, but the tumour islets host cytotoxic M1 macrophages 
(Jackute et al., 2018). Recently, melanoma extracellular vesicles (EVs) have been shown to 
influence macrophage polarisation, towards a mixed M1/M2 phenotype (Bardi et al., 2018). In 
the light of these recent observations and to sum up, macrophage polarisation is a complex, 
dynamic and flexible process that depends on the surrounding environment. Therefore, 
classifying macrophages into M1 and M2 phenotypes often does not fully reflect what happens 
































1.3. Tribbles pseudo-kinases: regulators of inflammation, metabolism and 
cancer 
Described for the first time in Drosophila melanogaster as regulators of mitosis and 
morphogenesis via string/cdc25 (Mata et al., 2000), Tribbles genes are now the subject of 
intense investigation in mammals, due to their involvement in numerous signalling pathways. 
Here, we briefly describe the function and key interacting partners of Tribbles proteins, mostly 
focusing on Tribbles-1 and discussing its critical role in the control of inflammation, 
metabolism and cancer. 
 
1.3.1. Tribbles, a family of pseudo-kinases 
Tribbles (TRIBs) genes encode for an evolutionary conserved family of pseudo-kinases that 
control a wide range of interacting signalling pathways. In mammals, three TRIB family 
members have been identified (TRIB1, TRIB2, TRIB3) and they have been associated with a 
significant number of human diseases, including cancer, cardiovascular disease, inflammation 
and immune-metabolic disorders (Hegedus et al., 2006, Kiss-Toth 2011, Yokoyama et al., 
2011). Sequence alignments revealed a high conservation of TRIB proteins between human 
and mouse (identities: TRIB1, 97.5%, TRIB2, 99.2%, TRIB3, 81.2%) and a high degree of 
similarity among different human TRIBs (TRIB1/TRIB2, 71.3%, TRIB1/TRIB3, 53.3%, 
TRIB2/TRIB3, 53.7%). It is thought that TRIB proteins are mainly located in the nucleus, but 
can also interact with their partners in the cytoplasm. TRIB1 and TRIB2 are strongly associated 
with subsets of acute myeloid leukemia (AML), while TRIB3 has mainly been studied in the 
context of metabolic disorders, including insulin resistance, atherosclerosis (Yokoyama et al., 
2011) and cancer (Dong et al., 2016, Yu et al., 2019). 
 
1.3.2. Overview of Tribbles binding partners 
Structurally, TRIBs are three-domain proteins that contain an N-terminal PEST region, a 
pseudo-kinase domain and a C-terminal, COP1-binding region. However, they lack a 
functional adenosine 5’-triphosphate (ATP) binding site and therefore classified as 
catalytically inactive pseudo-kinase proteins. It has been proposed that through the pseudo-
kinase domain, TRIBs act as adaptors or scaffold kinases facilitating the assembly with other 
proteins (Hegedus et al., 2007, Lohan et al., 2013). In addition, structural studies demonstrated 
that TRIB proteins have a unique C-terminal domain defined by two distinct motifs: the HPW 
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[F/L] motif binding to the MAPKK/MEK family members and the DQVXP [D/E] that targets 
the E3-ubiquitin ligases, including the constitutive photomorphogenic protein 1 (COP1) 
(Yoshida et al., 2013, Eyers et al., 2017) (Figure 1.6.). Through these motifs, TRIB proteins 
exert multiple functions in different cell types and tissues, important for the development of 
cancer and in the control of inflammatory signalling. TRIBs selectively regulate several 
members of the mitogen-activated protein kinase kinase (MAPKK) pathway, including ERKs, 
JNKs and p38 MAPK. It has been shown that TRIB1 is able to control the extent and specificity 
of MAPK activation depending on its expression level (Kiss-Toth et al., 2004, Sung et al., 
2005, Guan et al., 2016). By recruiting E3 ubiquitin ligases, TRIBs have been shown to 
promote target protein degradation. In fact, both TRIB1 and TRIB2 cause the degradation of 
C/EBPα and this has been associated with the development of acute myelogenous leukemia in 
murine models (Keeshan et al., 2006, Dedhia et al., 2010). Furthermore, by blocking C/EBPβ, 
TRIB1 impairs TLR-mediated responses and leads to a dysregulation of LPS-inducible genes 
and NF-IL6 in murine macrophages (Yamamoto et al., 2007).  TRIB2 also promotes the 
proteolysis of C/EBPβ and this together with the inhibition of AKT has a strong inhibitory 
effect on adipocytes differentiation in mice (Naiki et al., 2007). Similarly, TRIB3 has been 
associated with the degradation of acetyl coenzyme carboxylase (ACC) in adipose tissue 
through the recruitment of COP1. In fact, adipose tissue lacking TRIB3 accumulates ACC (Qi 
et al., 2006). In adipose tissue, TRIB3 also interacts with PPARγ which results in the 
suppression of adipocytes differentiation (Takahashi et al., 2008). Moreover, TRIB3 is thought 
to contribute to insulin resistance by inhibiting the phosphorylation of AKT. In fact, hepatic 
overexpression of TRIB3 leads to hyperglycemia and glucose intolerance (Du et al., 2003). 
Notably, diabetic patients show an increased expression of TRIB3 compared to healthy 
controls suggesting a central role of TRIB3 in the pathogenesis of insulin resistance (Liu et al., 












Figure 1.6. TRIB protein structure and interactions 
TRIB proteins contain a N-terminal PEST domain, a Ser/Thr kinase-like domain lacking a 
functional ATP binding pocket and a C-terminal domain that mediate the interactions of TRIB 
with other factors. Due to the presence of two motifs HPW[F/L] and DQVXP[D/E] in the C-
terminal domain, TRIBs interact with MAPKK/MEK family members and E3-ubiquitin 
ligases, respectively. Interactions with MAPKK/MEK mainly affect inflammatory and 
proliferative pathways, whilst via binding the ubiquitin E3 ligases, such as COP1, TRIBs 










Table 1.2. TRIB protein-protein interactions and their biological effect 
TRIB interactions with target proteins mainly occur through their C-terminal domain, 
containing specific MAPKK/MEK and E3-ligases binding sites. Most biological effects are 










Tribbles Protein Biological Effect Cell Type Reference














Du et al., 2003, Naiki et al., 2007
TRIB1,
TRIB2
C/EBPα Acute myelogenous leukemia Haematopoietic
stem cells
Dedhia et al., 2010
TRIB1,
TRIB3




Sung et al., 2007





Ohoka et al., 2005, Ohoka et al.,
2007
TRIB3 SIAH1 Inhibition of TGF-β signaling HEK293T Zhou Y et al., 2008
TRIB1,
TRIB2





Naiki et al., 2007, Yamamoto et
al., 2007
TRIB3 PPARγ Suppression of adipogenesis 3T3-L1 adipocytes Takahashi et al., 2008
TRIB1-3 COP1 Target proteins degradation Adipocytes, 32Dcl3,
HEK293T
Qi et al., 2006, Keeshan et al.,
2010, Yoshida et al., 2013
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1.3.3. Cell-context dependent functions of Tribbles 
TRIBs can exert opposing roles in a cell-dependent manner. In fact, it is well appreciated that 
they can act both as oncogenes and oncosuppressors, activators and repressors of inflammation. 
Several groups have shown that TRIB3 is critical in breast cancer pathogenesis: it supports 
cancer cells stemness by regulating FOXO1-AKT interaction (Yu et al., 2019) and NOTCH1 
signalling pathway (Izrailit et al., 2013); it is also thought to contribute to the development of 
breast cancer radiation resistance (Lee et al., 2019). TRIB3 knockdown in radiation-resistant 
breast cancer cell lines was shown to sensitize cells toward radiotherapy, by reducing NOTCH1 
activation (Lee et al., 2019). High levels of TRIB3 have been also associated with other 
neoplasia, including colorectal (Hua et al., 2019) and lung cancer (Zhou et al., 2013, Zhang et 
al., 2019). However, in different contexts TRIB3 can behave as an oncosuppressor: Salazar 
and colleagues reported that TRIB3 is implicated in the anti-tumoral activity of cannabinoids, 
by regulating autophagy. They also found that genetic inhibition of TRIB3 enhances 
tumorigenesis in different cancer models and this is due to TRIB3’s ability to control and 
modulate the extent of AKT activation (Salazar et al., 2015).  Similarly, TRIB1 seems to have 
a dual role in regulating inflammation, depending on the context. Ostertag and colleagues have 
demonstrated that Trib1 mRNA is upregulated in response to inflammatory stimuli (i.e. LPS) 
in the whole white adipose tissue (WAT) depot of mice, but not in the macrophage-enriched 
fractions; moreover, Trib1 acts as activator of inflammation in adipose tissue as its deficiency 
in adipocytes impairs IL-6 and IL-1β gene expression and also protects mice from high-diet 
induced obesity (Ostertag et al., 2010). On the contrary, the lack of Trib1 in the haematopoietic 
system causes an increase in pro-inflammatory cytokines, as well as hypertriglyceridemia and 
insulin resistance (Akira et al., 2013). The role of TRIB1 in inflammation is further discussed 
in the next section.    
 
1.3.4. TRIB1-mediated control of macrophages 
TRIB1 is a critical regulator of tissue resident macrophage differentiation. Tissue resident 
macrophages are M2-like cells which mainly display an anti-inflammatory phenotype under 
homeostatic condition. A massive reduction of M2 macrophages has been observed in bone 
marrow, spleen, lung and adipose tissue of mice lacking Trib1 in the haematopoietic system. 
This is due to the aberrant expression of C/EBPα, a TRIB1 downstream factor (Satoh et al., 
2013). Interestingly, the lack of macrophages in these mice has also been associated with an 
increase in lipolysis and a reduction of adipose tissue mass. This pathological phenotype was 
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rescued when M2-macrophages were injected in the mice. Notably, when fed with a high fat 
diet, Trib1 knockout mice developed insulin resistance and hypertriglyceridemia. These results 
show that by regulating macrophages differentiation TRIB1 is also essential for the 
maintenance and functioning of adipose tissue, as well as lipid homeostasis (Satoh et al., 2013). 
TRIB1 also plays a role in macrophage migration. TRIB1 knock-down in RAW264.7 cells 
impairs macrophage migration behaviour mediated via C/EBPβ and TNF-α and is also 
associated with a change in cell morphology (Liu et al., 2013). It has been demonstrated that 
in absence of TRIB1, macrophages do not show MCP-1 induced chemotaxis, they detach and 
appear rounded with monocyte-like features (Liu et al., 2013). In addition, it has been reported 
that Trib1 deficiency change bone marrow-derived macrophages (BMDMs) phenotype, by 
downregulating both M1 markers (Il6, Il1, Nos2) and M2 genes (Arg1, Fizz1, Cd206) (Arndt 
et al., 2018). Recently, TRIB1 has been implicated in atherogenesis, particularly in 
macrophage foam cell formation (Fu et al., 2017, Johnston et al., 2019). Over-expression of 
TRIB1 in THP1-derived macrophages exposed to oxidized-LDL decreases intracellular lipid 
accumulation and increases cholesterol efflux (Fu et al., 2017). In contrast, work recently 
published from our group by Johnston and colleagues showed that myeloid specific knockout 
of Trib1 is atheroprotective, while myeloid overexpression is detrimental in vivo. Trib1 
overexpression upregulates the oxidized LDL receptor (OLR-1), increasing lipid uptake and 
foam cell formation in two distinct experimental models of atherosclerosis (Johnston et al., 
2019). Taken together these data suggest a pivotal role of TRIB1 in macrophage biology. 
However, considering the existence of contrasting results (Fu et al., 2017, Johnston et al., 
2019) and the lack of experimental data in human macrophages, further investigation is needed. 
 
1.3.5. TRIB1 and Prostate Cancer  
Prostate cancer (PCa) is one of the most common malignancies in men with over 1 million new 
cases diagnosed per year, worldwide. PCa is a slow-growing cancer, it usually has a long 
progression and it can also remain asymptomatic for a long period. However, the majority of 
patients experience urinary dysfunction and sexual discomfort (Shen et al., 2010). Although 
human PCa is considered to be highly heterogeneous, it has been reported that more than 95% 
of these cancers are classified as adenocarcinomas that, in common with most tumours, have 
the ability to spread from their original site and preferentially metastasize in the lungs, liver, 
pleura, adrenals, brain and bone (Shen et al., 2010). Bone metastasis has been described as the 
most common for PCa, as well as the most severe for patients; it is also characterised by the 
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presence of peculiar osteoblast lesions (Bubendorf et al., 2000, Logothetis et al., 2005). Despite 
recent progress and the existence of different therapeutic strategies, the management of 
advanced and metastatic PCa still remains a big challenge (Shen et al., 2010, Litwin et al., 
2017). Furthermore, the mutation rate in PCa is lower, compared to other cancer types. In fact, 
no single gene has been found to be responsible for the development of PCa but a significant 
number of genetic aberrations in multiple loci has been implicated (Lawrence et al., 2014, 
Wang et al., 2018, Testa et al., 2019). Among them it is important to mention mutations in 
androgen receptor (AR), phosphatase and tensin homolog (PTEN), Homeobox Protein NK-3 
Homolog A (NKX3-1), adenomatous polyposis coli (APC), breast cancer susceptibility genes 
(BRCA1 and BRCA2), ATM Serine/Threonine Kinase (ATM) and Speckle Type BTB/POZ 
Protein (SPOP) (Wang et al., 2018).  
TRIB1 has recently been reported to have a role in the tumorigenesis and progression of PCa. 
Mashima and colleagues found that TRIB1 is upregulated in PCa and required for the in vitro 
growth of the cancer under 3D conditions, by regulating the expression of endoplasmic 
reticulum (ER) chaperones (Mashima et al., 2014). Interestingly, the pseudo-kinase seems to 
promote M2 macrophage polarisation in the immune microenvironment of the tumour: in fact, 
the RNA expression of TRIB1 positively correlates with the amount of CD163+ macrophages 
infiltration (Liu et al., 2019). Moreover, data mining of PCa expression datasets shows 
overexpression and amplification of the TRIB1 gene, as well as correlation with risk, 
aggressiveness and survival. A short tandem repeat (STR) found in the 3’UTR of TRIB1 was 
significantly associated with prostate cancer risk and it is thought to alter TRIB1 mRNA 
expression and stability (Moya et al., 2018). However, despite published data and in silico 
analysis suggest an emerging role for TRIB1 in the pathogenesis of PCa, the mechanisms 
underlying its overexpression still remain unknown and require further investigation.  
More information about miRNAs and TRIB1 in PCa is provided in the introduction section of 
Chapter 6, miRNAs regulating TRIB1 in PCa.   
 
1.3.6. TRIB1: an unstable transcript 
The TRIB1 mRNA is highly unstable, showing a half-life shorter than 1 hour (Sharova et al., 
2009). This is often cell/tissue specific and likely due to the presence of endogenous post-
transcriptional regulators. In mouse embryonic stem cells Sharova and colleagues identified 
TRIB1 among the top 50 genes with the most unstable mRNA half-life. They also reported that 
genes with unstable mRNAs often exert regulatory functions (transcription factors), while 
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stable mRNA species with longer half-lives are genes related to cell structure and metabolism 
(Sharova et al., 2009). TRIB1 gene expression is highly variable among different cell types 
and tissues, suggesting it might be subject to cell type-dependent post-transcriptional regulation 
(Sung et al., 2006). In fact, the 3’UTR of TRIB1 mRNA represents more than 50% of the whole 
sequence (1.5 Kbp), it is highly conserved among different animal species and it is enriched in 
regulatory binding sites. Soubeyrand and colleagues have showed that blocking transcription 
through actinomycin-D dramatically reduced TRIB1 mRNA levels in HeLa and arterial smooth 
muscle cells (ASMCs) but inhibiting protein translation using cycloheximide and puromycin 
had the opposite effect (Soubeyrand et al.,2016). This may be explained with the presence of 
a compensatory mechanism enhancing TRIB1 transcription when the protein translation is 
compromised. Nevertheless, the post-transcriptional regulation of TRIB1 expression remains 
largely unknown. 
 
1.3.7. TRIB1 as a potential target of multiple microRNAs 
Currently, there is little information about TRIB1 upstream regulators. However, in silico 
analysis show that TRIB1 is a potential target of multiple miRNAs, both in human and in 
mouse. To date, only a few interactions have been experimentally validated. In PCa, TRIB1 
has been shown to be negatively modulated by miR-224, a miRNA often silenced in cancer. 
The expression level of miR-224 and TRIB1 negatively correlates in prostate tissue and their 
interaction results in the suppression of cell proliferation, invasion and metastasis (Lin et al., 
2014). Moreover, it has been shown that in hepatocellular carcinoma (HCC), where TRIB1 is 
usually overexpressed, miR-23a directly targets the 3’UTR of the pseudo-kinase, affecting 
HCC cell growth, through a mechanism involving p53 and -catenin (Ye et al., 2017). TRIB1 
is also regulated by miR-202 in HepG2 and primary hepatocytes, as was shown in our research 
group (Ilyas et al., 2015, unpublished, manuscript under development). We found an inverse 
correlation between miR-202 and TRIB1 expression levels in an inflammatory context (Ilyas 
et al., 2015, unpublished). Considering its role in a multitude of signalling pathways and its 
short half-life, investigating TRIB1 post-transcriptional regulation by miRNAs seems a 
promising strategy to identify endogenous upstream regulators of the pseudo-kinase that might 
be used to modulate its expression in a tissue-specific context. Therefore, further work in this 




1.4. Tribbles Research and Innovation Network (TRAIN) 
Tribbles Research and Innovation Network (TRAIN, http://train-itn.eu) is a project funded by 
the European Union’s Horizon 2020 research and innovation programme that started in 2017, 
under the Marie Sklodowska Curie ITN Project Grant No 721532. TRAIN has brought together 
a group of scientists working at the interface of metabolism, immunity and cancer, for a total 
of 15 distinct multi-disciplinary research projects, spread across 6 European countries. The 
purpose of the TRAIN Consortium is to unravel the role of Tribbles pseudo-kinases in the 
development and progression of prostate cancer, with particular focus on metabolic and 
immune responses. The TRAIN scientific programme contains at least four different work 
packages: metabolism, immunity, cancer and genomics/system biology; all of them mainly 
focus on the function of TRIB1 and TRIB3 in macrophages, adipocytes, T-regulatory cells, 
Natural Killer cells and prostate cancer cells. My individual PhD project sits in the 
genomics/system biology package, as it is based on the identification and characterization of 
miRNAs targeting TRIB1, by using a combination of wet lab and bioinformatics procedures. 
The cell type of my focus is human macrophage as it is closely involved in immunity and 
metabolism, as well as in cancer. Therefore, the work presented in this thesis is mostly related 
to macrophage biology. However, to integrate my PhD individual project within the TRAIN 
Consortium interests I have performed some experiments using prostate cancer cell lines, 







1.5. Hypothesis  
Although the downstream interactors of TRIB1 are well characterised, the mechanisms 
underlying its regulation are still largely unknown. Considering the length of its 3’UTR, 
we hypothesised that TRIB1 undergoes post-transcriptional regulation by microRNAs. 
The purpose of this study is to identify and characterise miRNAs regulating TRIB1 
expression by using a combination of computational and experimental approaches, with 
focus on human macrophages and prostate cancer in vitro models. Since TRIB1 genetic 
variants have been associated with disease traits and susceptibility, we also aim to 
























Chapter 2. General Materials and Methods 
Part I, In Silico 
2.1. microRNA-target prediction and databases management  
microRNA-target prediction analysis was performed to identify miRNAs regulating TRIB1 
expression. We used 7 prediction tools, listed in Table 2.1.; all of them were used online, 
except miRanda, which was downloaded and used locally as independent software.  
miRanda is a dedicated algorithm developed for the detection of miRNA binding sites in target 
sequences. It reads RNA from a first input file containing mature miRNA sequences and DNA 
or RNA sequences from a second input file containing genes of interest. Between the two sets 
of sequences (Reference and Query), miRanda algorithm performs a dynamic local alignment 
and calculates the thermodynamic stability of RNA/RNA duplexes. This step takes advantage 
of the ViennaRNA package written by Ivo Hofacker (Lorenz et al., 2011) and included in the 
script. miRanda detection software (Version 3.3a, Computational Biology Center of Memorial 
Sloan-Kettering Cancer Center, http://www.microrna.org/) was downloaded in C and used as 
an open source method under the GPL. The following default parameters were used, according 
to the original script: 
 
 Gap Open Penalty: -9.000000 
 Gap Extend Penalty: -4.000000 
 Score Threshold: 140.000000 
 Energy Threshold: 1.000000 kCal/mol 
 Scaling Parameter: 4.000000 
 
miRanda input files were used in FASTA format: human mature miRNAs sequences were 
downloaded from miRbase 22.1 (http://www.mirbase.org/ftp.shtml), while TRIB1 3’UTR 
sequence (NM_025195.4, transcript variant 1) was taken from NCBI database 
(https://www.ncbi.nlm.nih.gov/). The output files generated by miRanda algorithm were post-
processed and organised in tables by using Python (Python v3.6.2/BioPython v1.70). Tables 
were imported in MySQL database (pgAdmin version 4, Management Tools for PostgresSQL), 
along with the outputs generated by other prediction tools used (which were downloaded from 
the webpages of the tools). Results were filtered and analysed by using structural queries and 
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are explained in Chapter 3. The total number of miRNAs predicted to target the 3’UTR of 
TRIB1 was obtained following these filtering steps: 
 
 Detect the number of miRNAs predicted by each algorithm; 
 Eliminate duplicates (same miRNAs predicted by different algorithms); 
 Select only “high confidence” miRNAs, taken from miRbase 22.1 
(ftp://mirbase.org/pub/mirbase/22.1/). 
 Further filter the list selecting only miRNAs which are present in at least 3 databases 
(miRanda, TargetScan and Starbase); 
 
Scripts used to post-process miRanda output are listed in Chapter 8 (Appendix IV). 
 
Table 2.1. List of miRNA-target prediction tools 
Prediction tool/algorithm Link Reference 
miRanda http://www.microrna.org/microrna/home.do Betel et al., 2008 
TargetScan v.7.2 http://www.targetscan.org/vert_72/ Agarwal et al., 2015 
StarBase ENCORI http://starbase.sysu.edu.cn/ Li et al., 2014 
miRDB http://www.mirdb.org/ Chen and Wang 2020 
miRwalk v.3 http://mirwalk.umm.uni-heidelberg.de/ Sticht et al., 2018 
DIANA Tools, microT-CDS http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=microT_CDS/index 
Paraskevopoulou et al., 
2013, Reczko et al., 2012 
DIANA Tools, Tarbase v.8  http://carolina.imis.athena-
innovation.gr/diana_tools/web/index.php?r=tarbasev8/index 
Karagkouni et al., 2018 















2.1.1. miRNAs targeting TRIB1 genetic variants: Single Nucleotide 
Polymorphisms (SNPs) 
To predict miRNAs potentially targeting TRIB1 SNPs we used the algorithm miRanda, as 
described earlier. As input file, we used a list of 90 genetic variants affecting the 3’UTR of 
TRIB1, downloaded from NCBI database. This list included both SNPs and small 
insertions/deletions (INDELs). However, these sequences were downloaded as short sequences 
containing IUPAC ambiguity codes, therefore we pre-processed them using Python to generate 
the full-length 3’UTR sequences carrying each SNP. After executing miRanda, we used Python 
to organise the output file into tables. We created a table for the reference transcript and a table 
for all the SNPs; we then imported the tables in mySQL and used structural queries to intersect 
each dataset and find, for example, common interactions and non-common interactions. Results 
are explained in Chapter 5, while the list of SNPs and scripts is provided in Chapter 8 
(Appendix IV).  
 
2.1.2. Additional tools used  
As additional tools, we used the database PolymiRTS (http://compbio.uthsc.edu/miRSNP/) and 
the database miRCancer (http://mircancer.ecu.edu/). PolymiRTS is a web-based tool enabling 
the detection of miRNAs targeting SNPs and it is based on both TargetScan and experimental 
data (Bhattacharya et al., 2014) (see Chapter 5); miRCancer (Xie et al., 2013) was used to 
download a list of miRNAs dysregulated in prostate cancer according to published literature 
(see Chapter 6). 
 
2.2. RNA-sequencing 
RNA was isolated from human primary macrophages using the miRNeasy Mini Kit (QIAGEN) 
and sent to the sequencing company Novogene Co. Ltd (https://en.novogene.com) for two 
different type of RNA sequencing: a small non-coding RNA sequencing and a messenger RNA 
sequencing, which are the topic of Chapter 4. Prior to the sequencing, RNA samples were 
assessed for quality and concentration using Nanodrop, Agarose Gel Electrophoresis and 
Agilent 2100 (quality and concentration of representative samples are shown in Chapter 8, 
Appendix III). In the following sections we briefly describe the sequencing strategy, the 
bioinformatic pipelines and all the packages we used to analyse the data.  
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2.2.1. Small non-coding RNA sequencing 
Small non-coding RNA sequencing was carried out on unpolarised (M0) and polarised (M1, 
pro-inflammatory phenotype) macrophages isolated from 8 healthy donors, for a total of 16 
samples. The protocol of macrophage polarisation is specified below (Section 2.3.1.). For the 
cDNA library construction, 18-40 bp inserts were involved and for the sequencing an Illumina 
platform was used (NovaSeq platform, single-end 50 bp). Sequencing depth ranged from 18 to 
25 million reads (recommended sequencing depth is 10 million reads). First, we performed a 
quality control check (QC) on fastq files, generated by the sequencer, using the package 
MultiQC (Ewels et al., 2016). We also carried out a trimming phase using Cutadapt to remove 
“contaminating” adapter sequences and improve the mappability of the reads. By using the 
aligner Bowtie2 we performed the mapping. However, instead of mapping the reads to a 
reference genome, we used sequences downloaded from RNACentral, a comprehensive 
database of non-coding RNAs (RNAcentral Consortium, 2017). This was necessary to avoid 
the alignment of small RNAs to unrelated, complementary sequences in the genome. After 
mapping, we used SAMTools to post-process the alignments and generate raw counts. The 
latter were then passed into the limma R package to generate CPM values (Counts Per Million). 
Differential expression (DE) analysis was performed using Deseq2 package (p value cut off 
0.05; fold change threshold 1). A Principal Component Analysis (PCA) was also performed 
using the R functions “prcomp” and R package “factoextra”. PCA analysis shows clusters of 
samples according to their similarities and we generated PCA plots considering CPM values. 
Once DE microRNAs between M0 and M1 macrophages were identified, we used TargetScan 
algorithm to predict their target genes; the expression of these genes was then checked using 
an RNA seq experiment, previously generated in our lab (DOI: 10.17632/j2hmt7k9fh.1). We 
chose this dataset as it was carried out on human polarised macrophages (M0 vs M1) isolated 
from 8 healthy donors, following the same experimental protocol through which we generated 
our samples; moreover, both datasets are characterised by the same number of donors (n = 8). 
This RNA-seq was analysed starting from fastq files and following the same workflow 
described in the next section (Section 2.2.2. Messenger RNA sequencing). After overlapping 
the two sets of macrophage transcriptomic data, we carried out a downstream analysis to 
identify pathways and biological processes, using the R package GOSeq.  
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2.2.2. Messenger RNA-sequencing 
Messenger RNA sequencing was performed on transiently transfected macrophages, isolated 
from 6 healthy volunteers for a total of 24 samples (as specified in Table 2.2.). According to 
the small RNA sequencing results, we selected miR-125a-3p, miR-155-5p and miR-186-5p as 
candidate miRNAs and transiently overexpressed them for our second sequencing experiment 
(see Chapter 4). For the cDNA library construction, inserts of 250-300 bp were used and 
sequencing was performed using an Illumina platform (paired-end 150 bp). As we did for the 
previous sequencing, we performed a QC on fastq file, followed by trimming and mapping 
using the reference genome. This time, the trimming was carried out using the tool 
Trimmomatic and the mapping was performed using the human reference genome (GRCh38). 
We used Salmon tool to perform the quantification. The DE analysis was performed by using 
DESeq2 (p value cut off=0.05; fold change threshold=1). Table 2.3. lists all the R packages 
and functions used to analyse both the small RNA seq and the RNA seq data, along with 
relevant links and publications. All the sequencing related graphs presented in Chapter 4 were 




















Table 2.2. Experimental conditions for the RNA-seq experiment 
The table summarises the experimental conditions behind the mRNA-seq. We transiently 
transfected unpolarised macrophages (M0) isolated from 6 different individuals with candidate 
miRNA mimics and a negative control.  
 
Cell type 4 transfection conditions (24 hours) 
Monocyte-derived macrophages  
(isolated from 6 healthy volunteers) 
miR-125a-3p Mimic, 50nM 
miR-155-5p Mimic, 50nM  
miR-186-5p Mimic, 50nM  
Negative Control Mimic, 50nM 
 
Table 2.3. Packages, functions and database used to carry out the RNA-seq analysis 
The table lists all the tools used to analyse RNA-seq data. DE= differential expression; 
PCA=principal component analysis; GO=gene ontology; KEGG: Kyoto Encyclopedia of 
Genes and Genomes. 
 
Package/function/database Used for URL Reference 
MultiQC Quality Control https://multiqc.info/ Ewels et al., 2016 
Cutadapt Adapter trimming, miR-seq https://cutadapt.readthedocs.io/en/stable/ Martin et al., 2011 
Trimmomatic Adapter trimming, RNA-seq http://www.usadellab.org/cms/?page=tri
mmomatic 
Bolger et al., 2014 
RNA Central (v14) Mapping, alignment  
(non-coding RNA sequences 
as reference genome) 
https://rnacentral.org The RNACentral 
Consortium 2019 





Bowtie2 Mapping, alignment http://bowtie-
bio.sourceforge.net/bowtie2/index.shtml 
Langmead et al., 2012 
SAMtools Quantification http://www.htslib.org/ Li et al., 2009 
Salmon tool Quantification https://salmon.readthedocs.io/en/latest/s
almon.html 
Patro et al., 2017 




Ritchie et al., 2015 
DESeq2 DE analysis http://bioconductor.org/packages/release
/bioc/html/DESeq2.html 
Love et al., 2014 
Prcomp Generate PCA https://stat.ethz.ch/R-manual/R-
devel/library/stats/html/prcomp.html 
Mardia et al., 1979, 
Becker et al., 1988, 
Venables et al., 2002 
Factoextra Visualise PCA https://rpkgs.datanovia.com/factoextra/i
ndex.html 
Le et al., 2008 




Young et al., 2010 
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Part II, In Vitro 
 
2.3. Cell culture and maintenance 
2.3.1. Primary cells 
2.3.1.1. Human monocyte-derived macrophages (MDMs) 
Statement of Ethics  
To isolate primary human blood monocytes, up to 80 mL of venous blood was taken from 
healthy donors. The study was ethically approved by the University of Sheffield Ethics 
Committee (Reference Number: 031330; previously SMBRER310) and written informed 
consent was obtained from all volunteers.  
Blood Monocytes isolation and macrophages differentiation  
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using a Ficoll 
gradient centrifugation. All steps were performed at room temperature. In a 50 mL conical 
centrifuge tube, 40 mL of fresh whole blood was added along with 5 mL of 3.8% (w/v) Sodium 
Citrate to prevent coagulation; 30 mL of the mixture was slowly layered over 15 mL of Ficoll-
Paque Plus (GE Healthcare) (2 volumes of blood per 1 volume of Ficoll) and centrifuged at 
900xg for 20 minutes (accel and brake 1). Plasma was aspirated and the mononuclear cell layer 
was transferred to a new 50 mL conical tube filled with PBS-EDTA; the mixture was 
centrifuged at 265xg for 5 minutes. Red blood cells lysis buffer 1X (16.6 g NH4Cl, 2 g KHCO3, 
400 uL 0.5 M EDTA, 200 mL distilled, sterile H2O) was added for the removal of platelets 
and erythrocytes and left at room temperature for 5 minutes. Cells were further centrifuged and 
counted for the CD14
+ 
positive magnetic selection using the Miltenyi Biotech MACS 
magnetic cell separation system and the anti-CD14 human antibody-beads. CD14
+ 
monocytes 
purity was assessed by Flow Cytometry and cells were subsequently cultured in RPMI-1640 
(Gibco) supplemented with 10% (v/v) of Low Endotoxin Heat Inactivated Foetal Bovine 
Serum, 1% (v/v) Penicillin/Streptomycin, 1% (v/v) L-Glutamine. Human recombinant 
macrophage-colony stimulating factor (M-CSF, Human, Prepotech) was added (100 ng/mL) to 
enable the differentiation of monocytes into macrophages. Cells were incubated for 7 days at 
37°C, 5% CO2.  
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Macrophages in vitro polarisation  
After 7 days of differentiation, human macrophages were activated towards three different 
phenotypes by adding the following cytokines to the media:  
 
 M1 pro-inflammatory phenotype: 20 ng/mL IFN-γ (Human, Peprotech) and 100 
ng/mL E. coli lipopolysaccharide (Serotype R515 TLR grade TM, Enzo Life Sciences);  
 M2a anti-inflammatory phenotype: 20 ng/mL IL-4 (Human, Peprotech);  
 M2c anti-inflammatory phenotype: 20 ng/mL IL-10 (Human, Peprotech).  
 
After 24 hours of treatment, cells were washed twice with PBS 1X and cell pellets were 
collected and stored at -80°C for further RNA/protein isolation. 
 
2.3.2. Established cell lines 
2.3.2.1. Immortalised BMDMs (iBMDMs) 
Immortalised BMDMs were used for transient transfection of miRNA mimics (see Chapter 3).  
The line was generated from wild-type male mice as described by Hornung et al., 2008 and 
they were a gift from Professor David Brough (University of Manchester). The cells were 
grown in T75 flasks in DMEM (Gibco) supplied with 10% (v/v) of Low Endotoxin Heat 
Inactivated Foetal Bovine Serum, 1% (v/v) Penicillin/Streptomycin and 1% Sodium Pyruvate 
and passaged every 2 days, by using cell scraping.  
 
2.3.2.2. HEK293T cell line 
Human embryonic kidney cell line 293T (HEK293T) was used to perform transient 
transfection and luciferase reporter assay, as it is highly transfectable with either DNA and 
RNA constructs. Cells were grown in DMEM (Gibco) supplied with 10% (v/v) of Low 
Endotoxin Heat Inactivated Foetal Bovine Serum, 1% (v/v) Penicillin/Streptomycin, 1% Non-




2.3.2.3. Prostate cancer cell lines 
Cell lines from prostate cancer (PC3, DU145, LNCAP, 22RV1) and normal epithelium 
(PNT1A, PWRE1, RWPE1) were cultured and used to investigate TRIB1 and miRNAs 
endogenous expression, as well as for transient transfection experiments (see Chapter 6). PC3 
and DU145 cell lines were grown in DMEM (Gibco) supplemented with 10% (v/v) of Low 
Endotoxin Heat Inactivated Foetal Bovine Serum, 1% (v/v) Penicillin/Streptomycin, 1% Non-
Essential Amino acids; LNCAP, 22RV1 and PNT1A were grown in RPMI-1640 (Gibco) 
supplemented with 10% (v/v) of Low Endotoxin Heat Inactivated Foetal Bovine Serum, 1% 
(v/v) Penicillin/Streptomycin, 1% (v/v) Glutamine, 1% (v/v) Non-Essential Amino acids; 
PWRE1 and RWPE1 were cultured in Keratinocyte Serum Free Media (K-SFM, Gibco) 
supplied with 1% (v/v) Penicillin/Streptomycin, 0.05 mg/mL bovine pituitary extract (BPE) 
and 5ng/mL human recombinant epidermal growth factor (EGF), both provided with the K-
SFM kit. All cell lines were grown in T75 flasks and passaged every 2-3 days in a 1:5 ratio, by 
using Trypsin/EDTA. 
 
2.4. Gene expression profiling 
2.4.1. RNA extraction 
Total RNA isolation was performed by using the miRNeasy Mini Kit (QIAGEN) according to 
manufacturer’s instructions. The kit enables the purification of total RNA, including small 
RNA from approximately 18 nucleotides and are based on silica-spin columns which optimize 
the RNA binding. RNA concentration and purity were measured by NanoDropTM 
Spectrophotometer (260/280 ratio= 1.8/2.0; 260/230 ratio=1.8/2.0). Prior to the small-RNA 
sequencing and the mRNA sequencing, RNA integrity and concentration were also assessed 
by using Agarose Gel Electrophoresis (Gel Con: 1%; voltage: 180v; Run Time: 16min) and 
Bioanalyzer Agilent 2100 (RNA Integrity Number ≥ 7.5) (details in Chapter 8, Appendix III). 
 
2.4.2. cDNA synthesis 
cDNA synthesis was performed by using the iScript cDNA synthesis kit (Biorad) and the 
miRCURY Universal cDNA synthesis kit (QIAGEN) according to manufacturer’s 
instructions. The latter enable the reverse-transcription of all miRNAs in one single reaction 
which includes the following steps: (1) a poly-A tail is first added to the mature miRNA 
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template and (2) the cDNA is synthesized using a poly T primer with a 3’ degenerate anchor 
and a 5’ universal tag. Protocols, incubation and heat inactivation steps for both kits are listed 
below (Table 2.4.).  
 
2.4.3. Real Time-quantitative PCR 
Real Time qPCR was performed using SYBR Green Master Mix (Primer Design) for the 
messenger RNA; the miRCURY LNA miRNA PCR Assay (QIAGEN) was used for miRNAs. 
SYBR primers were designed and checked for specificity using the BLAST Primer Design 
Tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast) and purchased from Sigma-Aldrich; 
miRNA Primer Mix were purchased from QIAGEN (sequences and details are listed in Chapter 
8, Appendix I). Protocols are listed below (Table 2.5. and Table 2.6.). Results were analysed 
upon a CFX384 C1000 Touch Thermal Cycler (Biorad) using the PCR cycle conditions listed 
below (Table 2.7. and Table 2.8. and the 2(-Delta Ct)) method described below. 
 
2.4.4. Gene expression analysis: 2–∆Ct method 
Prior to the analysis, specificity of each primer pair was confirmed by Melt Curve Analysis, 
provided by the qPCR thermal cycler. Data were then exported in Excel and analysed by using 
the 2–∆Ct method which enables the calculation of the expression of a gene relative to a 
housekeeping gene. The method consists in the following formulas: 
 
1. Average Ct (or Cq) for each gene and sample; 
2. ∆Ct calculation for each sample:  
Ct gene of interest – Ct housekeeping gene 
3. 2-∆Ct calculation for test sample and control sample:  














Table 2.5. RT-qPCR reagents and protocol: Primer Design 
 
 












iScript cDNA synthesis (Biorad) miRCURY Universal cDNA synthesis (QIAGEN)
5x iScript Reaction Mix: 4 uL
iScript Reverse Transcriptase: 1 uL
Nuclease-free water: variable
RNA template (100 fg-1 ug total RNA)
5x miRCURY RT Reaction Buffer: 2 uL
RNase-free water: 4.5 uL
10x miRCURY RT Enzyme Mix: 1 uL
Synthetic RNA spike ins, optional: 0,5 uL
Template RNA (5 ng/uL): 2 uL
Reactions volume: 20 uL                           
• Priming for 5 min at 25 ̊C.
• Reverse transcription for 20 min at 46 ̊C.
• RT inactivation for 1 min at 95 ̊C.
• Immediately cool to 4°C.
• Store at 4°C or freeze.
Reactions volume: 10 uL 
• Incubate for 60 min at 42 ̊C.
• Heat-inactivate the reverse transcriptase for 5 min at 
95 ̊C. 
• Immediately cool to 4°C.
• Store at 4°C or freeze.
Component SYBR Green Master Mix (Primer Design)
SYBR Green Master Mix 5 uL
Primer Forward 10uM 0,3 uL
Primer Reverse 10uM 0,3 uL
Diluted cDNA (0,2-1ng/uL) 5 uL
Total Reaction Volume 10,6 uL
Component miRCURY LNA miRNA PCR Assay (QIAGEN)
2x miRCURY SYBR Green Master Mix 5 uL
Nuclease-free water 1 uL
Primer Mix 1 uL
Diluted cDNA (1:60) 3 uL
Total Reaction Water 10 uL
Component SYBR Green Master Mix (Primer Design)
SYBR Green Master Mix 5 uL
Primer Forward 10uM 0,3 uL
Primer Reverse 10uM 0,3 uL
Diluted cDNA (0,2-1ng/uL) 5 uL
Total Reaction Volume 10,6 uL
Co ponent miRCURY LNA miRNA PCR Assay (QIAGEN)
2x miRCURY SYBR Green Master Mix 5 uL
Nuclease-free water 1 uL
Primer Mix 1 uL
Diluted cDNA (1:60) 3 uL
Total Reaction Water 10 uL
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Amplification 40 amplification cycles at
95°C, 15sec
60 °C ,1min
Melting Curve Analysis Yes 60°C-95°C/0.5 °C Increment




Amplification 40 amplification cycles at
95°C, 10sec
56 °C ,1min
Melting Curve Analysis Yes 60°C-95°C/0.5 °C Increment
A
B




Amplification 40 amplification cycles at
95°C, 15sec
60 °C ,1min
Melting Curve Analysis Yes 60°C-95°C/0.5 °C Increment




Amplification 40 amplification cycles at
95°C, 10sec
56 °C ,1min




2.5.  Protein analysis 
2.5.1. Protein Extraction 
Proteins were extracted from cell pellets using the RIPA Buffer ready-to-use-solution (Sigma-
Aldrich) and 1 uL/mL of Protease Inhibitor (100 uL each 1x10
6 
cells). Cell lysates were further 
sonicated using the ultrasonic bath at voltage 220-240 and Hertz 50-60 for 15-30 minutes 
(Ultrawave, Cardiff, UK). Lysates were then centrifuged at 10.000xg for 20 minutes at 4°C; 
proteins (supernatants) were transferred in a new tube while the debris was discarded.  
 
2.5.2. BCA Protein Quantification Assay 
Total protein concentration was measured compared to a protein standard (Bovine serum 
albumin, BSA) using the Pierce BCA Protein Assay kit according the manufacturer’s 
instructions (Thermo Fisher Scientific). Concentration was estimated by a colorimetric 
microplate reader at 562nm. Data were analysed using GraphPad Prism 8.0 (GraphPad 
Software, La Jolla, CA, USA); the BSA standard curve was log transformed and plotted to 
allow the interpolation of unknown samples with 95% confidence intervals. 
 
2.5.3. Western Blotting 
Western Blotting was performed using the InvitrogenTM  Novex XCell SureLockTM Mini- Cell 
(Invitrogen). 10-20 ug of sample protein was added to 5x Loading Buffer (10% SDS (w/v), 
25% (v/v) beta-mercaptoethanol, 50% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 0.125M 
Tris-HCl, pH 6.8) up to a final volume of 30 uL (volumes were adjusted with RIPA buffer) 
and incubated at 95 °C for 10 minutes; 25 uL of proteins was then loaded into the wells of a 
NuPAGE 4-12% Bis-Tris SDS-PAGE gel Novex (Invitrogen) together with a standard protein 
size marker (SeeBlue, Plus2 Prestained Standard, Invitrogen). Electrophoresis was performed 
at 150 V for 60/80 minutes in NuPAGE MOPS/MES SDS Running Buffer (Novex, Invitrogen). 
Proteins were then transferred onto a nitrocellulose membrane at 35 V for 60 minutes in 
NuPAGE Transfer Buffer (5% (v/v) 20x transfer buffer, 0.1% (v/v) antioxidant, 20% (v/v) 
methanol (Novex, Invitrogen). Transfer efficiency was further determined by staining the 
membrane with Red-Ponceau S Solution (Sigma-Aldrich) for 5-10 minutes at room 
temperature. The membrane was washed in TBS-T (Tris Buffered Saline pH 8.0 powder 
dissolved in 1 L of distilled water, 0.1% (v/v) Tween 20, Sigma-Aldrich) and blocked at room 
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temperature for 1 hour in 5% Milk TBS-T. Primary antibody was diluted in 5% Milk TBS-T 
and left at 4°C, overnight. After the overnight incubation, the membrane was washed 3 times 
for 5 min in TBS-T and incubated with the HRP-conjugated secondary antibody (1:1000, 5% 
Milk TBS-T) at room temperature for 1 hour. The membrane was then washed again (3x5min 
in TBS-T). In order to use different primary antibodies (i.e. protein of interest and 
housekeeping) the membrane was cut when possible or stripped in ReBlot Plus Strong 
Antibody Stripping Solution 1X (EMD, Millipore) and re-blocked in 5% Milk TBS-T at room 
temperature for 1 hour. Prior to the development a chemiluminescent substrate (ECL Prime 
Western Blotting Detection Reagent, GE Healthcare) was added to the membrane for 60-90 
seconds. Specific protein bands were detected by using either C-DiGit Blot Scanner (LI-COR 
Bioscience) and the ChemiDoc XRS+ Imaging System (Biorad). Primary and secondary 
antibodies and their working concentrations are specified in Chapter 8, Appendix I. Results 
were analysed in Excel through ImageStudio Digit version 5 (LI-COR Bioscience) and 
ImageLab version 6.0 (Biorad), as follows: 
 
1. Calculate intensity for each protein band; 
2. Background subtraction (adjusted intensity); 
3. Normalise intensity for each test and control sample:  
Adjusted Intensity protein of interest / Adjusted Intensity housekeeping 
 
2.6. Transient transfection 
Transient cell transfection was performed on both cell lines (HEK293T, iBMDMs, PC3) and 
primary cells (MDMs) by using different kits and different RNA and DNA constructs. 
Dharmafect DUO (Horizon Discovery) was used to co-transfect DNA (reporter plasmids) and 
RNA (miRNA mimics and inhibitors) in HEK293T cells for the dual luciferase reporter assay; 
Viromer Green and Viromer Blue kits (Cambridge Bioscience) were used to transiently 
transfect RNA constructs (miRNA mimics, inhibitors, siRNA and target-site blocker) into 
MDMs, iBMDMs and PC3. Lipofectamine 3000 (Invitrogen) was used to overexpress human 
TRIB1 into MDMs by using an expression plasmid. For each transfection protocol we followed 
the manufacturer’s instruction (see Table 2.9.). All the details about DNA and RNA constructs 




Table 2.9. Transient transfection assays 
List of the 4 transfection systems used in the present thesis along with details about cell type, 
experiment format, DNA/RNA concentrations and incubation time; constructs concentrations 




2.7. Molecular Cloning and Site-Directed Mutagenesis 
Molecular cloning was performed to generate gene reporter plasmids. Each cloning experiment 
was carried out performing the following steps: (1) PCR amplification of sequence to be 
cloned, (2) PCR-fragment purification from gel, (3) cloning reaction with an entry vector and 
a destination gateway vector, (4) competent bacteria transformation and antibiotic selection, 
(5) bacterial colonies harvesting, (6) plasmid mini/midi prep, (7) restriction digestion analysis 
and (8) Sanger sequencing (Figure 2.1.). For Sanger sequencing, we have sent our samples to 
Source BioScience laboratory (Nottingham, UK) and further analysed the sequences by using 
the software DNASTAR LaserGene (https://www.dnastar.com).  
Site-directed mutagenesis was performed to generate miRNA-binding site mutants and SNPs 
in the TRIB1 3’UTR reporter plasmid. PCR primers for mutagenesis were designed with 
mutations using the Agilent website (QuickChange Primer Design, 
https://www.agilent.com/store/primerDesignProgram.jsp) and purchased from Sigma-Aldrich; 
the mutagenesis reaction was prepared using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent) following the manufacturer’s instruction.  
Details about kits, reagents, bacteria and plasmids are specified in Chapter 8 (Appendix I). 
Protocols used for cloning and mutagenesis are described below.  
 
 
Transfection system Cell type Experiment format DNA RNA Incubation time

















Target Site Blocker 50 nM
24 hours
Lipofectamine 3000 MDMs 6-well plate
12-well plate
human TRIB1 1-2,5 ug/well





Figure 2.1. Schematic overview of molecular cloning steps 
The sequence of interest is first amplified through a standard PCR (1); the PCR product is 
excised and purified from the gel (2) and then cloned in a specific vector (3). The obtained 
plasmid is used to transform competent bacteria (4). As soon as the bacteria grow (5), the 
plasmid is isolated using a commercial kit (6), digested (7) and sequenced (8). 
 
2.7.1. Cloning reaction 
Cloning was carried out using the pENTR Directional TOPO cloning kit (Invitrogen) and the 
Gateway LR Clonase kit (Invitrogen) according to manufacturer’s instruction. Directional 
cloning enables to clone a blunt-end PCR fragment into an entry vector which is subsequently 
cloned into a gateway system through a set of recombination sequences. We first cloned the 
3’UTR of TRIB1 in a TOPO vector; then we used EF1 GWB Renilla Luciferase plasmid as a 
gateway system to further clone the 3’UTR of TRIB1 downstream to the luciferase gene. 
2.7.1.1. pENTR Directional TOPO cloning 
The DNA fragment to be cloned was mixed together with a salt solution and a topo vector (4 
uL of DNA fragment, 1 uL of salt solution and 1 uL of topo vector) and left at room temperature 
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for 10 minutes; 50 uL of bacteria (E. Coli C2987H) was then mixed with 3 uL of the cloning 
reaction and incubated on ice for 30 minutes, followed by 90 seconds at 42 °C and 5 minutes 
on ice again. Up to 1mL of lysogeny broth (LB) was then added and the mixture was incubated 
at 37 °C for 40 minutes. The tube was centrifuged at 6000 rmp for 5 minutes at room 
temperature and 100 uL of the mixture was plated on agar plates prepared with antibiotic. Plates 
were incubated over night at 37 °C. The next days, colonies were picked up with a pipette tip, 
mixed with super broth (SB) and left to grow at 37 °C in a water bath shaker. Plasmid mini and 
midi preps were carried out by using GenElute ™ Plasmid Midiprep Kit/Miniprep Kit (Sigma 
Aldrich) following the manufacturer’s instructions.  
 
2.7.1.2. Gateway Cloning  
The Gateway cloning was used to clone the 3’UTR of TRIB1 (entry clone) downstream of a 
renilla luciferase gene (destination vector, EF1 GWB Renilla Luciferase). The two plasmids 
were mixed together with LR clonase enzyme (1 uL plasmid1, 1 uL plasmid2, 0.5 uL LR 
clonase) and the mixture was incubated for 1 hour at room temperature; 1.5 uL of clonase 
reaction was then mixed with 50 uL of competent bacteria (E. Coli C2987H) and incubated as 
follows: 
 
 30’ on ice; 
 30’’ at 42°C; 
 5’ on ice. 
 
Up to 1 mL of SB was added to the mixture, which was incubated for 1 hour at 37 °C. The 
mixture was then centrifuged (2000xg for 5’) and up to 100 uL of mixture was plated on agar 
plate prepared with antibiotic. Plates were incubated over night at 37 °C. The next day, colonies 
were harvested with a pipette tip, mixed with super broth (SB) and left to grow at 37 °C in a 
water bath shaker. Plasmid mini and midi preps were carried out by using GenElute ™ Plasmid 
Midiprep Kit/Miniprep Kit (Sigma Aldrich) following the manufacturer’s instructions. 
Plasmids were digested using restriction enzymes and sequenced (Sanger sequencing).  
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2.7.2. Site-directed mutagenesis 
Being a PCR reaction, site-directed mutagenesis is mediated by oligonucleotide primers that 
introduce a mutation of interest (deletion, insertion, substitution) in a target sequence. After the 
mutagenesis reaction, we performed from step 4 to step 8 of the molecular cloning pipelines.  
 
PCR machine settings for mutagenesis 
1. Segment 1: 95°C for 2 minutes; 
2. Segment 2: 95°C for 20 seconds; 55-60°C for 10 seconds; 68°C for 30 seconds/kb 
plasmid length; 18-30 cycles; 
3. Segment 3: 68°C for 5 minutes; 
4. Segment 4:  hold at 4°C. 
 
2.8. Dual Luciferase Reporter Assay 
The Dual Luciferase Reporter Assay (DLR) is widely used as a quantitative assay to test the 
negative effect of a specific miRNA on a predicted target gene using a luciferase reporter clone 
(usually renilla and firefly luciferase enzymes from Renilla reniformis and Photinus pyralis, 
respectively). The experimental procedure first requires the cloning of the predicted target 
sequence (mostly the 3’UTRs) downstream of a luciferase reporter. Next, after transfecting the 
construct together with the miRNA into a cell line, the reporter activity is measured by adding 
a substrate. Negative changes in luciferase transcriptional activity will indicate whether or not 
the specific miRNA binds to its target, regulating its expression and stability which, in turn, 
affect the upstream gene. A schematic illustration of the DLR assay is shown in Figure 2.2. 
The DLR assay was performed in HEK293T cell line to assess the impact of the 3’UTR of 
TRIB1 on mRNA stability (reference alleles and genetic variants, see Chapter 5) and also to 
validate miRNA-target interactions (see Chapter 3, 5 and 6). We used renilla luciferase reporter 
plasmids (TRIB1 3’UTR and control plasmid without UTRs) and a firefly reporter as internal 
control. Each condition was performed in triplicate. The kit was purchased from Promega. The 
preparation of the reagents, the assay procedure and data analysis are described below.  
 
Preparations: 
Passive Lysis Buffer (PLB) 5x was diluted in distilled water in a 1:5 ratio to obtain the working 
concentration 1x and stored at 4°C; Luciferase Assay Reagent II (LAR II, Firefly) was prepared 
by resuspending the provided lyophilized Luciferase Assay Substrate in 10 mL of the supplied 
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Luciferase Assay Buffer II and stored at -80°C; Stop & Glo reagent (Renilla) was prepared by 




After 24 hours of transient transfection performed in a 96-well plate, the media was 
removed and each well was washed twice in PBS 1x; 35 uL of PLB 1x was then added and 
cells were lysed by pipetting up and down. Up to 5 uL of cell lysates were transferred into 
a nunc-384 well plate; 5 uL of the first substrate (LARII, Firefly) were added to each well 
and the plate was read at 560 nm using a microplate reader (luminometric). After the 
first reading, 5 uL of the second substrate (Stop & Glo, Renilla) were added and the plate 
was read at 580 nm. Data generated by the plate reader were exported and analysed in 
Excel, as described below.  
 
Data analysis: 
Data were analysed by calculating the average of firefly and renilla readings (OD, optical 
density) for each replicate and condition. For the background subtraction, the OD 
readings generated by untransfected cells were subtracted to each test reading. To correct 
variations due to cell density, transfection efficiency and pipetting error, Firefly/Renilla 
ratio was calculated for each condition and the numbers generated were plotted in a 







Figure 2.2. Overview of the dual luciferase reporter assay 
After 24 hours transient transfection (1), HEK293T cells are lysed in 35 uL of PLB 1x (2), 5 
uL of the lysate is transferred to a 384-well nunc plate (3). Then, the first substrate LARII 
(Firefly) is added and the plate is read at 560 nm (4,5); subsequently, the second substrate Stop 
& Glo (Renilla) is added and the plate is read again at 580 nm (6, 7). Data are exported and 
analysed in Excel (8).  
 
2.9. Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) was used to assess the secretion of the pro-
inflammatory interleukin-8 (IL-8) from polarised and treated human MDMs. This assay is 
widely used for the detection of secreted/extracellular proteins and it relies on the “sandwich” 
principle: detect and quantify antigens between two antibodies. In fact, ELISA assay involves 
the use of two antibodies: the capture antibody, which is immobilised to a solid support (usually 
a plastic 96-well plate) and the detection antibody, which is conjugated with an enzyme, able 
to generate a signal (light, colour, fluorescence) when its substrate is added. ELISA kits were 
purchased from R&D Systems company and the assay was performed according to 
manufacturer’s instruction. Each condition was performed in triplicate. The preparation of the 
plate, the assay procedure and data analysis are described below. 
 
Plate Preparation: the Capture Antibody was diluted to the working concentration in PBS 
and added to a 96-well plate (100uL/well). The plate was then sealed and incubated at room 
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temperature overnight. The following day, the plate was washed three times with 300 uL of 
Wash Buffer (PBS 0.05% Tween) using an automated microplate washer. The plate was 
blocked with 300 uL of Reagent Diluent (PBS 1% BSA) for at least 1 hour at room temperature. 
After blocking, the plate was washed again three times with 300 uL of Wash Buffer. 
 
Assay Procedure: all ELISA steps were performed at room temperature. Up to 100 uL of 
samples and standards diluted in Reagent Diluent were added to the plate, which was covered 
and incubated for 2 hours; the plate was washed and the Detection Antibody, diluted at its 
working concentration in Reagent Diluent, was added to each well for 2 hours; then 100 uL of 
the working dilution of Streptavidin-HRP was added to each well for 20 minutes. From this 
step on the plate was protected from direct light. The wash step was repeated and 100 uL of 
Substrate Solution (1:1) were added for 20 minutes. Without washing the plate, 50 uL of Stop 
Solution (2N Sulfuric Acid) were added to each well and the plate was read using a microplate 
reader set to 450 nm. 
 
Data analysis: the data were exported and analysed in Excel. The average of OD readings 
(triplicate) for each condition (both standards and samples) was calculated; the OD values were 
then copied and pasted into a XY table in GraphPad Prism 8.0 and the concentration of the 
target protein was calculated by interpolating the test samples from the standard curve, with 
95% confidence intervals.  
 
2.10. Viability Assay (MTT) 
Viability assay was carried out on MDMs transfected with miRNA mimics by using the 
commercial kit RealTime-Glo™ MT Cell Viability Assay (Promega) following the 
manufacturer’s instructions. The kit measures reduction potential and enables an estimation of 
cell viability in a non-lytic context. NanoLuc Luciferase and MT Cell Viability Substrate are 
added to cell culture media. The MT Cell Viability Substrate enters the cells where it is reduced 
to form a NanoLuc Substrate, which exits the cell and is used by NanoLuc Luciferase in the 
media, realising luminescence. Only metabolically live cells can reduce the substrate and the 




Immunofluorescence was carried out to determine TRIB1 protein expression in polarised 
MDMs. Cells were plated in 8 well chamber slides (100,000 cells per well); after 24 hours in 
vitro polarisation, cells were washed with PBS twice and fixed using 200 uL of 4% (w/v) PFA-
PBS for 30-40 minutes. Cells were then washed with PBS twice and permeabilised using 200 
uL of 0.1% (v/v) Triton-PBS for 15 minutes. After permeabilization, cells were washed again 
with PBS and then blocked with 2% (w/v) BSA-PBS for 1 hour. Primary antibody was then 
added in 200 uL of 1 % BSA-PBS and the chamber slide was incubated overnight at 4 °C. The 
following day, cells were washed with PBS and the secondary antibody was added in 200 uL 
of 1 % BSA-PBS and left it for 1 hour at room temperature. After washing in PBS, DAPI 
Solution (Thermo-Fisher Scientific) was added for 10 minutes at room temperature (1:1000 
dilution in PBS). Cells were washed with PBS and the chambers were covered using coverslips 
and a mounting solution. Cells were left in the dark for at least 1 hour before imaging. The 
antibodies used for immunofluorescence are listed in Chapter 8 (Appendix I), along with their 
working dilution.  
 
2.12. Microscope Imaging and analysis 
Immunofluorescence experiments were analysed using the automated inverted microscope 
Leica AF6000LX, acquiring images using LAS-X software (Leica) and phase-contrast, blue, 
red and green filters. 3 or more images of each condition and isotype control per each donor 
were taken, saved in TIF and analysed with Fiji/ImageJ. The analysis was done by calculating 













2.13. Cholesterol Efflux Assay 
Cholesterol efflux assay was carried out in MDMs transfected with miRNA mimic and 
inhibitor. The assay was previously optimised in my lab by Dr Jessica Johnston. Cells were 
transfected with 50 nM of miRNA mimic/inhibitor for 24 hours and then treated with 2.5 uM 
of TopFluor Cholesterol (23-(dipyrromtheneboron difluoride)-24-norcholesterol (Avanti Polar 
Lipids) for 24 hours in RPMI 0.2% BSA fatty-acid free (Sigma-Aldrich) for other 24 hours. 
Media was changed RPMI 0.2% BSA fatty-acid free for 18 hours (equilibration step). After 
that, a cholesterol acceptor was added:  50ug/mL of HDL (Biorad) for 4 hours. At end of 
incubation, the media was collected and cells were lysed using a solution of 1% Cholic Acid 
in 100% Ethanol (Sigma-Aldrich). Both cells lysates and supernatants were added to a nunc 96 
well plate (black) in triplicates and fluorescence was read using a microplate reader (excitation 
490nm, emission 520nm). Data were analysed as follows in Excel (Low et al., 2012): 
 
% cholesterol efflux = SN/ (lysate * dilution factor) + SN * 100 
Final % efflux = % cholesterol efflux-% blank efflux (no acceptor) 
 
where SN is the supernatant.  
 
2.14. Flow cytometry 
Flow cytometry was carried out to assess CD14+ monocyte purity and transfection efficiency, 
by using BD LSR II machine (BD Bioscience). In the flow cytometry experiment we used TO-
PRO-1 Iodide (515/531) staining for live/dead cells (1:10000) (Invitrogen). Flow cytometry 
results are shown in Chapter 8 (Appendix II). 
 
2.15. Statistics 
All experiments were performed at least three times and data are presented as means ± SEM. 
Graphs and statistical analysis were generated in GraphPad Prism 8.00 (GraphPad, San Diego, 
CA, USA). Statistical methods are specified in each figure legend. P‐values < 0.05 were 





Chapter 3. miR-101-3p negatively regulates Tribbles-1 in primary 
human macrophages  
 
Declaration 
This part of the work is intended to be published along with additional data not shown here 
(manuscript in preparation). The experiments and the bioinformatics analysis described in this 
chapter have been entirely performed by myself. The only exception is Figure 3.15.: the KEGG 




Tribbles-1 (TRIB1) is an evolutionarily conserved pseudo-kinase protein that in mammals 
control a wide range of interacting signalling pathways. In myeloid cells, TRIB1 controls 
macrophage polarisation and dysregulated myeloid Trib1 expression has been shown to alter 
adipose homeostasis and atherosclerosis burden. However, mechanisms that regulate TRIB1 
expression remain elusive. Taking advantages of in-silico predictions, we showed that the 
3’untranslated region (3’UTR) of TRIB1 is enriched in microRNA-binding sites and when 
cloned downstream of a luciferase reporter gene, leads to a significant reduction of the reporter 
activity. Macrophage-specific knock-down of DICER1 and AGO2, key enzymes involved in 
miRNAs biogenesis and activity, causes an increase of TRIB1 RNA and protein, suggesting a 
role for microRNAs in its post-transcriptional regulation. We demonstrated that miR-101-3p, 
miR-132-3p and miR-214-5p are able to negatively modulate TRIB1 expression in 
macrophages and have validated the direct interaction of miR-101-3p and TRIB1 by employing 
site-directed mutagenesis. Through regulation of TRIB1, miR-101-3p induced an M1-like 
macrophage polarisation, altering the levels of pro-inflammatory markers. Our results suggest 
that the TRIB1-miR-101-3p interaction is biologically relevant in the context of human 
macrophage polarisation in vitro and should be further investigated in vivo, in the context of 
those diseases, in which the activation of macrophages towards different phenotypes plays a 




Tribbles-1 (TRIB1) pseudo-kinase regulates cell function in a range of contexts, via regulating 
MAP kinase activation (Kiss-Toth et al., 2004) and mediating protein degradation via the COP1 
ubiquitin ligase (Yoshida et al., 2013). Its expression is detectable in all tissues, but it is highly 
enhanced in the bone marrow and in the thyroid gland (The Human Protein Atlas, 
https://www.proteinatlas.org). In fact, TRIB1 has been shown to play a pivotal role in the 
differentiation of anti-inflammatory M2-macrophages, in the pathogenesis of early 
atherosclerosis and during adipose tissue inflammation (Ostertag et al., 2010, Satoh et al., 
2013, Johnston et al., 2019). In murine bone-marrow derived macrophages, Trib1 deficiency 
has been reported to alter polarisation markers, impairing the transcription of both pro-
inflammatory and anti-inflammatory genes (Arndt et al., 2018). Besides, TRIB1 is also an 
established oncogene in acute myeloid leukemia, a cancer that arise from monocytes 
(Röthlisberger et al., 2007, Yoshida et al., 2013).  
At the gene level, TRIB1 is highly unstable, showing a mRNA half-life shorter than 1 hour 
(Sharova et al., 2009). Its expression is also highly variable among different cell types and 
tissues, suggesting it might be subject to cell type-dependent post-transcriptional regulation 
(Sung et al., 2006). The 3’untraslated region (3’UTR) of TRIB1 mRNA represents more than 
50% of the whole sequence, it is highly conserved among different animal species and it is 
enriched in regulatory binding sites. Recently, Soubeyrand and colleagues have showed that 
blocking transcription through actinomycin-D dramatically reduced TRIB1 mRNA levels in 
different in vitro models (Soubeyrand et al., 2016). However, the regulation of human TRIB1 
at the post-transcriptional level has not been investigated.  
One of the main gene regulatory mechanisms described in eukaryotes is mediated by 
microRNAs (miRNAs) in a process called RNA Interference (RNAi). miRNAs are small non-
coding RNAs that bind to the 3’UTR of target, complementary mRNAs and via association 
with effector proteins form the RNA-induced silencing complex (RISC). This ultimately leads 
to RNA degradation and inhibition of protein translation (Bartel et al., 2004). The role of 
miRNAs in macrophage development and function has been extensively studied (Roy et al., 
2016, Curtale et al., 2019).  
In the current work, we investigated for the first time the post-transcriptional regulation of 
TRIB1 by miRNAs. To date, only a few studies identified miRNAs regulating TRIB1 in the 
context of prostate and liver cancer (Lin et al., 2014, Ye et al., 2017). Considering its 
predominant role in myeloid cells we focussed on human macrophage function and 
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polarisation. In fact, the role of TRIB1 in human macrophages has not been extensively 
investigated and the majority of published studies are related to mice models and murine cell 
lines.  
 
3.2. Hypothesis and aims 
We hypothesised that TRIB1 is subject to post-transcriptional regulation by miRNAs in human 
macrophages. The aims of this study were (1) to investigate the expression and the function of 
TRIB1 in human macrophages; (2) to identify and validate macrophage-specific miRNAs 

































3.3.1. Endogenous TRIB1 expression in human polarised macrophages  
TRIB1 expression has been reported to be highly variable among different cell types, both at 
the mRNA and protein levels and it appears to be regulated in response to inflammatory stimuli 
(Sung et al., 2006, Soubeyrand et al., 2016). By using GTEx Portal database 
(https://gtexportal.org/home/), we checked TRIB1 mRNA expression among 54 different 
human tissues; the top 5 tissues in which TRIB1 is expressed the most are thyroid (median 
Transcript Per Million, TPM 155), lung (median TPM 50.96), whole blood (median TPM 
38.28), visceral adipose tissue (median TPM 37) and liver (median TPM 34.61) (Figure 3.1.). 
As TRIB1 is critical in the myeloid system (Yokoyama et al., 2010, Satoh et al., 2013), we 
measured its mRNA expression in human primary unpolarised (also referred as M0 and Mun 
macrophages) macrophages (MDMs), isolated from 18 different individuals of mixed age and 
gender, by using RT-qPCR. Prior to the RNA isolation, we polarised the cells towards M1, 
M2a and M2c phenotypes for 24 hours, as described in Chapter 2. The result is shown in Figure 
3.2.: TRIB1 mRNA expression is highly variable among different individuals. However, it is 
significantly increased in M1LPS+INF- and M2aIL-4 conditions, compared to Mun (2.6-fold 
change, p=0.02; 2.6-fold change, p=0.0002). TRIB1 expression seems to increase also in 
response to IL-10 (M2cIL-10) but the change is not statistically significant (1.4-fold change, 
p=0.3). We also investigated TRIB1 protein expression by using immunofluorescence. We first 
observed a nuclear localisation of TRIB1 in human macrophages, which was consistent with 
what have been reported before (Kiss-Toth et al., 2006, Yokoyama et al., 2010, Guan et al., 
2016). As expected, we observed variability among different donors (Figure 3.3. B-F) and we 
did not find any statistically significant changes in the expression of TRIB1 protein (Figure 
3.3. A). This was potentially due to the low n number (n=5). Representative 
immunofluorescence pictures are shown in Figure 3.4., while the isotype control staining for 
each condition is shown in Chapter 8 (Appendix II). TRIB1 is expressed in human 
macrophages differentiated from blood monocytes and it increases in response to both anti-





















































































































































































































































































































































Figure 3.2. Assessment of TRIB1 RNA expression in polarised human macrophages by 
RT-qPCR 
Relative TRIB1 RNA expression normalised to the housekeeping GAPDH, after 24 hours 
polarisation. Cells were treated with LPs and INF- (M1), IL-4 (M2a) and IL-10 (M2c); Mun 
refers to untreated/unpolarised macrophages, used as a control. Data are presented as mean  






























































Figure 3.3. Assessment of TRIB1 protein expression in polarised human macrophages 
by immunofluorescence 
Geometric Mean of integrated density of TRIB1-positive cells measured in Fiji/Image J in 
polarised human macrophages isolated from 5 different individuals; data are presented as mean 
 SEM (n = 5, One-way ANOVA with Dunnett’s post-test, ns p0.05) (A). Integrated density 
of TRIB1-positive cells for each donor (B-F); each graph represents an n=1, so no statistical 

































































































































































































































































Figure 3.4. Representative immunofluorescence images 
Representative immunofluorescence images for Donor B showing polarised MDMs stained for 
dapi (blue) tubulin (green), TRIB1 (red); merged channels are also shown in the last panel. 
Images were acquired using a 20x objective magnification. Integrated density analysis was 
performed in Fiji/ImageJ.  
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3.3.2. TRIB1 overexpression in human macrophages 
Our lab previously investigated the role of Trib1 manipulation in tissue-resident macrophages 
with focus on metabolic tissues (liver and adipose). By using Trib1 knockout and transgenic 
mice, we observed that Trib1 does not alter macrophage number but changes their phenotype. 
Specifically, Trib1KO mice exhibit more pro-inflammatory cells, compared to Trib1WT; 
conversely, macrophages from Trib1Tg mice show an anti-inflammatory phenotype (data not 
shown, manuscript in preparation). A recent study performed on murine bone-marrow derived 
macrophages (BMDMs) has also shown that Trib1 alters macrophage phagocytosis, migration 
and polarisation (Arndt et al., 2018). However, no data is available about the role of TRIB1 in 
human primary macrophages. Therefore, we carried out a TRIB1 plasmid overexpression in 
unpolarised MDMs and checked the gene expression of macrophage markers and pro-
inflammatory cytokines. First, we confirmed the overexpression of TRIB1 RNA by using RT-
qPCR (Figure 3.5.), which is highly variable, probably due to different transfection efficiency 
as well as different endogenous levels of TRIB1 transcript in different individuals. We found 
that when TRIB1 is upregulated, there is a significant increase in anti-inflammatory 
macrophage markers (MSR-1, CD163 and IL-4) at the RNA level (Figure 3.6. A-C) and a 
decrease in the pro-inflammatory IL-6 and IL-8 RNA expression (Figure 3.6. D-E). We also 
measured IL-8 protein secretion by performing ELISA on supernatants and found that it is 
significantly decreased and this was consistent with the RNA data (Figure 3.6. F). This was in 
line with what was reported by Arndt and colleagues who showed that BMDMs from Trib1 














Figure 3.5. Assessment of TRIB1 overexpression in MDMs by RT-qPCR 
Relative TRIB1 RNA expression normalised to the housekeeping GAPDH in MDMs 
transfected with a control plasmid (GFP) and a TRIB1 overexpression plasmid (24 hours 
transfection); total DNA transfected was 2500ng/well in a 6 well plate. Data are presented as 




















































Figure 3.6.  Impact of TRIB1 overexpression on MDMs phenotype 
Relative RNA expression of MSR-1 (A), CD163 (B), IL-4 (C), IL-6 (D) and IL-8 (E) 
normalised to the housekeeping GAPDH in MDMs transfected with a plasmid control (GFP) 
and TRIB1 overexpression plasmid (24 hours transfection); total DNA transfected was 
2500ng/well in a 6 well plate. IL-8 protein levels measured by using ELISA in supernatants 
























































































































































































































3.3.3. Post-transcriptional regulation of TRIB1: impact of the 3’UTR  
It has been reported that TRIB1 exhibits an mRNA half-life shorter than 1 hour (Sharova et 
al., 2009) and it is likely to be post-transcriptionally regulated by either proteasomal or non-
proteasomal mechanisms (Soubeyrand et al., 2016). Therefore, we investigated the role of the 
3’UTR in the post-transcriptional regulation of TRIB1. We cloned the full-length sequence of 
the 3’UTR of TRIB1 downstream of a renilla luciferase gene and evaluated the impact of this 
region on the enzyme activity, by using a dual luciferase reporter assay. We observed a robust 
reduction of the enzymatic activity (> 40% reduction, p<0.0001), suggesting that this region 
contributes to the post-transcriptional regulation of TRIB1 (Figure 3.7.). In fact, the 3’UTR of 
coding genes is the main target of miRNAs (Bartel et al., 2009). To investigate whether TRIB1 
might be regulated by miRNAs, we performed a transient knock-down of DICER1 and AGO2, 
both key regulators of miRNA biogenesis and function (O'Brien et al., 2018) and checked 
TRIB1 mRNA and protein levels. Figure 3.8. shows the confirmation of efficient DICER1 and 
AGO2 enzyme knock-down in MDMs by RT-qPCR (DICER1 70% knock-down, p=0.001; 
AGO2 80% knock-down, p=0.02). In both conditions, TRIB1 mRNA levels tended to increase 
but with high variability and not in all the individuals and the change was not statistically 
significant (siDICER1, 1.3-fold-change, p=0.069; siAGO2 1.6-fold-change, p=0.36) (Figure 
3.9.). Similarly, TRIB1 protein in siDICER1 samples tended to increase but the change was 
not statistically significant (1.6-fold-change, p=0.23) (Figure 3.10.). In fact, by genetically 
impairing the biogenesis and the activity of miRNAs we are likely perturbating multiple genes, 
















Figure 3.7. Impact of the 3’UTR of TRIB1 on gene reporter activity 
Relative luciferase activity measured in HEK293T cell line after 24 hours co-transfection of a 
renilla luciferase reporter (control plasmid, no UTR) and a TRIB1 3’UTR reporter with a firefly 
luciferase control (required for normalisation). Total DNA transfected 100 ng/well (96-well 




Figure 3.8. Confirmation of DICER1 and AGO2 knock-down by RT-qPCR 
Relative RNA expression of DICER1 and AGO2 normalised to the housekeeping GAPDH in 
MDMs transfected with DICER1 siRNA (A) and AGO2 siRNA (B) (48 hours transfection); 
total RNA transfected was 50nM in a 6 well plate. Data are presented as mean  SEM (n=3-8, 








































































































































Figure 3.9. Effect of DICER1 and AGO2 knock-down on TRIB1 mRNA expression  
Relative RNA expression of TRIB1 normalised to the housekeeping GAPDH in MDMs 
transfected with DICER1 siRNA (A) and AGO2 siRNA (B) (48 hours transfection); total RNA 
transfected was 50nM in a 6 well plate. Data are presented as individual points (n=3-8, paired 




Figure 3.10. Effect of DICER1 knock-down on TRIB1 protein expression 
Relative TRIB1 protein expression normalised to the housekeeping HSP90 in MDMs 
transfected with DICER1 siRNA/scramble (A) (48 hours transfection); total RNA transfected 
was 50nM in a 6 well plate; western blot representative picture (B); letters (a, b, c, d) refer to 
































































































3.3.4. Identification of miRNAs potentially targeting TRIB1 
Our previous findings suggest that TRIB1 might be subject to post-transcriptional regulation 
by miRNAs, so our next aim was to in silico identify potential regulators of the pseudo-kinase. 
We performed a comprehensive miRNA-target prediction analysis taking advantage of 
multiple web-based tools and algorithms, as described in Chapter 2. Table 3.1. lists the 
predicted number of miRNAs targeting the 3’UTR of TRIB1, according to 7 different 
prediction tools. We identified a total of 1237 miRNAs predicted to target TRIB1: the list was 
further narrowed down by selecting high-confidence miRNAs and those predicted by at least 
3 databases. Next, we selected miR-101-3p, miR-132-3p and miR-214-5p for experimental 
validation, according to the following criteria: 
 
 miR-101-3p is known to regulate macrophage function (Wei et al., 2015, Zhang et al., 
2015, Huang et al., 2020); it is a high-confidence annotated miRNA and the predicted 
interaction, detected in  3 databases, is well conserved among different species;  
 
 miR-132-3p is also established to regulate inflammatory responses in different contexts 
(Shaked et al., 2009, Liu et al., 2014, Leinders et al., 2016) and it is a high confidence 
miRNA, detected in  3 databases; however, the 2 binding sites on the 3’UTR of TRIB1 
are poorly conserved among different species; 
 
 miR-214-5p is not listed among the high-confidence miRNAs, but it has been 
previously associated with inflammation (Iizuka et al., 2012, Yang et al., 2019); the 2 
predicted binding sites are poorly conserved, but the interaction was predicted by  3 
databases. 
 
Moreover, we also considered that all the predicted interactions are characterised by a 
canonical seed region (7mers). The characteristics of miR-101-3p, miR-132-3p and miR-214-
5p are summarised in Table 3.2.; binding site position, seed region types and phylogenetic 
conservation were taken from TargetScan, while high confidence miRNAs were taken from 
miRbase. Next, we checked the expression of these miRNAs in polarised MDMs, by using a 
small non-coding RNA-seq, performed on M0 and M1 macrophages (sequencing experiment 
is explained in Chapter 4). Figure 3.11. shows the counts per million values (CPM) of the 
candidate miRNAs in M0 and M1 macrophages. None of the miRNAs was differentially 
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expressed between the two groups. However, considering that the highest CPM value among 
the small RNA sequenced was 17 and the lowest was -2, we can conclude that miR-101-3p and 
miR-132-3p were abundant in both M0 and M1 macrophages (miR-101-3p average CPM 
M0=7, average CPM M1=7.3; miR-132-3p average CPM M0=7.6 average CPM M1=7.8), 
whilst miR-214-5p was the least expressed (average CPM M0= -0.4, average CPM M1= -0.8).  
To investigate whether these miRNAs are able to modulate TRIB1 expression, we transiently 
transfected miRNA mimics in unpolarised MDMs and iBMDMs and performed RT-qPCR on 
both human and murine TRIB1. We first evaluated that the overexpression of miRNAs by 
transfection of mimics in MDMs was successful (Figure 3.12.) and then we determined the 
downstream effect on TRIB1 RNA. MiR-101-3p, miR-132-3p and miR-214-5p significantly 
impaired TRIB1 expression in human macrophages, causing a 40% reduction (Figure 3.13. 
A-C); similarly, in murine macrophages, Trib1 expression was negatively modulated by the 
mimics (30% decrease). However, the change induced by miR-214-5p was not statistically 
significant (p=0.1) (Figure 3.14.). This may be due to the high variability of the negative 
control in transfected iBMDMs. Lastly, we performed a pathway enrichment analysis of all 
predicted target genes of candidate miRNAs by using Reactome (https://reactome.org/) (p-
value cut off 0.05). The list of target genes of each miRNA was downloaded from TargetScan. 
Table 3.3. lists the top 10 significant pathways for miRNAs target genes. The majority of miR-
101-3p target genes appear to be involved in chromatin organization and oestrogen-mediated 
signalling pathways; miR-132-3p target genes seem to be transcription factors, regulating AKT 
and PTEN signalling pathways, while genes targeted by miR-214-5p are involved in 
development and axon guidance. We then filtered the list of target genes, selecting only those 
differentially expressed by human polarised macrophages (M0 vs M1), by using an RNA-seq 
dataset, previously generated in our lab (DOI: 10.17632/j2hmt7k9fh.1). We performed a 
KEGG pathway enrichment analysis using GOSeq R package (cut off p value 0.05). Figure 
3.15. shows the results for miR-101-3p and miR-132-3p; unfortunately, miR-214-5p did not 
show any significant enrichment. Interestingly, among the most significant enriched pathways 
for miR-101-3p we observed MAPK signalling pathway, which is a master regulator of 
inflammation, and chemokine signalling pathway, while for miR-132-3p was either WNT-
signalling pathway or actin regulation. We then decided to go on with the full validation of 





Table 3.1. miRNA-TRIB1 target prediction analysis 
The table lists the number of miRNAs predicted to target the 3’UTR of TRIB1 according to 7 
different prediction tools; the total number of predicted miRNAs is the result of each tools, 





Table 3.2. Characteristics of candidate miRNAs 
The table summarises the characteristics of miR-101-3p, miR-132-3p and miR-214 binding 
sites on TRIB1. Target sites positions, seed region type and phylogenetic conservation were 










Prediction tool Target Number of predicted miRNAs Total number of predicted 
miRNAs
miRanda TRIB1 3’UTR 681
1237
TargetScan TRIB1 3’UTR 673
StarBase TRIB1 3’UTR 194
miRWalk TRIB1 3’UTR 406
MicroT-CDS TRIB1 3’UTR 140
TaRbase TRIB1 3’UTR 147













miR-101-3p Yes Position 1526-1532, 7mer m8





Wei et al., 2015, Zhang et 
al., 2015, Huang et al., 2020
miR-132-3p Yes Position 554-560, 7mer m8





Shaked et al., 2009, Liu et 
al., 2014, Leinders et al., 
2016
miR-214-5p No Position 61-67, 7mer m8





Iizuka et al., 2012




Figure 3.11. Endogenous expression of candidate miRNAs in human polarised MDMs: 
small RNA-seq 
miR-101-3p (A), miR-132-3p (B) and miR-214-5p (C) abundance in M0 and M1 macrophages, 
expressed as counts per million values (log2 CPM +1), from small RNA sequencing analysis. 





























































Figure 3.12.  Confirmation of miRNAs overexpression in MDMs by RT-qPCR  
Relative expression of miR-101-3p (A), miR-132-3p (B) and miR-214-5p (C) normalised to 
the housekeeping U6 in samples transfected with miRNA mimics (24 hours transfection). Total 
RNA transfected was 50nM per well in a 6 well plate. Data are presented as mean  SEM (n = 
4-8, paired t-test, *** p<0.001). Plots showing PCR amplification of a representative sample 












































































































Figure 3.13. Assessment of TRIB1 endogenous expression in transfected MDMs by RT-
qPCR 
Relative TRIB1 RNA expression normalised to the housekeeping GAPDH in MDMs treated 
with miR-101-3p mimic (A), miR-132-3p mimic (B) and miR-214-5p mimic (C) and a 
negative control (24 hours transfection). Total RNA transfected was 50nM per well in a 6 well 




Figure 3.14. Assessment of mTrib1 endogenous expression in transfected iBMDMs by 
RT-qPCR 
Relative Trib1 RNA expression normalised to the housekeeping Gapdh in iBMDMs treated 
with miRNA mimics and negative control (24 hours transfection). Total RNA transfected was 
50nM per well in a 6 well plate. Data are presented as mean  SEM (n = 4, ordinary one-way 


























































































































































































Table 3.3. Reactome pathway analysis of candidate miRNAs target genes 
Top 10 significant enriched pathways of miR-101-3p, miR-132-3p and miR-214-5p target 
genes, downloaded from TargetScan. Reactome was used online and results were downloaded 
as tables (p-value cut off 0.05).   
Entities found refer to the number of input genes found in each specific pathway overlapping 
with the total genes involved in the pathway.   
Entities total refer to the total number of genes involved in each specific pathway. 
Entities ratio refers to the ratio of reactions from each pathway that contain the input genes.   








Pathway name #Entities found #Entities total Entities ratio Entities pValue
Chromatin organization 38 256 1.76E-02 1.07E-04
Chromatin modifying enzymes 38 256 1.76E-02 1.07E-04
Transcriptional Regulation by MECP2 20 100 6.89E-03 1.21E-04
Estrogen-dependent gene expression 26 154 1.06E-02 1.91E-04
Regulation of MECP2 expression and activity 11 39 2.69E-03 2.55E-04
PKMTs methylate histone lysines 12 49 3.38E-03 4.79E-04
MET activates RAP1 and RAC1 6 13 8.96E-04 5.50E-04
ESR-mediated signaling 35 256 1.76E-02 8.34E-04
MECP2 regulates neuronal receptors and channels 9 32 2.20E-03 9.22E-04
HDMs demethylate histones 8 31 2.14E-03 2.94E-03
Pathway name #Entities found #Entities total Entities ratio Entities pValue
PIP3 activates AKT signaling 32 316 2.18E-02 9.62E-07
Intracellular signaling by second messengers 33 363 2.50E-02 6.22E-06
FOXO-mediated transcription 15 110 7.58E-03 3.11E-05
PTEN Regulation 18 171 1.18E-02 1.42E-04
Diseases of signal transduction by growth factor 
receptors and second messengers 36 484 3.33E-02 1.47E-04
Regulation of MECP2 expression and activity 8 39 2.69E-03 1.56E-04
Transcriptional Regulation by MECP2 13 100 6.89E-03 1.64E-04
Gene expression (Transcription) 100 1850 1.27E-01 2.22E-04
FOXO-mediated transcription of cell death genes 6 23 1.58E-03 2.96E-04
MECP2 regulates transcription factors 4 10 6.89E-04 6.47E-04
Pathway name #Entities found #Entities total Entities ratio Entities pValue
Transcriptional Regulation by E2F6 5 46 3.17E-03 1.06E-03
Oxidative Stress Induced Senescence 7 114 7.85E-03 3.01E-03
Nuclear Receptor transcription pathway 6 86 5.93E-03 3.20E-03
Axon guidance 19 584 4.02E-02 3.84E-03
POU5F1 (OCT4), SOX2, NANOG activate genes 
related to proliferation 3 21 1.45E-03 5.22E-03
Cellular Senescence 9 199 1.37E-02 6.06E-03
Post-transcriptional silencing by small RNAs 2 7 4.82E-04 6.08E-03
Transcriptional regulation of pluripotent stem cells 4 45 3.10E-03 6.79E-03
Nervous system development 19 620 4.27E-02 7.14E-03


























Figure 3.15.  KEGG enrichment pathway analysis of macrophage-specific genes targeted 
by miR-101-3p and miR-132-3p 
Top 10 significant enriched pathways of miR-101-3p (A) and miR-132-3p (B) macrophage-
specific target genes. miRNA-target prediction analysis was performed using TargetScan; the 
list of target genes was filtering selecting only genes differentially expressed in macrophages 
(M0 vs M1) from RNA-seq dataset (DOI: 10.17632/j2hmt7k9fh.1). KEGG analysis was done 















3.3.5. Experimental validation of miR-101-3p/TRIB1 interaction 
miR-101-3p, a miRNA well known to regulate inflammatory responses in 
monocyte/macrophages (Wei et al., 2015, Zhang et al., 2015, Huang et al., 2020), is predicted 
to bind to the 3’UTR of TRIB1 between positions 1526-1532 (Figure 3.16. A). The interaction 
is characterised by one of the most effective canonical seed region type (7mer-m8 site), an 
exact match to position 2-8 of the mature miRNA, which is known to strongly correlate with 
targeting efficiency (Friedman et al., 2009, Agarwal et al., 2015). As mentioned earlier, the 
binding site is highly conserved among different animal species (Figure 3.17.) and this is a 
strong factor, associated with biological relevance (Agarwal et al., 2015). Then, to confirm the 
direct interaction between miR-101-3p and TRIB1 3’UTR, we co-transfected the TRIB1 
3’UTR reporter plasmid and 50nM of miR-101-3p mimic/ negative control in HEK293T cells 
and carried out a dual luciferase reporter assay. Overexpression of miR-101-3p led to a 
significant reduction of the reporter activity compared to control (50% reduction, p=0.006) 
(Figure 3.16. B). In contrast, when we used the TRIB1 3’UTR mutant, lacking the 7 
nucleotides complementary to the miR-101-3p seed region (Figure 3.18. A) there was no effect 
on TRIB1 3’UTR reporter activity (p=0.8) (Figure 3.18. B). This confirms the specificity of 
the miR-101-3p mimic. Mutagenesis was confirmed by Sanger sequencing (Figure 3.19.). 
However, we did not generate a mutant for the second binding site in position 1424-1430, 
which is not well conserved and despite it being characterised by a canonical, strong seed 
region, was not predicted by all the 7 tools we used. Our data suggest that the activity of miR-
101-3p is mainly exerted via the binding site in position 1526-1532. We also tested the impact 
of an inhibitor, which is designed to antagonise the activity of the endogenous miR-101-3p. 
This led to a significant rescue of the TRIB1 3’UTR reporter activity (16% increase, p=0.005) 
and had no effect when co-transfected together with a control plasmid, without the 3’UTR of 
TRIB1 (p=0.4) (Figure 3.20.). Next, we evaluated the effect of miR-101-3p mimic on TRIB1 
protein levels in transfected human MDMs, as we previously showed that the mRNA of both 
human and murine TRIB1 is negatively modulated (Figure 3.13. A). TRIB1 protein was 
reduced by approximately 60% which was statistically significant when compared to control 
(p=0.03) (Figure 3.21.). Lastly, we investigated whether or not the activity of miR-101-3p on 
endogenous TRIB1 mRNA and protein levels in macrophages is directly due to their physical 
interaction. To this aim, we transiently transfected MDMs with 50nM of a miR-101/TRIB1 
Target Site Blocker (TSB), an antisense oligonucleotide designed to selectively compete with 
miR-101-3p for binding the TRIB1 3’UTR. The TSB does not activate the RISC complex but 
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prevents the access of a miRNA to a given target gene. This enables the study of a single 
miRNA in the context of a single gene. The TSB treatment caused a significant increase of 
both TRIB1 mRNA (1.3-fold change, p=0.004) and protein levels (76%, p=0.04), compared 
to controls (Figure 3.22.). Taken together, these data indicate that miR-101-3p is a negative 






















Figure 3.16. Impact of miR-101-3p on gene reporter activity 
Nucleotide alignment between miR-101-3p and TRIB1 3’UTR (A); relative luciferase activity 
measured in HEK293T cells after 24 hours co-transfection of TRIB1 3’UTR reporter, firefly 
luciferase reporter (required for data normalisation) and 50nM of miR-101-3p mimic or 
negative control. Total DNA transfected 100 ng/well (96-well plate).  Data are presented as 




Figure 3.17. Phylogenetic conservation of miR-101-3p binding site on the 3’UTR of 
TRIB1  
The figure, taken from TargetScan, shows that miR-101-3p binding site on TRIB1 is highly 
conserved.  
 
5’… .CCGUGUAUACCUCAGUACUGUG…3’  TRIB1 3’UTR 1526-1532
3’     AAGUCAAUAGUGUCAUGACAU   5’  miR-101-3p
5’… .CCGUGUAUACCUCA - - - - - - - G…3’  TRIB1 3’UTR mutant
3’   AAGUCAAUAGUGUCAUGACAU   5’  miR-101-3p






Figure 3.18. Impact of miR-101-3p on TRIB1 3’UTR mutant  
Nucleotide alignment between miR-101-3p and TRIB1 3’UTR mutant lacking the 7 bases 
complementary to the seed-region of the miRNA (A); relative luciferase activity measured in 
HEK293T cells after 24 hours co-transfection of TRIB1 3’UTR mutant, firefly luciferase 
reporter (required for data normalisation) and 50nM of miR-101-3p mimic or negative control. 
Total DNA transfected 100 ng/well (96-well plate). Data are presented as mean  SEM 





Figure 3.19. Confirmation of site-directed mutagenesis: miR-101-3p binding site deletion 
TRIB1 3’UTR mutagenesis to generate was confirmed by reverse Sanger sequencing: 1 out of 
3 plasmids had the 7-nucleotides deletion (screenshot taken from SeqMan Pro alignment 










Figure 3.20. Impact of miR-101-3p inhibitor on TRIB1 gene reporter activity 
Relative luciferase activity measured in HEK293T cells after 24 hours co-transfection of renilla 
control reporter (control plasmid) and TRIB1 3’UTR reporter with firefly reporter (required 
for data normalisation) and 25nM of miR-101-3p inhibitor or negative control. Data are 








Figure 3.21. Effect of miR-101-3p mimic on Trib1 protein expression 
Relative Trib1 protein expression normalised to the housekeeping alpha-tubulin in human 
MDMs transfected with 50nM of miR-101-3p mimic/negative control (24 hours transfection); 
data are presented as mean  SEM (n = 5, paired t-test, * p<0.05) (A); western blot membrane 








































































Figure 3.22. Assessment of miR-101-3p specificity: miR-101/TRIB1 target site blocker 
Relative TRIB1 RNA level normalised to the housekeeping GAPDH in MDMs transfected 
with 50nM of TSB/Negative Control for 24 hours (A); relative Trib1 protein expression 
normalised to the housekeeping Hsp90 in MDMs transfected with 50nM of TSB/Negative 
Control for 24 hours (B); representative western blot membrane showing band intensities for 
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3.3.6. Impact of miR-101-3p on human macrophages  
Our previous results demonstrated that miR-101-3p is a negative regulator of TRIB1 
expression by direct interaction. Next, we evaluated the effect of these miRNAs on DUSP1 
and ABCA1, which have been previously identified and experimentally validated as miR-101-
3p target genes in macrophages (Wei et al., 2015, Zhang et al., 2015). DUSP1, dual specificity 
phosphatase, interacts with MAPK proteins as a negative regulator, limiting inflammatory 
responses (Abraham et al., 2006). ABCA1, ATP-binding cassette transporter A1, is responsible 
for cholesterol efflux from macrophages to lipid-free apoA-I, the main component of HDL 
(Zhao et al., 2012). The binding site of miR-101-3p on the 3’UTR of DUSP1 and ABCA1 is 
characterised by canonical seed regions (8mer and 7mer A1, respectively) and they are both 
well conserved among different species (from TargetScan). Accordingly, in response to miR-
101-3p mimic, both genes were significantly downregulated at the mRNA levels (Figure 3.23. 
A, B). We evaluated also the effect of miR-101-3p mimic and inhibitor on cholesterol efflux 
in transfected MDMs and found that in the presence of the mimic the % of total cholesterol 
efflux from macrophages to HDL was reduced by 20% (p=0.008). Similarly, when we used 
the inhibitor we observed an increase of 20% (p=0.003) (Figure 3.23. C). Despite the 
significance, the effect of miR-101-3p on cholesterol efflux was quite small, but this is likely 
due to the assay itself, requiring frequent media changes and testing 2 days post-transfection. 
However, this effect of miR-101-3p is not TRIB1-dependent. Therefore, we investigated the 
expression of IL-6 and IL-8 genes, which were significantly impaired in response to TRIB1 
overexpression in MDMs (see Figure 3.6.). Macrophages transfected with miR-101-3p mimic 
showed a significant increase of both IL-6 and IL-8 mRNA levels, compared to control 
(p=0.03, p=0.04, respectively) (Figure 3.24. A, B). We also measured IL-8 protein through 
ELISA and observed that there was a significant increase in response to miR-101-3p mimic 
(p=0.007) (Figure 3.24. C). IL-6 ELISA did not show any differences among conditions, as 
levels measured were below the threshold of detection (data not shown). To understand 
whether the effect on IL-8 is TRIB1-dependent, we performed IL-8 ELISA in MDMs 
transfected with the TSB. The TSB led to a small but significant decrease of IL-8 protein 
(p=0.01) (Figure 3.24. D). This suggests that TRIB1 might be an upstream regulator of IL-8 
gene, by either direct or indirect regulation. M1-like macrophages, challenged with LPS and 
INF-, are also characterised by an increase in IL-8 production, compared to unpolarised cells 
(Figure 3.24. E). Lastly, we looked at the gene expression of other macrophage polarisation 
markers: miR-101-3p increased the expression of the M1 markers CD80 (p=0.04), CD86 
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(p=0.02), TNF- (p=0.04) and FAM26F (p=0.01) (Figure 3.25.). The latter was characterised 
in our lab as M1 macrophage marker and it is strongly induced by LPS and INF- (manuscript 
in submission). However, we did not observe any miR-101-3p mediated changes in M2 
markers IL-4 (p=0.5), IL-10 (p=0.7), CD36 (p=0.3) and CD163 (p=0.4) (Figure 3.26.).  
Overall, we can conclude that miR-101-3p induces an M1-like phenotype in human 
macrophages, partially by directly targeting TRIB1, which, as mentioned earlier, is a positive 





Figure 3.23. Impact of miR-101-3p mimic on DUSP1 and ABCA1 genes in human 
macrophages  
Relative RNA expression of DUSP1 (A) and ABCA1 (B) normalised to the housekeeping 
GAPDH in MDMs transfected with miR-101-3p mimic/control (50nM, 24 hours transfection). 
Percentage of total cholesterol efflux to HDL measured on MDMs transfected with miR-101-
p mimic/control (50nM) and miR-101-3p inhibitor/control (25nM) (C). Data are presented as 










































































































Figure 3.24. miR-101-3p effect on pro-inflammatory IL-6 and IL-8 
Relative RNA expression of IL-6 (A) and IL-8 (B) normalised to the housekeeping GAPDH in 
MDMs transfected with miR-101-3p mimic/control (24 hours transfection). IL-8 protein levels 
measured by using ELISA in supernatants collected after 24 hours MDMs transfection with 
miR-101-3p mimic/control (C), TSB/control (D) and 24 hours MDMs polarisation (E). Total 
RNA transfected was 50nM per well in a 6 well plate. Data are presented as mean SEM (n=4-





















































































































Figure 3.25. miR-101-3p impact on M1 polarisation markers expression by RT-qPCR 
Relative RNA expression of CD80 (A), CD86 (B), TNF (C) and FAM26F (D) normalised to 
the housekeeping GAPDH in MDMs transfected with miR-101-3p/control (50nM, 24 hours 





























































































































































Figure 3.26. miR-101-3p impact on M2 polarisation markers expression by RT-qPCR 
Relative RNA expression of IL-4 (A), IL-10 (B), CD36 (C) and CD163 (D) normalised to the 
housekeeping GAPDH in MDMs transfected with miR-101-3p/control (50nM, 24 hours 































































































































































To date, multiple in vivo and in vitro studies highlighted the critical role of TRIB1 in the 
function and polarisation of macrophages, in both physiological and pathological contexts 
(Satoh et al., 2013, Akira et al., 2013). TRIB1, along with its family members TRIB2 and 
TRIB3, are considered master regulators of inflammation, metabolism and cancer, given their 
ability to interact with proteins such as MAPK, AKT and COP1 (Dugast et al., 2013, Johnston 
et al., 2015, Eyers et al., 2017).  
It is well appreciated that TRIB1 can have a context-dependent function, acting as either 
activator or inhibitor of inflammation in different tissues (Ostertag et al., 2010, Akira et al., 
2013). In addition, TRIB1 is characterised by an unstable transcript and it was ranked among 
the top 50 most unstable genes, with a mRNA half-life shorter than 1 hour (Sharova et al., 
2009). It has been estimated that more than half of the protein-coding genes in the human 
genome are post-transcriptionally repressed by miRNAs (Friedman et al., 2009).   
In the present work, we aimed to investigate the post-transcriptional regulation of TRIB1 
mRNA, focussing on miRNA-mediated gene regulation in human macrophages. We 
investigated the expression of TRIB1 mRNA in human polarised macrophages and showed 
that it significantly increases in response to LPS and INF- (M1 stimuli), as well as IL-4 (M2a 
stimulus). Immunofluorescence staining of MDMs highlighted that Trib1 protein is mainly 
located in the nucleus, where it ultimately acts as a transcription factor. Indeed, the 
overexpression of the pseudo-kinase in MDMs resulted in increased M2 markers (MSR-1, 
CD163 and IL-4) and decreased M1 markers (IL-6, IL-8). However, this was not consistent 
with what Arndt and colleagues found in murine BMDMs, where Trib1 deficiency resulted in 
the impairment of both M1 and M2 genes, including Il6 (Arndt et al., 2018). However, it is 
well known that genetic manipulation in animals is often associated with gene compensatory 
events and it is not equally comparable to in vitro settings (El-Brolosy et al., 2017).  
To determine whether TRIB1 is post-transcriptionally regulated by miRNAs, we took 
advantage of bioinformatics analysis and experimental approaches. For the first time, we 
demonstrated that the 3’UTR of TRIB1 exerts a robust, negative effect on gene regulation and 
it is enriched in miRNA-binding sites, some of them highly conserved among different species. 
We identified a total of 1237 potential regulators of TRIB1 using 7 different miRNA-target 
prediction tools, but we narrowed down the list, selecting high-confidence miRNAs and 
miRNAs predicted by  3 tools. We showed that miR-101-3p, miR-132-3p and miR-214-5p 
are expressed in human macrophages and they are able to negatively modulate TRIB1 
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transcript in both human and murine macrophages. However, we decided to focus on miR-101-
3p: as suggested by previous studies, miR-101-3p targets key genes regulating inflammatory 
and metabolic outcomes in macrophages, such as DUSP1 and ABCA1 (Wei et al., 2015, Zhang 
et al., 2015). In addition, our enrichment analysis suggested that the target genes of miR-101-
3p, specifically expressed by human macrophages, are involved in inflammatory signalling 
pathways (i.e. MAPK pathway, chemokines pathway). By using a dual luciferase reporter assay 
in HEK293T cell line, we fully validated the interaction between miR-101-3p and TRIB1. Site-
directed mutagenesis experiment confirmed that the binding site in position 1526-1532 on the 
3’UTR of TRIB1 is functional. To substantiate further our findings, we employed a novel 
approach: the use of a target-site blocker. Target site blockers (TSB) are antisense 
oligonucleotides (18-20 nucleotides long), designed to bind selectively to the miRNA target 
site within a mRNA, competing with the endogenous miRNA and without activating the RNA 
interference mechanism (RISC complex). By using this approach, we could evaluate the impact 
of miR-101-3p inhibition on TRIB1 without using an inhibitor. In fact, the use of inhibitors is 
associated with changes in multiple genes, as a single miRNA can target hundreds of different 
genes simultaneously. When we transfected the TSB in MDMs, we observed a small but 
significant increase in TRIB1 at both mRNA and protein level. This suggests that miR-101-
3p/TRIB1 interaction is biologically relevant in macrophages. Finally, we observed that miR-
101-3p induced an M1-like phenotype in macrophages, partially due to TRIB1 downregulation. 
Particularly, the pro-inflammatory IL-8 was downregulated in TRIB1 overexpressing cells and 
upregulated in cells treated with miR-101-3p mimic. Notably, IL-8 significantly increased in 
response to the TSB treatment, hinting that TRIB1 is an upstream negative regulator of IL-8 
transcription. However, this should be investigated further.  
In conclusion, our data suggest that TRIB1 undergoes miRNAs-mediated regulation. MiR-101-
3p is a direct regulator of TRIB1 expression in human macrophages. As it also controls the 
expression of DUSP1 and ABCA1 genes, miR-101-3p offers an interesting, potential target to 
antagonise inflammation and improve cholesterol metabolism.  Future efforts are needed to 
investigate this interaction in in vivo environments and in the context of human disease, in 







Chapter 4. Integrated transcriptome analysis of small non-coding 
RNAs and mRNAs in pro-inflammatory macrophages 
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Abstract 
Macrophage polarisation is a crucial process through which macrophages respond to 
environmental signals, adapting and integrating multiple clues from damaged and healthy 
tissues. This process is highly dynamic and it is regulated by complex signalling networks, 
including miRNA-mediated regulation of gene expression. However, studies that correlate 
miRNAs and target gene expression in polarised macrophages are missing. Here, we 
investigated the expression of miRNAs and their target genes in human polarised macrophages 
by using an integrative approach and multiple RNA-seq experiments. We found that 73 
miRNAs were differentially expressed between M0 and M1-polarised macrophages: 47 were 
downregulated and 26 upregulated. By using TargetScan we predicted their target genes and 
investigated their expression by using data from a second M0/M1 RNA-seq experiment. 
Interestingly, we observed that 1573 upregulated genes in M1 macrophages are predicted to be 
targets of 44 downregulated miRNAs; the M1 polarising stimuli led to the increased expression 
of genes involved in immune responses and inflammation. Similarly, 1790 downregulated 
genes are potential targets of 26 upregulated miRNAs. Significantly, enriched terms in a KEGG 
analysis for downregulated genes included cell cycle and proliferation. We identified 9 
differentially expressed miRNAs (miR-7-5p, miR-125a-3p, miR-3614-5p, miR-4773, miR-
186-5p, miR-4709-3p, miR-1343-3p, miR-766-3p, miR-335-3p) which were predicted to target 
more than 500 different genes and named them “super regulators”. We evaluated the direct 
impact of some of these on M0 macrophage transcriptome, by employing the transient 
transfection of miRNA mimics followed by RNA-seq and observed altered gene expression 
that recapitulate those seen in M1-like phenotype. Our results demonstrate the existence of a 
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macrophage-specific targetome that underpin many of the critical biological pathways 
involved in inflammation.  
 
4.1. Introduction 
Macrophages are the most plastic cell type of the haematopoietic system, playing a crucial role 
in maintaining all tissues in a physiological state and influencing disease development and 
progression. This is due to their ability to sense microenvironmental signals, adopting different 
phenotypes in a process named “polarisation” (Mills et al., 2012). Macrophage polarisation has 
been extensively studied in both in vitro and in vivo models: it is not a fixed event and can be 
triggered by a multitude of biological and mechanical events, such as infection, tissue injury 
and carcinogenesis (Murray et al., 2017). Polarisation is often simplified into two main 
phenotypes: pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages. 
However, this definition finds significant limitations in in vivo contexts, where classifying 
macrophages remains a big challenge, due to their high plasticity and the existence of mixed 
phenotypes (Martinez et al., 2014).  
One of the major mechanisms controlling macrophage polarisation is transcriptional regulation 
of gene expression. Macrophage polarisation results in distinct genetic signatures that 
recapitulate their phenotype and function (Martinez et al., 2006). It has been shown that the 
main gene networks involved in M1/M2 polarisation are those related to membrane receptor 
signalling pathways, cytokine and chemokine release, lipid metabolism and apoptosis 
(Martinez et al., 2006). Key transcription factors involved in macrophage activation are STATs 
(Signal Transducers and Activators of Transcription), PPARs (Peroxisome Proliferator 
Activated Receptors), IRFs (Interferon Regulatory Factors), NFκB (Nuclear Factor κB), GRs 
(glucocorticoid receptors), HIFs (Hypoxia-Inducible Factors) and KLFs (Krüppel-Like 
Factors) (Tugal et al., 2013). Transcriptional changes behind macrophage polarisation are also 
affected by the activity of endogenous miRNAs (Essandoh et al., 2016, Curtale et al., 2019). 
miRNAs are a class of small non-coding RNAs that negatively regulate gene expression via 
binding to complementary sequences located on the 3’UTR of target mRNAs (Bartel et al., 
2004). To date, numerous studies highlight the potential of miRNAs in regulating macrophage 
activation by direct interaction with multiple genes: this has been particularly studied in the 
context of cancer and metabolic diseases (Fernández-Hernando et al., 2013, Deiuliis et al., 
2016, Essandoh et al., 2016). However, the extent of the association between miRNAs and 
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their target genes during macrophage polarisation has not been investigated in a systematic 
manner.  
In the present work, we aimed to address the differential expression between miRNAs and their 
putative target genes in human macrophages challenged with LPS and INF- (M1-like cells), 
by using an integrative approach. We identified 73 differentially expressed miRNAs during 
M1-polarisation which could lead to the dysregulation of 3363 genes. We identified 9 distinct 
miRNAs, each predicted to target more than 500 genes in macrophages, and named them 
“super regulators”. Gene Ontology and KEGG pathway enrichment analysis indicate that these 
miRNAs are key regulators of innate immune responses and cell division, thus contributing to 
the transcriptional changes underlying the M1-like phenotype. Further research is needed to 
experimentally validate miRNA-target gene networks and determine functional outcomes by 
dedicated in vitro assays.  
 
4.2. Hypothesis and aims 
We hypothesised that the transcriptional changes induced in M1 polarised macrophages are 
due to the activity of miRNAs. Therefore, we aimed to: 
 
 identify differentially expressed miRNAs between M0 and M1 macrophages; 
 investigate their association with differentially expressed genes; 
 address the extent of this association; 















4.3.1. Small RNA sequencing data quality and analysis strategy 
To investigate the expression of miRNAs in human macrophages, we performed a small non-
coding RNA sequencing on unpolarised (Mun or M0) and polarised (M1LPS+INF- or M1) 
monocyte-derived macrophages (MDMs), isolated from 8 healthy volunteers. The sequencing 
was performed with an Illumina platform by the genome sequencing company Novogene. 
Illumina technology uses a “sequencing by synthesis” approach and it is usually associated 
with an error rate of 0.1% per nucleotide (Pfeiffer et al., 2018). Errors are due to either the 
consumption of the sequencing reagents or the imperfect binding of the primers to the template 
(Erlich and Mitra, 2008, Jiang et al. 2011). In our cases, the error rate was very low (>0.03% 
per nucleotide) for all the samples (representative sample is shown in Figure 4.1.). The 
recommended sequencing depth for small RNAs is > 10,000,000 raw reads; the depth of our 
sequencing ranged from 18,959,214 to 24,618,695. Table 4.1. shows the data quality summary 
provided by the company. The raw data were further processed by the company in order to 
eliminate some contaminants and to obtain the final clean reads. The data filtering is 
summarised in Table 4.2. Specifically, they eliminated reads of which more than 50% bases 
show a base quality score ≤ 5, reads containing more than 10% of unsolved bases (“N”), reads 
with 5’ primer contaminants, reads without 3’ primer and without the insert tag and reads with 
poly A/T/G/C. However, the percentage of these contaminants was very low. After performing 
the quality check, the company sent us fastq files. The fastq files were analysed as described 
in Chapter 2 (Section 2.2.1.). For the mapping phase, we did not use the reference human 
genome, but sequences downloaded from RNA Central, a comprehensive database containing 
sequences of all type of non-coding RNAs (RNAcentral Consortium, 2017). We observed a 
strong signal for a sequence of 23 nucleotides corresponding to hsa-miR-21 
(UAGCUUAUCAGACUGAUGUUGAC), therefore we decided to exclude it from the 
analysis to avoid biased results. This sequence was over represented in all the samples (30-
50%, shown in Chapter 8, Appendix III). When we performed the analysis considering miR-
21, gene differential expression was not statistically significant, but removing this sequence 
improved the results. In fact, miR-21 is known to be one of the most abundant miRNAs in 
macrophages with roles in both inflammatory and anti-inflammatory mechanisms (Sheedy 
2015).  The overview of the analysis described in this chapter is briefly illustrated in Figure 






Figure 4.1. Sequencing error distribution rate 
Sequencing error distribution rates of two representative samples. The horizontal axis shows 
the reads position, the vertical axis shows the percentage of single base error rate. Graphs were 
provided by Novogene company. 
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Table 4.1. Data quality summary 
The table summarises our sequencing data quality and it was provided by the company. 
Sample: sample ID; raw reads: four rows as a unit to calculate the sequence number of each 
raw data file. Clean reads: calculated as raw reads, statistics object is clean data file. The 
subsequent analyses are all based on clean reads: raw bases= (Number of sequences) * 
(sequence length), use G for unit. Clean bases= (Number of sequences) * (sequence length), 
use G for unit. Error rate: base error rate. Q20, Q30= (Base number of Phred value > 20(> 30)) 
/ (Total base number). GC content: (G&C base number) / (Total base number). Description 




























D199_M0 20665801 20665682 1.033 1.033 0.01 98.42 95.66 47.27
D199_M1 20536744 20536643 1.027 1.027 0.01 98.42 95.66 48.02
D204_M0 24266598 24266499 1.213 1.213 0.01 98.45 95.91 47.41
D204_M1 20581158 20581061 1.029 1.029 0.01 98.39 95.54 47.45
D179_M0 24417998 24417855 1.221 1.221 0.01 98.49 95.87 46.91
D179_M1 18959214 18959113 0.948 0.948 0.01 98.34 95.62 46.84
D194_M0 22670952 22670839 1.134 1.134 0.01 98.31 95.56 47.87
D194_M1 21464756 21464646 1.073 1.073 0.01 98.44 95.75 47.19
D206_M0 24618695 24618559 1.231 1.231 0.01 98.50 96.05 46.44
D206_M1 20304336 20304235 1.015 1.015 0.01 98.47 95.84 47.09
D221_M0 23995072 23994973 1.200 1.200 0.01 98.43 95.68 47.48
D221_M1 20639156 20639049 1.032 1.032 0.01 98.42 95.67 48.49
D223_M0 24130715 24130600 1.207 1.207 0.01 98.43 95.67 47.39
D223_M1 23468860 23468724 1.173 1.173 0.01 98.40 95.57 48.12
D225_M0 24096600 24096468 1.205 1.205 0.01 98.46 95.82 47.55
D225_M1 21805125 21805021 1.090 1.090 0.01 98.25 95.53 47.08
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Table 4.2. Data filtering summary 
The table contains a summary of data filtering and it was provided by the company. Sample: 
Sample id; total_reads: total sequenced reads; N% > 10%: Percentage of reads with N > 10%; 
low quality: percentage of low quality reads; 5_adapter_contamine: Percentage of reads with 
5'adapter contamination; 3_adapter_null or insert_null: Percentage of reads with 3'adapter null 
or insert null; with polyA/T/G/C: Percentage of reads with polyA/T/G/C; clean reads: total 




























































































































Figure 4.2. Overview of analysis strategy 
RNA isolated from polarised macrophages (M0, M1) was sequenced (1) and analysed for the 
identification of differentially expressed small non-coding RNAs (i.e. microRNAs) (2). A 
microRNA-target prediction analysis was performed to identify the predicted target genes of 
the differentially expressed microRNA, which were detected using TargetScan and then 
evaluated their expression using a macrophage RNA-seq dataset (DOI: 
10.17632/j2hmt7k9fh.1) (3,4); differentially expressed miRNAs with more than 500 predicted 
target genes were named “super regulators” (5). We selected three of them and evaluate their 


















Identification of “super 
regulators” miRNAs










4.3.2. Differential expression of miRNAs in response to LPS and INF- in 
human primary macrophages 
The majority of small RNAs sequenced consisted of miRNAs (80%), but also other types, 
including piwi-interacting RNAs (piR), ribosomal RNAs, transfer RNAs (tRNA) and Y RNAs 
were found in our sequencing (20%) (Figure 4.3.). The Principal Component Analysis 
(PCA), displayed as two-dimensional plot in Figure 4.4., shows the distance between the two 
groups of samples. We observed that the majority of samples cluster according to the treatment 
(M0 and M1). The heatmap (Figure 4.5. A) highlights the differential expression of small 
RNAs across the samples. The volcano plot (Figure 4.5. B), showing the statistical significance 
(y axis) versus the magnitude of the fold change (x axis), highlights upregulated and 
downregulated small RNAs (green), as well as small RNAs passing the threshold of our 
analysis (orange and red) (adjusted p value 0.05, fold change 1). A total of 272 small non-
coding RNAs were differentially expressed between the two groups; among them, 73 were 
miRNAs: 47 were downregulated and 26 were upregulated in M1 macrophages, compared to 
unpolarised cells. A previous study performed on murine BMDMs by using a miRNA-
microarray, detected a total of 120 miRNAs differentially expressed between M0 and M1 
polarised cells, but with only 1 miRNA downregulated (Zhang et al. 2013). In our analysis, the 
majority of differentially expressed miRNAs were downregulated in M1 cells. Cobos Jimenez 
and colleagues also identified a total of 303 differentially expressed miRNAs across human 
monocytes and polarised macrophages by using SOLID sequencing and RT-qPCR (Cobos 
Jimenez et al. 2013). Among the differentially expressed miRNAs we observed miR-155-5p 
(up), miR-125a-3p (up), miR-149-5p (down) and miR-191-3p (down). These miRNAs have all 
been reported to control macrophage M1/M2 polarisation and response to infection (Curtale et 
al., 2019). Differentially expressed miRNAs are listed in Table 4.3. and Table 4.4., while the 
complete list of differentially expressed small RNAs is provided in Chapter 8 (Appendix III), 
along with expression and p-values. However, small RNAs other than miRNAs were not 








Figure 4.3. Percentage of RNA types sequenced 
Bar chart graph showing the % of RNA classes sequenced in our small non-coding sequencing 
(figure made in R). miR= microRNA; piR= piwi-interacting RNA; tRNA=transfer RNA; 
letters refer to different individuals; M1 and M0 refer to polarised (LPS+INF-) and 








Figure 4.4. PCA plot of small RNA-seq 
PCA plot of small non-coding RNA-seq data showing the clustering of the samples according 
their gene expression. Dots represent different samples; larger dots represent the class-centroid. 






Figure 4.5.  Differential expression of small RNAs in pro-inflammatory M1 macrophages 
Heatmap of small non-coding RNA sequencing showing the differential expression of small 
RNAs across the two groups of samples (heatmap generated in R) (A); volcano plot showing 
small RNAs passing cut off of adjusted p value 0.05 (red), small RNAs passing threshold of 
log fold change 0 (orange); significant small RNAs with cut off of adjusted p-value 0.05 and 
























Table 4.3. List of upregulated miRNAs 
The table lists the miRNAs significantly upregulated in M1 macrophages, compared to M0 
cells; baseMean is the average of the normalised count values; log2FoldChange represents the 
effect size estimate: how much the expression of a gene changed due to the treatment (M0 vs 
M1); lfcSE is the standard error estimate for the log2FoldChange; stat represents the wald 
statistics; pvalue is attained by the wald test; padj is the pvalue corrected for multiple testing 





















rnacentral_id description baseMean log2FoldChange lfcSE stat pvalue padj
URS0000D54CAD hsa-miR-155-5p 211862.08 2.83 0.23 12.05 1.89E-33 3.67E-31
URS00004208C5 hsa-miR-9-5p 1644.39 1.60 0.18 8.89 5.88E-19 3.36E-17
URS00003D4175 hsa-miR-3614-5p 66.96 3.59 0.44 8.17 3.01E-16 1.17E-14
URS000040DCFF hsa-miR-186-5p 1826.38 1.36 0.17 8.09 6.10E-16 2.15E-14
URS0000410073 hsa-miR-4773 11.84 6.73 0.86 7.82 5.47E-15 1.63E-13
URS0000424278 hsa-miR-147b 300.29 2.37 0.32 7.37 1.69E-13 3.87E-12
URS0000591950 hsa-miR-7-5p 298.69 1.44 0.21 6.80 1.07E-11 1.98E-10
URS00001F0C23 hsa-miR-125a-3p 55.30 2.32 0.35 6.70 2.05E-11 3.61E-10
URS00002DABEA hsa-miR-125b-1-3p 13.47 4.97 0.74 6.67 2.56E-11 4.33E-10
URS00002198F3 hsa-miR-449c-5p 16.15 2.95 0.45 6.58 4.59E-11 7.13E-10
URS0000593537 hsa-miR-221-5p 178.13 1.70 0.26 6.48 9.34E-11 1.39E-09
URS000061B694 hsa-miR-146b-5p 12821.77 1.13 0.19 5.86 4.72E-09 6.54E-08
URS00003496BE hsa-miR-9-3p 71.05 1.44 0.25 5.82 5.88E-09 7.86E-08
URS000075BEBE hsa-miR-324-5p 35.93 2.09 0.37 5.64 1.75E-08 2.19E-07
URS00001F5B39 hsa-miR-449a 15.61 2.16 0.42 5.18 2.17E-07 2.10E-06
URS00000FC8EB hsa-miR-1301-3p 1694.09 1.06 0.22 4.84 1.32E-06 1.13E-05
URS00004B1671 hsa-miR-1307-3p 1602.06 1.48 0.31 4.83 1.34E-06 1.13E-05
URS000001C659 hsa-miR-135b-5p 7.14 4.50 0.93 4.83 1.40E-06 1.16E-05
URS00001C308D hsa-miR-99b-3p 1258.45 1.28 0.29 4.34 1.44E-05 1.01E-04
URS00001123BD hsa-miR-29b-1-5p 24.72 1.41 0.33 4.24 2.20E-05 1.50E-04
URS000031B6ED hsa-miR-365a-5p 8.28 1.87 0.45 4.13 3.58E-05 2.28E-04
URS000043D1A9 hsa-miR-30a-5p 93.87 1.03 0.27 3.84 1.23E-04 6.63E-04
URS000034309A hsa-miR-155-3p 8.34 3.31 0.87 3.79 1.54E-04 8.05E-04
URS00000AA464 hsa-miR-193b-3p 22.03 1.39 0.40 3.50 4.59E-04 2.09E-03
URS0000381B86 hsa-miR-3200-3p 5.17 1.82 0.60 3.05 2.32E-03 8.80E-03
URS0000244A71 hsa-miR-181c-3p 5.05 1.47 0.55 2.67 7.57E-03 2.41E-02
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Table 4.4. List of downregulated miRNAs 
The table lists the miRNAs significantly downregulated in M1 macrophages, compared to M0 
cells; baseMean is the average of the normalised count values; log2FoldChange represents the 
effect size estimate: how much the expression of a gene changed due to the treatment (M0 vs 
M1); lfcSE is the standard error estimate for the log2FoldChange; stat represents the wald 
statistics; pvalue is attained by the wald test; padj is the pvalue corrected for multiple testing 
using the Benjamini and Hochberg method.  
 
 
rnacentral_id description baseMean log2FoldChange lfcSE stat pvalue padj
URS000056B04E hsa-miR-425-3p 240.87 -3.61 0.3 -1.21E+01 7.05E-34 2.73E-31
URS000005D4F5 hsa-miR-345-5p 407.73 -2.21 0.24 -9.16E+00 5.00E-20 4.85E-18
URS0000237FB8 hsa-miR-30c-1-3p 64.7 -2.52 0.28 -9.01E+00 2.06E-19 1.60E-17
URS0000045DBD hsa-miR-3613-5p 163.6 -1.8 0.2 -8.89E+00 6.07E-19 3.36E-17
URS00002CBC6D hsa-miR-4787-3p 280.84 -1.87 0.21 -8.72E+00 2.78E-18 1.35E-16
URS0000080D0A hsa-miR-548o-3p 809.22 -1.63 0.2 -8.32E+00 8.94E-17 3.85E-15
URS00002B2B5C hsa-miR-191-3p 15.6 -4.75 0.61 -7.85E+00 4.02E-15 1.30E-13
URS000060AABB hsa-miR-1249-3p 428.54 -1.22 0.16 -7.63E+00 2.36E-14 6.55E-13
URS000075E96D hsa-miR-7974 35.02 -2.97 0.39 -7.62E+00 2.60E-14 6.73E-13
URS00001C770D hsa-miR-149-5p 15.83 -3.04 0.41 -7.47E+00 8.12E-14 1.97E-12
URS000002103A hsa-miR-1296-5p 11.92 -4.6 0.63 -7.33E+00 2.22E-13 4.78E-12
URS00001012BC hsa-miR-766-3p 58.79 -1.56 0.22 -7.11E+00 1.19E-12 2.30E-11
URS00004E57E7 hsa-miR-23b-3p 65.82 -1.66 0.23 -7.11E+00 1.16E-12 2.30E-11
URS00000CF1D2 hsa-miR-361-5p 827.74 -1.22 0.18 -6.63E+00 3.38E-11 5.47E-10
URS000075C34D hsa-miR-1273h-3p 288.28 -1.71 0.29 -5.89E+00 3.97E-09 5.71E-08
URS0000241987 hsa-miR-181a-2-3p 172.07 -1.65 0.29 -5.76E+00 8.52E-09 1.10E-07
URS00001597DC hsa-miR-331-5p 11.68 -2.18 0.39 -5.57E+00 2.56E-08 3.10E-07
URS00003FFA6C hsa-miR-550a-5p 20.68 -1.84 0.33 -5.51E+00 3.51E-08 4.12E-07
URS0000384021 hsa-miR-106b-3p 23.54 -1.6 0.29 -5.45E+00 5.04E-08 5.75E-07
URS000003F252 hsa-miR-181a-3p 1081.27 -1.07 0.2 -5.35E+00 8.95E-08 9.92E-07
URS00000DA3DF hsa-miR-1343-3p 8.82 -4.13 0.79 -5.24E+00 1.65E-07 1.73E-06
URS000050E4BA hsa-miR-941 1798.91 -1 0.19 -5.22E+00 1.81E-07 1.84E-06
URS00000451A1 hsa-miR-378a-3p 131428.28 -1.05 0.21 -5.07E+00 3.93E-07 3.72E-06
URS00003E16E5 hsa-miR-148a-5p 140.82 -1.15 0.23 -5.07E+00 4.08E-07 3.77E-06
URS0000079D48 hsa-miR-1180-3p 196.05 -1.36 0.28 -4.90E+00 9.73E-07 8.58E-06
URS00004B2A47 hsa-miR-30d-3p 49.73 -1.37 0.29 -4.81E+00 1.51E-06 1.22E-05
URS000015D23B hsa-miR-26a-2-3p 22.22 -1.39 0.31 -4.50E+00 6.96E-06 5.40E-05
URS00004FCB5F hsa-mir-RG-126 variant 1 6.12 -3.24 0.72 -4.48E+00 7.60E-06 5.78E-05
URS00004C9052 hsa-miR-133a-3p 100.63 -1.26 0.28 -4.45E+00 8.43E-06 6.29E-05
URS000003ABC4 hsa-miR-26b-3p 22.32 -2.37 0.55 -4.32E+00 1.56E-05 1.08E-04
URS000023BE29 hsa-miR-139-3p 154.63 -1.26 0.3 -4.14E+00 3.41E-05 2.24E-04
URS0000554A4F hsa-miR-199a-5p 33.16 -1.09 0.28 -3.93E+00 8.49E-05 4.92E-04
URS000052AB63 hsa-miR-4684-3p 14.5 -1.49 0.38 -3.90E+00 9.82E-05 5.52E-04
URS00005092C2 hsa-miR-335-3p 8.62 -1.59 0.41 -3.86E+00 1.12E-04 6.22E-04
URS00000BD1DE hsa-miR-219a-1-3p 24.48 -1.3 0.36 -3.66E+00 2.54E-04 1.28E-03
URS0000065D58 hsa-miR-30a-3p 18.51 -1.52 0.42 -3.60E+00 3.18E-04 1.58E-03
URS00002F8148 hsa-let-7f-1-3p 9.54 -1.62 0.45 -3.58E+00 3.43E-04 1.66E-03
URS0000D55DFB hsa-miR-224-5p 14.74 -1.73 0.52 -3.33E+00 8.53E-04 3.76E-03
URS0000246356 hsa-miR-885-5p 23.42 -1.14 0.34 -3.32E+00 8.91E-04 3.88E-03
URS000075AEBC hsa-miR-6813-5p 5.52 -1.99 0.6 -3.32E+00 9.02E-04 3.89E-03
URS000023133F hsa-miR-4709-3p 31.81 -1.08 0.34 -3.16E+00 1.58E-03 6.32E-03
URS00001C85C7 hsa-miR-1294 12.23 -1.29 0.42 -3.04E+00 2.34E-03 8.80E-03
URS0000156390 hsa-miR-4746-5p 43.49 -1.04 0.35 -2.99E+00 2.80E-03 1.02E-02
URS000044EF2B hsa-miR-4664-3p 29.8 -1.25 0.42 -2.96E+00 3.05E-03 1.09E-02
URS0000383E7F hsa-miR-133a-5p 9.07 -1.18 0.44 -2.68E+00 7.44E-03 2.39E-02
URS00005918D5 hsa-let-7b-3p 8.67 -1.1 0.42 -2.61E+00 9.11E-03 2.83E-02
URS000030C9DE hsa-miR-652-5p 10.6 -1.15 0.46 -2.52E+00 1.17E-02 3.54E-02
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4.3.3. Identification of “super regulator” miRNAs: miRNA-target prediction 
analysis and datasets overlapping 
miRNAs regulate gene expression through physically targeting the mRNA of protein-coding 
genes, therefore once we identified candidate miRNAs differentially expressed between M0 
and M1 macrophages, we performed a target prediction analysis by using TargetScan 
(http://www.targetscan.org/vert_72/). We downloaded the predicted target genes of both 
upregulated and downregulated miRNAs and carried out a Gene Ontology and KEGG Pathway 
Enrichment analysis by using GOSeq. However, among the putative target genes, we only 
considered those differentially expressed in human polarised macrophages. To this aim, we 
used an RNA-seq dataset previously generated in our lab (DOI: 10.17632/j2hmt7k9fh.1) and 
performed an overlaying between DE miRNAs and DE target genes. We chose this dataset as 
it was carried out following the same cell isolation and polarisation protocol (Mun and 
M1LPS+INF-) and it was done using the same number of donors (n=8 per group). The method 
used to analyse the RNA-seq dataset is described in detail Chapter 2 (Section 2.2.). The PCA 
of the RNA-seq is shown in Figure 4.6.  We observed two distinct groups of samples 
suggesting that the M1-polarising stimuli caused a robust gene expression profile change, 
consistent in all samples. The volcano plot shows that 5681 genes are significantly 
differentially expressed: 2728 genes are upregulated, 2953 are downregulated (Figure 4.7.). 
We found that 1573 upregulated genes are predicted targets of 44 downregulated miRNAs 
(Table 4.5.). Similarly, 1790 downregulated genes are potential targets of 26 upregulated 
miRNAs (Table 4.6.). Distinct miRNAs are also predicted to have common target genes. When 
we counted the number of predicted target genes of each DE miRNA it ranged from 9 to 740 
(Figure 4.8.): we selected those targeting more than 500 genes and named them “super 
regulators” (Table 4.7.). Next, we assessed the expression of selected super regulators by using 
RT-qPCR. For the upregulated miRNAs, we also chose to include miR-155-5p which has less 
than 500 target genes but it is a well characterized miRNA in pro-inflammatory macrophages 
(Jablonski et al., 2016, Curtale et al., 2019). Therefore, we used it as a “positive control” in 
the further analysis. Similarly, for the downregulated miRNAs, we included miR-149-5p as it 
is negatively modulated in response to inflammatory stimuli (Xu et al., 2014). We measured 
the expression of the upregulated miRNAs in polarised MDMs from 9 different donors: miR-
155-5p and miR-125a-3p were significantly upregulated in M1 macrophages, compared to 
unpolarised cells (p<0.0001, p=0.003, respectively) (Figure 4.9. A, B); miR-186-5p expression 
was also increased but the change was not statistically significant (p=0.07) (Figure 4.9. C). 
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However, the expression of the downregulated miRNAs, measured in 5 donors, was highly 
variable and in some samples was increased in M1, compared to M0 and miR-149-5p was 
expression was not detected in samples from 2 different donors (Figure 4.9. D-F). This could 
be explained by the very low expression levels of these miRNAs: the Ct values generated in 
the RT-qPCR were very high, compared to the housekeeping gene (average Ct values for the 
housekeeping U6 was 20, average Ct values for miR-766-3p, miR-149-5p and miR-1343-3p 
was > 33). KEGG pathway enrichment analysis (Figure 4.10. A) highlights that the target 
genes of downregulated miRNAs are involved in cytokine and chemokine signalling pathways, 
antigen presentation, T cell receptor signalling pathway, apoptosis and MAPK signalling 
pathway, while the target genes of upregulated miRNAs seem to participate in cell cycle and 
DNA replication mechanisms. Similarly, the gene ontology terms (Figure 4.10. B), divided 
into biological process, cellular component and molecular function, show that the target genes 
of downregulated miRNAs are involved in innate immune and cytokine-mediated cellular 
responses: they localise in the plasma membrane or cell surface, regulating 
chemokine/cytokine receptor and ligand activity. Conversely, when we looked at genes 
potentially targeted by upregulated miRNAs, we observed that they act as regulators of mitosis 
and cell cycle and localise intracellularly. In fact, M1-like macrophages and macrophages 
activated with LPS and INF- are highly cytotoxic and less viable, compared to M2 cells 
(Martinez et al., 2008). We also performed a gene enrichment component analysis on the 
potential targets of super regulator miRNAs: the most significant enriched terms for the genes 
targeted by upregulated miRNAs were chromosome assembly and condensation (Figure 4.11. 
A), while for the genes targeted by downregulated miRNAs, which are overexpressed in M1 
macrophages, significant enriched terms were responses to the cytokine INF- (Figure 4.11. 
B). This suggests that super regulators also have common target genes and it is particularly 
evident for the targets of downregulated miRNAs. In fact, we can observe that INF- signalling 
pathway is not only the most significant (-log10 FDR > 4), but it is also common between 3 
super regulators. To substantiate this, we calculated the overlap between super regulator target 
genes, by using Jaccard Index analysis. The Jaccard index of two or more gene lists counts the 
number of genes in the intersection divided by the number of genes in the union of the gene 
lists and it is a number between 0 and 1: the higher the index, the higher the overlap (Bass et 
al., 2013). We found that there is an overlap of 19% to 33% between upregulated miRNAs 
target genes (Figure 4.12. A) and of 29% to 39% between downregulated target genes (Figure 
4.12. B). The highest % was for miR-1343-3p and miR-766-3p pair (39% genes overlapping). 
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Interestingly, miR-1343-3p was also one of the most downregulated by M1-polarising stimuli, 
as it shows a log2 fold change of -4.13 (see Table 4.4.), suggesting it might have a big impact 
























Figure 4.6. PCA plot of RNA-seq data 
PCA plot of RNA-seq data showing the clustering of the samples according their gene 
expression. Dots represent different samples; larger dots are the class-centroids. Plots were 




Figure 4.7. Volcano plot of RNA-seq data 
Volcano plot of RNA-seq data showing genes passing cut off of adjusted p value 0.05 (red), 
genes passing threshold of Log fold change 1 (orange); significant genes with cut off of 



















small RNA seq RNA seq
miRNA M1 expression Target genes M1 expression
hsa-miR-193b-3p Upregulated 26 Downregulated
hsa-miR-135b-5p Upregulated 42 Downregulated
hsa-miR-449a Upregulated 55 Downregulated
hsa-miR-146b-5p Upregulated 56 Downregulated
hsa-miR-99b-3p Upregulated 58 Downregulated
hsa-miR-125b-1-3p Upregulated 59 Downregulated
hsa-miR-147b Upregulated 95 Downregulated
hsa-miR-181c-3p Upregulated 175 Downregulated
hsa-miR-30a-5p Upregulated 185 Downregulated
hsa-miR-449c-5p Upregulated 193 Downregulated
hsa-miR-1307-3p Upregulated 212 Downregulated
hsa-miR-3200-3p Upregulated 258 Downregulated
hsa-miR-324-5p Upregulated 324 Downregulated
hsa-miR-155-3p Upregulated 333 Downregulated
hsa-miR-155-5p Upregulated 362 Downregulated
hsa-miR-365a-5p Upregulated 401 Downregulated
hsa-miR-221-5p Upregulated 430 Downregulated
hsa-miR-9-3p Upregulated 471 Downregulated
hsa-miR-1301-3p Upregulated 480 Downregulated
hsa-miR-9-5p Upregulated 481 Downregulated
hsa-miR-29b-1-5p Upregulated 490 Downregulated
hsa-miR-7-5p Upregulated 533 Downregulated
hsa-miR-125a-3p Upregulated 555 Downregulated
hsa-miR-3614-5p Upregulated 566 Downregulated
hsa-miR-4773 Upregulated 617 Downregulated
hsa-miR-186-5p Upregulated 739 Downregulated
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small RNA seq RNA seq
miRNA M1 expression Target genes M1 expression
hsa-miR-550a-5p Downregulated 9 Upregulated
hsa-miR-23b-3p Downregulated 38 Upregulated
hsa-let-7b-3p Downregulated 39 Upregulated
hsa-miR-4787-3p Downregulated 48 Upregulated
hsa-miR-30d-3p Downregulated 53 Upregulated
hsa-miR-181a-3p Downregulated 54 Upregulated
hsa-miR-26a-2-3p Downregulated 59 Upregulated
hsa-miR-1180-3p Downregulated 62 Upregulated
hsa-miR-4664-3p Downregulated 65 Upregulated
hsa-miR-106b-3p Downregulated 66 Upregulated
hsa-miR-191-3p Downregulated 71 Upregulated
hsa-miR-1249-3p Downregulated 72 Upregulated
hsa-miR-425-3p Downregulated 92 Upregulated
hsa-miR-4746-5p Downregulated 92 Upregulated
hsa-miR-6813-5p Downregulated 100 Upregulated
hsa-miR-941 Downregulated 105 Upregulated
hsa-let-7f-1-3p Downregulated 143 Upregulated
hsa-miR-1296-5p Downregulated 208 Upregulated
hsa-miR-30c-1-3p Downregulated 210 Upregulated
hsa-miR-3613-5p Downregulated 243 Upregulated
hsa-miR-652-5p Downregulated 257 Upregulated
hsa-miR-331-5p Downregulated 266 Upregulated
hsa-miR-885-5p Downregulated 297 Upregulated
hsa-miR-4684-3p Downregulated 310 Upregulated
hsa-miR-219a-1-3p Downregulated 321 Upregulated
hsa-miR-139-3p Downregulated 327 Upregulated
hsa-miR-361-5p Downregulated 347 Upregulated
hsa-miR-133a-5p Downregulated 351 Upregulated
hsa-miR-378a-3p Downregulated 363 Upregulated
hsa-miR-1294 Downregulated 374 Upregulated
hsa-miR-199a-5p Downregulated 376 Upregulated
hsa-miR-148a-5p Downregulated 389 Upregulated
hsa-miR-345-5p Downregulated 402 Upregulated
hsa-miR-1273h-3p Downregulated 418 Upregulated
hsa-miR-224-5p Downregulated 444 Upregulated
hsa-miR-26b-3p Downregulated 447 Upregulated
hsa-miR-7974 Downregulated 460 Upregulated
hsa-miR-181a-2-3p Downregulated 468 Upregulated
hsa-miR-30a-3p Downregulated 494 Upregulated
hsa-miR-149-5p Downregulated 497 Upregulated
hsa-miR-4709-3p Downregulated 506 Upregulated
hsa-miR-1343-3p Downregulated 620 Upregulated
hsa-miR-766-3p Downregulated 653 Upregulated
hsa-miR-335-3p Downregulated 734 Upregulated
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Figure 4.8. Number of differentially expressed miRNA-target genes  
The graph shows the number of predicted target genes (y axis) of differentially expressed 
miRNAs (x axis); downregulated miRNAs are shown in red, upregulated miRNAs are shown 
in blue. miRNA-target prediction analysis was done by using TargetScan. The list of the target 




Table 4.7. List of “super regulator” miRNAs with more than 500 target genes in 
macrophages 
The table lists the number of target genes of differentially expressed miRNAs in human 
macrophage (M1LPS+INF), predicted by the algorithm TargeScan. Genes were filtered selecting 





















Figure 4.9. Assessment of “super regulator” miRNAs by RT-qPCR 
Relative abundance of miR-155-5p (A), miR-125a-3p (B) and miR-186-5p (C) normalised to 
the housekeeping U6 (upregulated miRNAs); relative abundance of miR-149-5p (D), miR-766-
3p (E) and miR-1343-3p (F) normalised to the housekeeping U6 (downregulated miRNAs). 
Data were analysed using the log2 transformed 2-DCT values and presented as individual 
points (n = 3-9, paired t-test, **** p< 0.0001, ** p<0.01, ns p0.05).  
 




































































































































































































































Figure 4.10. Gene Ontology and KEGG Pathway Enrichment analysis of DE miRNAs 
target genes  
KEGG Pathway enrichment analysis (A) and Gene Ontology terms (B) of macrophage-specific 
genes, predicted to be regulated by differentially expressed miRNAs. First column shows the 
condition in which miRNAs are downregulated and their target genes are upregulated; the 
second column shows the opposite, downregulated genes and upregulated miRNAs. BP= 
biological process, CC= cellular component, MF= molecular function. Analysis was performed 























Figure 4.11. Gene Ontology terms of target genes of “super regulator” miRNAs  
Gene Ontology terms of genes targeted by upregulated miRNAs (A) and downregulated 






Figure 4.12. Target genes overlapping: Jaccard Index 
Target gene overlapping analysis using Jaccard Index: overlapping between upregulated (A) 




4.3.4. Impact of “super regulator” miRNAs on macrophage transcriptome 
To substantiate the role of “super regulator” miRNAs in macrophages, we performed an RNA-
seq on MDMs, transfected with mimics of selected miRNAs. Our previous RNA-seq on 
polarised macrophages showed that M1-polarising stimuli led to more gene downregulation, 
compared to upregulation (2953 were downregulated, 2728 genes were upregulated). Although 
the difference in the number of genes down- and up-regulated is small (only 225 genes), we 
decided to focus on the activity of upregulated miRNAs, which in turn could contribute to the 
downregulation of these genes and to the M1 phenotype. We transiently overexpressed miR-
155-5p, miR-125a-3p and miR-186-5p in MDMs by using miRNA mimics and analysed their 
impact on gene expression. miRNA-155-5p is not a super regulator by our definition, but we 
included it as a positive control, due to its well characterised biological function in macrophage 
polarisation. We used MDMs isolated from 6 different individuals and transfected them for 24 
hours with 50nM of miRNA mimics or negative control. Prior to the RNA-seq we confirmed 
the overexpression of the 3 miRNAs by using RT-qPCR (Figure 4.13.). The sequencing was 
carried out by the company Novogene using Illumina technology. We performed 3 
simultaneous paired-analysis: each miRNA mimic versus the negative control. Unfortunately, 
the PCA plots (Figure 4.14.) did not show defined clusters between conditions. This can be 
explained by several reasons: miRNAs endogenous expression is highly variable among 
different individuals and this can have a different impact on the overexpression experiment (as 
shown by RT-qPCR data), primary cells isolated from different donors might also respond 
differently to transient transfection. Results described in Chapter 3 are also affected by high 
variability, as macrophages are extremely sensitive and being cells of the innate immune 
system can be easily activated by in vitro procedures. Moreover, in this experiment, we used 
cells isolated from 3 male individuals and 3 female individuals, aged 23 to 28 and with different 
ethnicity. It is well appreciated that miRNAs expression can be different between males and 
females, as some studies have reported (Dai et al., 2014, Cui et al., 2018). Interestingly, the 
global PCA, plotted on the 3 overexpression experiments (miR-155-5p, miR-125a-3p, miR-
186-5p vs negative control) (showed in Figure 4.15.) suggests that there is a clustering 
according to the gender of the donors. However, this was not further investigated in the present 
analysis due to the low number of individuals.  
When we performed the differential expression analysis (each miRNA versus the negative 
control), we found only few significant differentially expressed genes (adjusted p value ≤ 0.05). 
Specifically, we found 158, 4 and 1 DE genes, for miR-155-5p, miR-125a-3p and miR-186-5p 
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respectively (list of significant DE genes is provided in Chapter 8, Appendix III). This was not 
surprising, as it is believed that the effect of miRNAs on gene expression is small and 
overexpressing a single miRNA not always leads to the downregulation of target genes, which 
is also seed region type- and context-dependent (Liu et al., 2019). Nevertheless, we carried on 
with the downstream analysis, considering the directional changes of the genes, rather than the 
p-values. The volcano plots on the DE analysis for each overexpressed miRNA are shown in 
Figure 4.16. The dots in green represent genes with an FDR  0.05, including those with 
adjusted p values ≤ 0.05. For miR-155-5p-overexpressing cells (Figure 4.16. A) there are more 
dysregulated genes passing the FDR threshold, both up- and downregulated, in comparison to 
miR-125a-3p and miR-186-5p overexpressing cells (Figure 4.16. B, C). When we compared 
the DE genes in each miRNA overexpression condition with DE genes between M0 and M1, 
we observed an interesting overlap (Figure 4.17.): 
 
1. miR-155-5p: 362 target genes, previously identified as downregulated in M1 
macrophages, 82 were upregulated and 280 were downregulated; 
 
2. miR-125a-3p: among its 555 target genes, previously identified as downregulated in 
M1 macrophages, 336 were upregulated and 219 were downregulated; 
 
3. miR-186-5p: among its 739 target genes, previously identified as downregulated in M1 
macrophages, 326 were upregulated and 413 were downregulated.  
 
Despite it being well established that miRNAs work by repressing the expression of target 
genes, the presence of upregulated transcripts is not surprising, even among their potential 
target genes. Overexpressing a miRNA by cell transient transfection leads to a massive 
perturbation of gene expression, by either direct or indirect activity (Khan et al., 2009). 
However, when we looked at the gene ontology terms of downregulated genes we found results 
consistent with the M1-like phenotype (Figure 4.18.): enrichment of genes involved in mitosis, 
cell cycle, DNA replication and chromosome condensation/segregation. The enriched terms 
for each miRNA overexpression experiment are specified below.  
 
1. miR-155-5p: downregulation of genes related to DNA replication, mitosis and cell 
cycle; upregulation of genes involved in B cells activation and proliferation as well as 
chemokine signalling pathway; 
 139 
 
2. miR-125a-3p: downregulation of genes involved in chromosome segregation and 
condensation; upregulation of genes related to inositol phosphate metabolism; 
 
3. miR-186-5p: downregulation of genes related to chromosome and DNA package; 
upregulation of genes involved in mitosis and chromosome segregation.  
 
The latter was not consistent with miR-155-5p and miR-125a-3p, as it shows similar 
enrichment for both down- and up-regulated genes. In fact, miR-186-5p has been well 
characterised in cancer, where it acts as either oncogene (inducing proliferation) or onco-
suppressor (inducing apoptosis), depending on the tissue (Wang et al., 2019). Overall, this data 
suggests that the overexpression of these miRNAs affect DNA replication and mitosis. 
Therefore, we evaluated the effect of miRNA mimics on cells viability, using an MTT assay. 
This assay measures cells viability thought a substrate that is reduced only by live and 
metabolically active cells. The assay did not show any significant difference (Figure 4.19.), 
likely due to either individuals or transfection variability, as well as the low n number. 
However, we can observe that samples transfected with the mimics tend to be less 
metabolically active, compared to the negative control.  
Lastly, we looked at the identity of the genes showing the same direction in fold change of 
those differentially expressed in M1 macrophages. Table 4.8. lists the top 10 genes selected 
according to adjusted p values, while Table 4.9. shows those filtered according to the fold 
change. For the latter we prioritised downregulation. We observed that not all the genes show 
the same expression status in M1 macrophages and only some of them are predicted targets of 
the miRNAs. Among the downregulated genes in both miRNA overexpression and M1 
macrophages we observed:  
 
 E2F2 (miR-155-5p target), a transcription factor regulating inflammation (Wang et al., 
2018);  
 
 DUSP1 (miR-125a-3p target), negative regulator of MAPK signalling pathway;  
 
 CCL1 (miR-214-5p target), ligand of the chemokine receptor CCR8, driving 
inflammation (Kishi et al., 2016). 
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Taken together, our results suggest that these miRNAs, strongly induced by LPS and INF-, 






Figure 4.13. Confirmation of miRNAs overexpression in transfected MDMs by RT-qPCR  
Relative abundance of miR-155-5p (A), miR-125a-3p (B) and miR-186-5p (C) normalised to 
the housekeeping U6 in MDMs transiently transfected with miRNA mimics or negative 
control. Total RNA transfected was 50nM per well, in a 6 well plate. Data were analysed using 
the log2 transformed 2-DCT values and presented as individual points (n =4, paired t-test, **** 

































































































































Figure 4.14. Single PCA plots of RNA-seq data: super regulator miRNAs overexpression  
PCA plots of paired RNA-seq analysis showing miR-155-5p/control (A), miR-125a-3p/control 
(B) and miR-186-5p/control (C) overexpression experiments in MDMs isolated from 6 
individuals. Dots represent different samples; larger dots are the class-centroids. Plots were 








Figure 4.15. Global PCA plot of RNA-seq data: gender-dependent clustering?  
Global PCA plot of super regulators overexpression RNA-seq analysis showing a potential 
clustering of the samples, according to gender, highlighted by blue circles. Plot was generated 





Figure 4.16. Volcano plots of RNA-seq data: super regulators overexpression  
Volcano plot showing the log2fold change vs the log adjusted p value of macrophage genes in 
response to miR-155-5p mimic (A), miR-125a-3p mimic (B) and miR-186-5p mimic (C). None 
of the genes is significantly differentially expressed (fold change threshold 0; FDR cut off 0.05; 











Figure 4.17. Number of target genes up- and downregulated in response to miRNA 
overexpression  
The bar graph shows the number of up- and downregulated genes in response to miR-155-5p, 
miR-125a-3p and miR-186-5p overexpression. These genes were previously identified as 
















































Figure 4.18. Gene ontology terms of genes differentially expressed in response to miRNA 
mimics 
Gene ontology terms of downregulated (left panel) and upregulated (right panel) genes in 
response to miR-155-5p (A), miR-125a-3p (B) and miR-186-5p (C) overexpression in MDMs 












Figure 4.19. MTT assay on MDMs transfected with miRNAs mimics 
MTT assay on MDMs transfected with 50nM of miRNA mimics/control (24 hours 
transfection). Cells viability is normalised to the control. Dots represent different donors (n=4, 












































































Table 4.8. Adjusted p-values-filtered differentially expressed genes 
Table listing the DE genes in response to miRNAs overexpression filtered according to 
adjusted p values; only those highlighted in red are statistically significant; last column shows 
the expression status of the same genes in M1 macrophages, according to the RNA-seq 





Gene Control vs miR-155-5p miR-155-5p target gene M0 vs M1 
SLC1A3 Upregulated No Downregulated
ARHGAP18 Downregulated No Downregulated
CSF1R Downregulated Yes Downregulated
MOCS2 Downregulated No Downregulated
MPEG1 Downregulated Yes Downregulated
MARCHF1 Upregulated No Downregulated
PICALM Upregulated Yes Downregulated
ANXA2 Downregulated No Downregulated
PTPN22 Downregulated No Downregulated
SPRED1 Downregulated Yes Downregulated
Gene Control vs miR-125a-3p miR-125a-3p target gene M0 vs M1 
DTX4 Downregulated Yes Downregulated
DUSP1 Downregulated Yes Upregulated
INF2 Downregulated Yes Downregulated
EHD1 Downregulated Yes Upregulated
TP53INP2 Downregulated Yes Upregulated
TRAF1 Downregulated Yes Upregulated
BCAT2 Downregulated Yes Downregulated
NFKBIA Downregulated Yes Upregulated
BBS5 Downregulated Yes Downregulated
SLC43A2 Downregulated Yes Upregulated
Gene Control vs miR-186-5p miR-186-5p target gene M0 vs M1 
CRTAP Downregulated No Downregulated
PDIA4 Downregulated No Downregulated
BLMH Downregulated Yes Downregulated
GINM1 Downregulated Yes Upregulated
OAZ2 Downregulated No Upregulated
DENND10 Downregulated No Upregulated
UBQLN2 Downregulated Yes Upregulated
ASIC1 Downregulated No Downregulated
PSAT1 Downregulated No Upregulated
PUDP Downregulated No Downregulated
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Table 4.9. Log fold change values-filtered differentially expressed  genes 
Table listing the DE genes in response to miRNAs overexpression filtered according to log 
fold change values; only those highlighted in red are statistically significant; last column shows 
the expression status of the same genes in M1 macrophages, according to the RNA-seq 




Gene Control vs miR-155-5p miR-155-5p target gene M0 vs M1 
LIN7A Downregulated No Downregulated
LGI2 Downregulated No Downregulated
S1PR3 Downregulated No Downregulated
CDC25A Downregulated No Downregulated
SYT1 Downregulated Yes Downregulated
RGS18 Downregulated No Downregulated
E2F2 Downregulated Yes Downregulated
FGD5 Downregulated No Downregulated
MPEG1 Downregulated Yes Downregulated
ANTXR1 Downregulated No Downregulated
Gene Control vs miR-125a-3p miR-125a-3p target gene M0 vs M1 
SLCO5A1 Downregulated Yes Upregulated
CCL1 Downregulated Yes Upregulated
UBD Downregulated Yes Upregulated
CHST3 Downregulated Yes Upregulated
CCR7 Downregulated Yes Upregulated
ACOD1 Downregulated No Upregulated
PTGS2 Downregulated Yes Upregulated
TRAF1 Downregulated Yes Upregulated
DYRK1A Downregulated Yes Upregulated
GUCY1A1 Downregulated No Upregulated
Gene Control vs miR-186-5p miR-186-5p target gene M0 vs M1 
SPIN3 Downregulated No Downregulated
EDNRB Downregulated No Downregulated
MRO Downregulated No Downregulated
FAM124B Downregulated Yes Downregulated
GPC5 Downregulated No Upregulated
C15orf41 Downregulated No Downregulated
AL139260.3 Downregulated No Upregulated
ASIC1 Downregulated No Downregulated
DLG2 Downregulated No Upregulated
LOXL4 Downregulated No Upregulated
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4.4. Summary 
Macrophages are involved in a multitude of physiological and pathological conditions. Hence, 
understanding the mechanisms behind their activation can lead to the identification of novel 
therapeutic targets. It has been reported that one of the major mechanisms regulating 
macrophages polarisation towards different phenotypes is transcriptional regulation (Martinez 
et al., 2006, Tugal et al., 2013). To date, a significant number of studies pointed out the 
potential role of miRNAs (Jablonski et al., 2016, Li et al., 2018, Curtale et al., 2019). However, 
the association of miRNA and their target genes in macrophages remains elusive, due to the 
lack of integrated and systematic studies.  
The work described in this chapter was designed to address the transcriptional changes induced 
by inflammatory stimuli, with a focus on miRNAs targetome. We investigated the gene 
expression profile of human macrophages challenged with LPS and INF-, taking advantage 
of computational tools and 3 RNA-seq experiments. We performed a small non-coding RNA-
seq on polarised MDMs and identified 73 miRNAs differentially expressed in M1 
macrophages, 44 were downregulated and 26 upregulated. Among them, we found miR-155-
5p which is on the most characterised in the context of pro-inflammatory macrophages and it 
was previously shown to control multiple genes (Jablonski et al., 2016). By using TargetScan 
we identified the potential target genes of differentially expressed miRNAs. We used 
TargetScan as its prediction is strongly based on phylogenetic conservation of miRNA-binding 
sites, which in turn can be predictive of biological relevance (Agarwal et al., 2015). We 
determined the expression of potential target genes using a second RNA-seq experiment, 
carried out on the same number of samples and experimental conditions. The differentially 
expressed genes between M0 and M1 macrophages were 5681. We observed that 1573 
upregulated genes are predicted targets of 44 downregulated miRNAs. Similarly, 1790 
downregulated genes are potential targets of 26 upregulated miRNAs. This is suggesting that 
more than 50% of the macrophage transcriptome could be controlled by miRNAs, during 
polarisation. However, we did not validate any of the interactions, therefore we are not sure 
whether all the predictions occur in our model. Gene ontology and KEGG pathway enrichment 
analysis indicate that the target genes of downregulated miRNAs are related to innate immune 
responses, while those targeted by upregulated miRNAs have a role in cell cycle regulation. 
Our enrichment analysis was consistent with what Jiang and colleagues reported in murine 
polarised macrophages (Jiang et al., 2017). In addition, we identified 9 “super regulators” 
miRNAs (miR-7-5p, miR-125a-3p, miR-3614-5p, miR-4773, miR-186-5p, miR-4709-3p, 
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miR-1343-3p, miR-766-3p, miR-335-3p) predicted to target more than 500 genes. In fact, the 
potential of miRNAs relies on their ability to simultaneously target multiple genes and the same 
gene can be regulated by multiple miRNAs at the same time (Bartel et al., 2009). In light of 
this, we determined the impact of two super regulators (miR-125a-3p and miR-186-5p) and 
miR-155-5p as positive control on unpolarised macrophage transcriptome. To this aim we 
employed the RNA-seq of samples transfected with miRNA mimics and a non-targeting 
control. As expected we did not find many statistically significant differentially expressed 
genes, due to either the variability among the individuals or the difference in transfection 
efficiency. Moreover, it is recognised that despite miRNAs are master regulators of gene 
expression, their individual effect on target genes is likely to be small (Liu et al., 2019). This 
is particularly evident if we compare it with the effect induced by M1 polarising stimuli after 
24 hours, which was strong and robust as shown by the PCA analysis. The mimics transfection 
was also carried on for 24 hours, as it was found efficient, for example, in causing the 
repression miR-101-3p target genes (TRIB1, DUSP1 and ABCA1), described in Chapter 3. 
Nevertheless, among the two datasets (M0/M1 RNA-seq and miRNA/control RNA-seq) we 
did find gene overlapping and the same directional changes in expression.   
Overall our findings indicate the existence of a gene network controlled by multiple miRNAs, 
which account for the regulation of the most relevant biological pathways activated or 
repressed during M1 macrophage polarisation. Further work is needed to validate miRNA 
target interactions and perform dedicated assay to evaluate the biological impact of super 















Chapter 5. miRNAs targeting TRIB1 non-coding variants and 
identification of two novel eQTLs 
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Abstract 
Non-coding single nucleotide polymorphisms (SNPs) are the most common variation in the 
human genome, affecting mRNA stability and disease susceptibility. SNPs in regulatory 
regions of the genome, can alter gene expression in a tissue-specific manner, acting as 
Expression Quantitative Trait Loci (eQTLs). The TRIB1 gene, a key regulator of cancer, 
inflammation and lipid metabolism, is characterised by a highly unstable transcript, it is 
enriched in non-coding variants and it is subject to post-transcriptional regulation with a 
context-dependent function. However, the role of non-coding SNPs in the post-transcriptional 
regulation of TRIB1 has not been investigated. We hypothesised that an association between 
TRIB1 non-coding variants and miRNA-binding sites exists as a mechanism of gene 
expression regulation. To investigate this, we took advantage of both computational and 
experimental approaches. In this chapter, we showed that TRIB1 genetic variants affect 
miRNA-target sites, by creating new binding sites. When tested in vitro, rs62521034 and 
rs56395423 significantly impaired TRIB1 gene stability (p=0.002, p=0.01) and rs62521034, 
but not the reference allele, was able to bind to miR-29a-3p (p=0.03), a miRNA implicated in 
cancer, inflammation and cardiovascular disease. By using an RNA microarray dataset 
generated within the Cardiogenics Consortium, we found that rs3201475 and rs62521034, 
located in the 5’UTR and 3’UTR of TRIB1, respectively, are associated with a significant 
reduction in the expression of distant genes (NLRC4, p=1.34E-07 and MRPS21, p =3.70E-06), 
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acting as trans-eQTLs. Although we demonstrated that TRIB1 non-coding SNPs have an effect 
on post-transcriptional regulation of TRIB1 itself and other genes, additional work is needed 
to investigate the impact of TRIB1 SNPs particularly in the context of disease. 
 
5.1. Introduction 
Single-Nucleotide Polymorphisms (SNPs) represent the most abundant genetic variation in the 
human genome, responsible for the diversity among individuals, such as differences in 
response to drugs, microorganisms, vaccines and other agents, as well as disease susceptibility 
and outcome. For this reason, SNPs are subject of intense genetic investigations for the 
development of personalised medicine (Laing et al., 2011). By definition, SNPs are 
substitutions of a single nucleotide in specific positions of the genome, estimated to occur 
approximately every 100-300 bases and present in more than 1% of the population; small 
insertions and deletions (INDELs) are also classified as SNPs (Brookes et al., 1999, Orr and 
Chanock, 2008). It has been reported that the majority of SNPs occur in non-coding regions of 
the genome. The main function of these non-coding variants is to regulate gene expression 
(Ward et al., 2012, Tak et al., 2015). Several studies reported that genetic variants in the 5’ 
untranslated region (5’UTR) of protein-coding genes affect translation. For example, Khan and 
colleagues found that a SNP in the 5’UTR of p53, the “guardian” of the genome, impairs 
translation by compromising internal ribosome entry sites (IRES) and ribosomal assembly 
(Khan et al., 2013). A number of SNPs have been also identified to affect the Kozak consensus 
sequence (containing the initiation codon required for translation) and impair translational 
outputs (Xu et al., 2010). Moreover, it is well established that regulatory SNPs can account for 
tissue-specific differential gene expression: these are named Expression Quantitative Trait Loci 
(eQTLs). By definition, eQTLs are genetic variants affecting local (cis-acting) and distal (trans-
acting) gene expression by mechanisms that are still not fully understood (Gilad et al., 2008, 
The GTEx Consortium, 2013). To date, multiple cis- and trans-eQTLs have been discovered: 
for example, the intronic SNP rs3129934, associated with an increased risk of multiple 
sclerosis (Comabella et al., 2008), is a cis-eQTL for several HLA transcripts (Wellcome Trust 
Case Control Consortium, 2007). Mangravite and colleagues identified the SNP rs9806699 as 
cis-eQTL for the gene glycine amidinotransferase (GATM) and they observed that there is an 
association with statin exposure and the risk of statin-induced myopathy (Mangravite et al., 
2013). Interestingly, the variation in gene expression mediated by SNPs is often due to the 
activity of endogenous microRNAs (miRNAs). miRNAs are abundant and critical in 
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maintaining the transcriptional profile of all tissues, therefore SNPs affecting miRNA-target 
sequences can perturbate gene expression and lead to disease traits (Sethupathy et al., 2008). 
For example, a SNP found in the oncogene MDM4 (rs4245739) creates new binding sites for 
miR-191 and miR-887-3p and this has been associated with decreased viability and 
proliferation of prostate cancer cells in vitro (Stegeman et al., 2015). Similarly, a SNP found 
in the 3’UTR of apolipoprotein C-III (APOC3) has been shown to create a binding site for 
miR-4271, increasing the risk of hypertriglyceridemia and coronary heart disease (CHD), due 
to APOC3 accumulation (Hu et al., 2016). SNPs can also abolish miRNA-binding sites: for 
instance, a single nucleotide substitution found in the 3’UTR of the heparin binding epidermal 
growth factor (HBEGF) has been shown to destroy the binding site for miR-1207-5p, leading 
to HBEGF dysregulation, which in turn aggravates C3-glomerulopathy (Papagregoriou et al., 
2012). Besides these, many other SNP/miRNA axes have been characterized, particularly in 
cancer (Wilk et al., 2018).  
The TRIB1 gene is a regulator of inflammation, metabolism and cancer and its function has 
been intensively investigated in the context of myeloid disorders and metabolic diseases (Satoh 
et al., 2013, Eyers et al., 2017). Multiple studies have reported that TRIB1 is characterized by 
a highly unstable transcript and a context-dependent expression (Sharova et al., 2009, 
Soubeyrand et al.,2016). Previously, we have shown that TRIB1 undergoes miRNA-mediated 
post-transcriptional regulation. According to different miRNA-target prediction tools, TRIB1 
is a potential target of multiple miRNAs; by knocking down DICER1 and blocking miRNA 
biogenesis in human macrophages, we observed that TRIB1 RNA expression tends to increase 
(see Chapter 3). Interestingly, genome-wide association studies (GWAS) have identified 
several SNPs in the TRIB1 gene linked to high plasma lipids, high cholesterol and triglycerides 
and the risk of cardiovascular disease (Kathiresan et al., 2008, Aulchenko et al., 2009, Wang 
et al, 2015). However, to date there is no information about the role of non-coding SNPs in the 
post-transcriptional regulation of TRIB1, as well as their impact on miRNA-binding sites and 
disease traits. Therefore, we investigated the association between 3’UTR SNPs and miRNAs, 
as well as the existence of regulatory eQTLs, employing both bioinformatics and experimental 
tools. We showed, for the first time, that TRIB1 non-coding variants influence miRNA-
mediated gene regulation, by creating multiple 3’UTR binding sites. We experimentally 
validated a non-canonical miRNA-target interaction (offset seed, 3-9) between a 3’UTR SNP 
(rs62521034) and miR-29a-3p. Also, we identified cis- and trans-eQTLs that have not been 
reported before. Overall, our results provide new insights into TRIB1 post-transcriptional 
regulation, suggesting that both SNPs and miRNAs play a role; however, due to the limitations 
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of this study, more experimental validation is needed (see Section 5.4. Limitations of this 
study). 
 
5.2. Hypothesis and aim of this study 
We hypothesised that an association between TRIB1 non-coding variants and miRNAs exists 
as a mechanism of gene expression regulation. Therefore, the aim of this study was to identify 
SNPs affecting miRNA-binding sites and investigate whether they associate with gene 

































5.3.1. Impact of the 3’UTR of TRIB1 on mRNA stability 
We first evaluated the impact of the 3’UTR of TRIB1 on mRNA stability, by using a dual 
luciferase reporter assay. We used two renilla luciferase reporter plasmids: a control plasmid 
with the renilla luciferase gene and a TRIB1 3’UTR reporter (consisting of the same plasmid 
with the 3’UTR of TRIB1 cloned downstream of the renilla luciferase gene). These were co-
transfected in HEK293T cell line in combination with a firefly luciferase reporter, used as 
internal control for data normalisation. The result is shown in Figure 5.1.: the presence of the 
3’UTR of TRIB1 significantly impaired (p = 0.0004) the gene reporter activity, causing a 42% 
reduction; this suggests that the 3’UTR of TRIB1, downstream of the renilla gene, exert a 
negative translational effect. We are not sure whether this is due to post-transcriptional 
regulation of TRIB1 by endogenous miRNAs expressed by HEK293T cells. However, we have 
previously showed that the 3’UTR of TRIB1 is enriched in miRNA-binding sites and inhibiting 
DICER1 in human macrophages resulted in the increase of TRIB1 mRNA and protein levels 
(see Chapter 3). Therefore, we do not exclude that the reduction of the reporter activity is due 





Figure 5.1. Impact of the 3’UTR of TRIB1 on mRNA stability 
Relative luciferase activity measured in HEK293T cell line after 24 hours co-transfection of a 
renilla luciferase reporter (control plasmid, no UTR) and a TRIB1 3’UTR reporter with a firefly 
luciferase control (required for normalisation). Total DNA transfected 100 ng/well (96-well 
plate). Data are presented as mean  SEM (unpaired t-test, n = 12, *** p < 0.001).  
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5.3.2. Identification of TRIB1 non-coding variants affecting miRNA-binding 
sites 
To determine whether TRIB1 3’UTR variants have an impact on miRNA-binding sites, we 
used the miRNA-target prediction algorithm miRanda to align human mature miRNA 
sequences with TRIB1 non-coding variants. The algorithm was downloaded and used as an 
independent script (http://microrna.org, August 2010 release). We applied a score cutoff of  
140 and a free energy threshold of 1 kcal/mol (default settings). These are considered non-
stringent parameters (Marin et al., 2011). As input files for the algorithm, we used TRIB1 
reference sequence (transcript variant 1, NM_025195.4) and 90 variants affecting the 3’UTR 
of TRIB1, downloaded from NCBI database (https://www.ncbi.nlm.nih.gov/snp). The TRIB1 
SNPs were downloaded as short sequences containing IUPAC ambiguity codes, therefore we 
pre-processed them using Python (Python v3.6.2/BioPython v1.70) to generate the full-length 
3’UTR sequences carrying each SNP (see Chapter 8, Appendix IV). An example of a SNP 
before and after the processing in Python in shown in Figure 5.2., while the complete list of 
TRIB1 variants is provided in Chapter 8 (Appendix IV). After executing miRanda, we used 
Python to organise the output file into tables. We created a table for the reference transcript 
and a table for all the SNPs; we then imported the tables in mySQL (pgAdmin tools version 4) 
and used structural queries to intersect each dataset and find, for example, common interactions 
and non-common interactions. By using this approach, we found that 62 of 90 3’UTR variants 
create new miRNA-binding sites for 135 distinct miRNAs which have not been detected for 
the reference allele (Table 5.1.); most of these variants are associated with a minor allele 
frequency (MAF) of less than 1% and only 6 SNPs are present in more than 1% of the 
population. We did not find any abolished interaction but we found that a number of SNPs 
modify the alignment score and the free energy values for multiple miRNAs, compared to the 
reference transcript. Possibly, those SNPs are predicted to modify the affinity of miRNAs for 
the 3’UTR of TRIB1, by either enhancing or weakening the interaction. However, as 
mentioned earlier, we used miRanda algorithm relying on relaxed parameters, therefore we do 
not exclude the possibility of abolished interactions. Next, we compared our output with the 
output generated by PolymiRTS (Version 3.0, http://compbio.uthsc.edu/miRSNP/) an online 
database, based on the miRNA-target prediction algorithm TargetScan (Bhattacharya et al., 
2014). The output from PolymiRTS is shown in Table 5.2.: 13 distinct 3’UTR SNPs create 
new binding sites for 29 miRNAs; the SNPs and miRNAs highlighted in yellow are those 
which are overlapping with our analysis. TargetScan is usually more stringent than miRanda 
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and it also considers the phylogenetic conservation of miRNA-target interaction. Therefore, it 
is not surprising that, using miRanda, we found a greater number of SNPs creating novel target 
sites. However, miRanda allowed us to detect also non-canonical binding sites which are 




Figure 5.2. Example of SNP sequence before and after Python processing 
SNP in TRIB1 downloaded as IUPAC ambiguity code (Y, C>T) flanked by two small 
sequences (A) was pre-processed in Python before the use of miRanda algorithm in order to 
generate the 3’UTR full-sequence containing the SNP (B). 
 
gnl|dbSNP|rs62521034|allelePos=256|totalLen=511|taxid=9606|snpclass=1|alleles='C/T'|mol=Genomic|build=151
CCTACTGCAC CCCTGGTTTG AGTCCGTCTT GGAACCCGGG TACATCGACT CAGAAATAGG
AACTTCAGAC CAGATTGTTC CAGAGTACCA GGAGGACAGT GACATTAGTT CCTTCTTCTG
CTAATCCCCA AAACCTCAGA AACCTCATAA TTCTTAACAC CTGGCATTTC CATTTCTAAA
GATGGACAGG CCCTTTGGCG TGGTACCAAC CAGATAATGA CTGCATCAGG ATGAAAGCTG
CTGAACTCGG CATGG
Y
GCCTCCTCTT CTCTGTTGGG ATGAGTGACT TTATTGATTT GAGCAGCATA TGCTGTGATT
GGCTGCCCTG CAAATTTGTT TCCCTTAAGG AACCCTCACC AACTATCTCT GCTGGATTTG
GGAGTTCCGC ATCTTTTGTG GAGGGCAGAG TATGGACATC TTACACCCGG TGGTCAAGTG






























Table 5.1. List of TRIB1 3’UTR SNPs creating new miRNA-binding sites 
List of TRIB1 non-coding SNPs creating new miRNA-binding sites, not detected for the reference 
allele. Highest population MAF refers to the highest Minor Allele Frequency observed in a population, 
taken from Ensembl database (https://www.ensembl.org). The prediction analysis was carried out using 
the algorithm miRanda (http://www.microrna.org/microrna/home.do); score cut off  140; free energy 
threshold 1 kcal/mol. 
 




rs751789944    C/- <1% miR-6508-5p, miR-8067, miR-4683 
rs754065243    A>T <1% miR-452-5p, miR-4719 
rs755860381    C>G <1% miR-6721-5p, miR-3126-3p, miR-4776-5p 
rs756175087    -/G <1% miR-652-3p, miR-6847-5p 
rs756397904    T>C <1% miR-3944-3p 
rs757344260    G>A <1% miR-7159-3p 
rs758576660    C/A/G <1% miR-544b 
rs758819773    A>G <1% miR-4685-3p, miR-4755-5p, miR-4287 
rs367637074   C>T < 1% miR-487a-3p, miR-3678-5p 
rs372324007   C>T < 1% miR-4477b 
rs375565353   A>G < 1% miR-4477b 
rs530681133    C>T < 1% miR-6508-3p 
rs533208547    C>G < 1% miR-6504-3p 
rs546479447    C>T < 1% miR-6797-5p, miR-4428, miR-4726-5p, miR-4776-5p 
rs550939781    C>T < 1% 
miR-130a-3p, miR-130b-3p, miR-301b-3p, miR-3666, miR-4295, miR-
454-3p 
rs557685029    G>A>C < 1% miR-659-3p 
rs560408937    C>T < 1% miR-6861-5p, miR-1229-5p, miR-3140-3p 
rs564442600    C>G < 1% miR-6841-5p 
rs72647345   C>T < 1% miR-454-3p 
rs72647346   C>G < 1% miR-4491, miR-4657 
rs72647347   G>A < 1% miR-145-3p 
rs759347835    C>G>T < 1% miR-190a-3p, miR-466, miR-500a-3p, miR-502-3p, miR-5580-3p 
rs761444485    G>A < 1% miR-6886-3p 
rs762994344    T>C < 1% miR-184 
rs764779399    T>A < 1% miR-211-5p, miR-4287, miR-4685-3p 
rs765360657    T>C < 1% miR-629-5p  
rs767431696   C>T < 1% miR-3121-3p 
rs768403240   G>A < 1% miR-4729, miR-181c-5p 
rs770137661   A>G>T < 1% miR-4653-3p, miR-3159 
rs772580999    C>G < 1% miR-4520-5p 
 158 
rs775724040    C>T < 1% miR-4477a 
rs776325924    C>T < 1% miR-7153-5p 
rs776449618    G>A < 1% miR-4784, miR-1262, miR-1269, miR-4428, miR-4515, miR-4529-3p 
rs777539484    TGTGAATGATTATTG/TG < 1% miR-4776-3p 
rs777776886   C>T < 1% miR-19b-5p, miR-620 
rs780519373   C>T < 1% miR-655-5p 
rs140952648   A>G 1% miR-8070 
rs145449131   C>T 1% miR-6768-5p 
rs149107463   C>A>T 1% 
miR-125b-3p, miR-4738-3p, miR-4769-3p, miR-548g-3p, miR-6801-5p, 
miR-6817-5p 
rs529289692    G>A 1% miR-452-5p 
rs530790403    T>C 1% miR-3686 
rs539767360    G>T 1% 
miR-942-3p, miR-98-3p, let-7a-3p, let-7b-3p, let-7f-1-3p, miR-300, miR-
3616-3p, miR-381-3p, miR-4761-3p, miR-493-5p, miR-624-3p 
rs540547779    C>T 1% miR-335-5p 
rs544175527    G>A 1% miR-607 
rs544226392    G>A 1% miR-6888-3p, miR-5699-3p 
rs546022723    A>T 1% 
miR-875-3p, miR-18a-5p, miR-3978, miR-519d-3p, miR-520g-3p, miR-
526b-3p 
rs546842228   C>T 1% miR-6736-5p, miR-1262, miR-4701-3p 
rs552692797    C>T 1% miR-3928-5p, miR-6806-3p 
rs554138846    T/TT 1% miR-488-5p, miR-597-5p 
rs555208281    A>G 1% miR-148a-5p 
rs555485182    A>G 1% miR-429, miR-1278, miR-200b-3p, miR-200c-3p  
rs568362286    C>T 1% miR-4744 
rs568453644    T>A 1% miR-21-5p 
rs568845890    G >A 1% miR-542-3p 
rs575198443    C>T 1% miR-148a-5p 
rs577356981    A>G 1% miR-518c-3p, miR-518e-3p 
rs548386397    G>C 2% miR-6516-3p, miR-4666a-5p 
rs80023284   G>A 6% miR-3920, miR-3929 
rs74486799   A>G 7% miR-4523, miR-4740-3p 
rs56395423   A>C>G 9% miR-4464, miR-4525, miR-4748, miR-5705, miR-6740-5p  
rs62521034   C>T 22% miR-593-5p, miR-29a-3p, miR-29b-3p, miR-506-3p, miR-767-5p 
rs2235108   G>A 41% miR-4659b-5p 









Table 5.2. Output generated by PolymiRTS database 3.0 
List of TRIB1 non-coding SNPs creating new miRNA-binding sites according to PolymiRTS database 
(version 3.0). Function class C=created, D=deleted (deleted binding sites are shown only for the 






Allele miR ID miRSite 
Function 
Class 







rs62521034  SNP  C  




































































































G  hsa-miR-4740-3p  caTCTCGGGgtgg C 
    
rs80023284  SNP  G  A  hsa-miR-3920  aTAATCAGcttct C 
rs76707681  SNP  A  
































































A  hsa-miR-3200-5p  TCAGATAaaatat C 








T  hsa-miR-3613-3p  tgtTTTTTTGtct C 
rs145449131  SNP  C  
C  hsa-miR-657  AACCTGCgtgtct D 
T  hsa-miR-6768-5p  aaCCTGTGTgtct C 
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5.3.3. Effect of TRIB1 3’UTR SNPs on gene reporter activity 
For experimental validation, we selected the two SNPs listed in Table 5.3. that we have 
generated in vitro through site-directed mutagenesis. Figure 5.3. shows the confirmation of 
3’UTR mutants by Sanger sequencing. We have chosen a triallelic (rs56395423) and a biallelic 
(rs62521034) SNP with a population frequency higher than 1% and associated with more than 
one miRNA. Moreover, both SNPs have not been linked to any clinical trait or disease 
susceptibility and they have not been investigated in the context of miRNA-mediated gene 
regulation. Therefore, we tested the impact of these two SNPs on the regulatory function of the 
3’UTR, using the reporter assay. We found that both rs56395423 and rs62521034 caused a 
small, significant reduction in the luciferase activity (17% reduction, p=0.01 and 20% 
reduction, p=0.002, respectively) (Figure 5.4.). However, for the triallelic SNP rs56395423 
only one allele (C), the less frequent in the population, had a negative effect on TRIB1 mRNA, 
while the other one (G) did not show any significant effect, compared to the reference sequence. 
In fact, the minor allele C is associated with 5 new miRNAs, whereas the allele G is predicted 
to create only 1 novel miRNA binding site. However, we cannot conclude that the negative 
impact of rs56395423 and rs62521034 is specifically due to the activity of endogenous 
miRNAs, because of the lack of experimental evidence. As they caused a reduction in the gene 
reporter activity and then in TRIB1 expression itself, rs56395423 (A>C) and rs62521034 
(C>T) are likely to be cis-eQTLs, which are tissue-dependent. This suggests that the assay 
could give different results in a different cell line/environment.   
 
  
Table 5.3. TRIB1 non-coding variants selected for experimental validation 
Triallelic and biallelic SNPs in TRIB1 3’UTR predicted to create new miRNA-binding sites 








SNP ID Allele Highest MAF Associated miRNAs
rs56395423 A>C <1% miR-4464, miR-4525, miR-4748, miR-5705, miR-6740-5p
rs56395423 A>G 9% miR-5705
rs62521034 C>T 22% 






Figure 5.3. Confirmation of TRIB1 3’UTR mutants: Sanger sequencing results 
TRIB1 3’UTR mutagenesis to generate rs62521034 (A) and rs5695423 (B) was confirmed by 












Figure 5.4. Effect of TRIB1 non-coding SNPs on gene reporter activity 
Relative luciferase activity measured in HEK293T cell line after 24 hours co-transfection of 
TRIB1 3’UTR reporter (reference allele and 3 minor alleles) with a firefly luciferase control 
(required for normalisation). Total DNA transfected 100 ng/well (96-well plate). Data are 
presented as mean  SEM (One Way ANOVA with Dunnett’s multiple comparison test n = 4-





















5.3.4. Experimental validation of rs62521034/miR-29a-3p interaction 
For the experimental validation of SNP/miRNA interaction, we selected rs62521034, as it is 
the SNP with the biggest impact on the luciferase reporter activity. According to our in-silico 
analysis, rs62521034 creates novel binding sites for miR-29a-3p, miR-29b-3p, miR-506-3p, 
miR-593-5p, miR-3612, miR-650, miR-767-5p. The alignment of these miRNAs with the SNP 
and the reference transcript are shown in Figure 5.5, along with the algorithm score, free-
energy values and seed-region type. Despite the fact we used the algorithm applying non-
stringent parameters (score threshold  140, free-energy threshold 1 kcal/mol), the predicted 
interactions between rs62521034 and miRNAs show an optimal alignment score (>140) and 
free energy (≤ -15). Interestingly, the seed region pairs for miR-29a/b-3p and miR-593-5p are 
non-canonical matches, as they start from the 3rd miRNA nucleotide and end with the 9th 
(“offset” 7-mer, 3-9). This seed region type is not widespread and it has not been investigated. 
However, there are a few studies showing that offset seed matches are functional in repressing 
the expression of target genes (Manzano et al., 2015, Broughton et al., 2016). Therefore, we 
experimentally validated the non-canonical interaction between rs62521034 and miR-29a-
3p/miR-29b-3p which belong to the same miRNA family and have the same seed region, 
despite small changes in the sequence. We performed a luciferase reporter assay and we used 
miR-29a-3p mimic in combination with the reporter plasmids, thus causing an overexpression 
of the miRNA within the host cell line. In line with our prediction, miR-29a-3p caused a small, 
significant reduction (15%, p=0.03) of the luciferase activity only when co-transfected with 
the rs62521034 reporter plasmid. No effect was observed for the reference allele (p=0.7) 
(Figure 5.6.). This confirms that off-set 3-9 non-canonical binding sites are functional. By 
using published literature, we identified some biological conditions in which both miR-29 and 
TRIB1 are active players, often with opposing roles (Table 5.4.). In fact, miR-29a/b is an 
established tumour suppressor, while TRIB1 is known to be overexpressed in cancer, acting as 
an oncogene. Moreover, both miR-29 and TRIB1 have been implicated in hepatic lipid 
metabolism and cardiovascular disease. Therefore, the interaction between miR-29 and the 










Figure 5.5. miRNA-target alignment calculated by the algorithm miRanda 
The figure shows the alignment of rs62521034 and TRIB1 reference transcript with miR-29a-
3p, miR-29b-3p, miR-593-5p, miR-506-3p and miR-767-5p along with the score and free 
energy predicted by miRanda and seed-region type (seed region classification according to 
Bartel et al., 2009, Seok et al, 2016). miRanda algorithm was used with relaxed parameters 







Free energy: -26 kcal/mol
Seed-region type: canonical 7mer site
(2-8)






Free energy: -15 kcal/mol
Seed-region type: non canonical, offset 7 
mer (3-9) 














Free energy: -21 kcal/mol
Seed-region type: non canonical, offset 
7 mer (3-9)








Free energy: -20 kcal/mol
Seed-region type: non canonical, offset 
7 mer (3-9)






Free energy: -23 kcal/mol
Seed-region type: canonical 8mer site
(2-9)









Figure 5.6. Experimental validation of rs62521034/miR-29a-3p interaction 
Relative luciferase activity measured in HEK293T cell line after 24 hours co-transfection of 
TRIB1 3’UTR reporter (reference allele and rs62521034) with a firefly luciferase control 
(required for normalisation) and miR-29a-3p mimic/negative control. Total DNA transfected 
was 100 ng/well, total RNA transfected was 50 nM/well (96-well plate). Data are presented as 
mean  SEM (One Way ANOVA with Bonferroni’s multiple comparison test n = 5, * p < 0.05, 
ns p > 0.05).  
 
Table 5.4. miR-29a/b and TRIB1 involvement in cancer and metabolism 
The table lists some of the biological processes and diseases in which both miR-29a/b and 
TRIB1 are actively involved, often with opposing roles.  
 
miR-29a/b-3p TRIB1 
Biological Process/Disease Status/Effect Biological Process/Disease Status/Effect 
Acute myeloid leukemia 
(Wang et al., 2012) 
Downregulated Acute myeloid leukemia  
(Röthlisberger et al., 2007) 
Upregulated 
Prostate cancer 
(Ru et al., 2012, Zhu et al., 2018) 
Downregulated Prostate Cancer 




(Wang et al., 2017) 
Downregulated Hepatocellular carcinoma 
(Ye et al., 2017) 
Upregulated 
Lung cancer 
(Liu et al., 2018)   
Downregulated Lung cancer 




(Kurtz et al., 2015) 
Increased lipogenesis Hepatic lipogenesis 

















5.3.5. Identification of two novel trans-eQTLs 
Next, we investigated whether TRIB1 non-coding variants have an effect on global gene 
expression. To do this, we used the microarray RNA data produced in the Cardiogenics 
Transcriptomic Study (CTS) (Heinig et al., 2010, Schunkert et al., 2011, Rotival et al., 2011). 
We found that two non-coding SNPs in TRIB1, one located on the 3’UTR rs62521034 
(previously discussed) and one in the 5’UTR rs3201475 are associated with a small, but 
significant reduction in the expression level of two distant genes: MRPS21 (Mitochondrial 
Ribosomal Protein S21) and NLRC4 (NLR family CARD domain containing 4), located on 
chromosome 1 and chromosome 2, respectively (p=0.0000037 and p=0.000000134) (Table 
5.5.). Rs62521034 and rs3201475 are then likely to be trans-eQTLs. To further substantiate 
this, we used a publicly available RNA-seq (GSE81046) of human monocyte-derived 
macrophage samples taken from 169 healthy individuals (Nedelec et al., 2016). Rs62521034 
was found in 20 individuals, whilst rs3201475 in 33 individuals; 10 of 169 donors carry both 
SNPs. We found that TRIB1 mRNA expression significantly correlates (negative correlation) 
with the expression of MRPS21 and NLRC4 (p<0.0001 and p=0.0005) (Figure 5.7. B, C). 
Although the low p-values indicate significance, the r squared values for both genes are low 
(r2= 0.20 and r2=0.07), suggesting that correlation of TRIB1 with MRPS21 and NLRC4 is 
weak, at least in this dataset. However, when we consider only those individuals carrying the 
SNPs (30 individuals for rs62521034 and 43 for rs3201475), there is a small improvement of 
the r squared values (r2= 0.30 and r2=0.13) (Figure 5.7. D, E). As TRIB1 has never been 
associated with these genes before, further work is required to confirm the role of the two non-
coding SNPs rs62521034 and rs3201475 as trans-eQTLs.  
 
Table 5.5. Identification of two novel trans-eQTLs 
Illumina Human Ref-8 Bead Chip array of 849 monocyte and 684 macrophage samples 
collected from 459 individuals with cardiovascular disease (394 males and 65 females) and 
458 controls (192 males and 266 females). Two SNPs located in the untranslated regions of 
TRIB1 are associated with a significant reduction in MRPS21 and NLRC4 genes. EA: effect 
allele; NEA: non-effect allele; EAF: effect allele frequency; beta:effect size estimate; beta_se: 
standard error of the beta; pvalue: statistical significance (cut off p value <0.05); rsq: r squared; 
FDR: false discovery rate.  
 
 
SNP_ID ILMN_Gene EA NEA EAF beta beta_se pvalue Rsq FDR
rs62521034 MRPS21 C T 0.8247 -0.07555 0.016202 3.70E-06 0.4465 9.43E-01





Figure 5.7. TRIB1 expression negatively correlates with MRSP21 and NLRC4 in 
GSE81046 dataset 
Total number of individuals and number of individuals carrying TRIB1 SNPs in GSE81046 
dataset (A); XY correlation between TRIB1 and MRSP21 (Counts per Million, n = 169, 
Pearson r test, **** p < 0.0001, r2=0.20) (B); XY correlation between TRIB1 and NLRC4 
(Counts per Million, n = 169, Pearson r test, *** p = 0.0005, r2=0.07) (C); XY correlation 
between TRIB1 and MRSP21 (Counts per Million, n = 30, Pearson r test, ** p < 0.003, r2=0.30) 
(D); XY correlation between TRIB1 and NLRC4 (Counts per Million, n = 43, Pearson r test, * 
p < 0.02, r2=0.13) (E).  
 

































































It is well appreciated that the 3’UTR of mRNA is fundamental in controlling the post-
transcriptional fate of protein-coding genes (Pesole et al., 2001). It is also well known that any 
mutation in this regulatory region further impact gene expression outcomes, by either 
enhancing and inhibiting post-transcriptional events (Chatterjee and Pal, 2009). The 
importance of the 3’UTR relies on the presence of multiple regulatory sequences, including 
miRNA-binding sites, AU-rich elements and a poly(A) tail which mediate export, stability, 
decay and expression of a transcript (Matoulkova et al., 2012). Interestingly, what happens to 
the 3’UTR of a gene influence the expression of other genes (Skeeles et al., 2013) and this has 
been often linked to the presence of genetic polymorphisms and the activity of endogenous 
miRNAs (Wilk et al., 2018). Therefore, investigating the association between SNPs and 
miRNAs is essential to unravel the molecular mechanisms underlying the complex post-
transcriptional regulation of eukaryotic genes. In this study, we focused on the TRIB1 gene. 
TRIB1 is characterized by a long (1934 bp) and conserved 3’UTR sequence and its mRNA has 
a half-life of less than 1 hour, hinting it is highly unstable and post-transcriptionally regulated 
(Sharova et al., 2009). In fact, we have previously reported that TRIB1 is negatively regulated 
by miR-101-3p, miR-132-3p and miR-214-5p in macrophages and in prostate cancer (see 
results Chapter 3 and Chapter 6).  Here, we have shown that polymorphisms in the 3’UTR of 
TRIB1 has an impact on miRNA-mediate gene regulation, by creating novel binding-sites and 
modifying the affinity of existing ones. Using a luciferase reporter assay, we observed that the 
regulatory region of TRIB1 itself exerts a negative effect on gene stability and expression, 
causing a 42% reduction in the luciferase activity (see Figure 5.1.). The presence of two SNPs 
(rs62521034 and rs56395423) further reduces the reporter activity, suggesting that these 
variants confer more instability to the TRIB1 gene (see Figure 5.2.). Both SNPs have been 
predicted to create novel miRNA-binding sites, characterised by good alignment scores and 
free energy values (see Figure 5.3.). As they affect TRIB1 expression, they are likely to be cis-
eQTLs but we need more experimental evidence to make a conclusion. Also, in our experiment 
the negative effect of the TRIB1 SNPs is relatively small (17-20%) and this could depend on 
the endogenous expression level of regulatory proteins and factors (including miRNAs) within 
the host cell line, which have not been investigated in the present work. Moreover, performing 
this assay using a different microenvironment and employing multiple cell lines would perhaps 
give us more answers about the impact of rs62521034 and rs56395423 on TRIB1 expression 
and whether it strictly depends on the presence and level of tissue-specific regulators. In 
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addition, we identified a non-canonical seed region match between rs62521034 and miR-29a/b-
3p and experimentally validated it as functional (see Figure 5.4.). This type of seed region is 
rare and to date only a few cases have been described (Manzano et al., 2015). According to 
published literature, either TRIB1 or miR-29a/b is implicated in acute myeloid leukemia 
(Röthlisberger et al., 2007, Wang et al., 2012) and in prostate cancer (Moya et al., 2018, Zhu 
et al., 2018), with contrasting roles: miR-29 is a tumour suppressing miRNA and it is usually 
downregulated, while TRIB1 plays the oncogene role. Whether they are correlated and whether 
their interaction is involved in these diseases, still remains to be investigated. Lastly, by using 
a published microarray dataset from myeloid cells, we identified two trans-eQTLs: TRIB1 non-
coding SNPs rs3201475 (5’UTR, highest MAF 48%) and rs62521034 (3’UTR, highest MAF 
22%) cause a small, but significant reduction in the expression of two distant genes (NLRC4 
and MRPS21, respectively). By using a public transcriptomic dataset carried out on human 
monocyte-derived macrophages, we found that TRIB1 expression negatively correlates with 
these genes (see Figure 5.5). However, the low r squared values indicate that the correlation is 
weak and there is no previous association of TRIB1 with NLRC4 and MRPS21. Therefore, a 
deeper investigation is required.  
 
5.5. Limitations of the study  
Although the association between TRIB1 SNPs and miRNAs has not been investigated before, 
the work presented in this Chapter has some limitations. First, we used only one miRNA-target 
prediction tool, miRanda, employing “relaxed” settings. On one hand, this allowed us to detect 
non-canonical binding sites which are recently emerging as functional. In fact, the non-
canonical interaction that we have tested in vitro were functional, despite the small effect on 
the gene reporter activity (approximately 15%). On the other hand, miRanda is usually 
associated with a high number of false positives, so applying stringent parameters (i.e. reduce 
free energy threshold) and a second screening with a different algorithm (i.e. TargetScan) could 
improve the accuracy of the output, by reducing the number of positive interactions and 
narrowing down the list of SNPs and miRNAs. This will perhaps add a number of miRNA-
binding sites abolished by the presence of SNPs, which we have not detected using miRanda 
algorithm. However, also the output generated by PolymiRTS do not show any abolished 
interaction for any of the minor alleles. We could further improve this analysis, by filtering the 
list of miRNA sequences and selecting only high-confidence miRNAs, which have been 
recently added in miRbase database, the “home” of miRNAs 
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(ftp://mirbase.org/pub/mirbase/CURRENT/). In fact, some of the novel miRNAs associated 
with TRIB1 SNPs are not confidentially annotated and often there is no knowledge about them. 
The second limitation of this study was the limited access to publicly available data and, above 
all, the lack of web-based tools enabling the correlation between miRNAs and their targets in 
a given tissue/disease using pre-existing data. For this reason, we could not investigate whether 
a correlation between TRIB1/rs62521034 and miR-29a-3p exists and if it could have an impact 
in acute myeloid leukaemia or in other types of cancer (see Table 5.4). Moreover, despite being 
confident about the identification of the two novel trans-eQTLs, we need more robust and 
convincing data. A good pilot experiment to understand whether those genes are somehow 
related will be a siRNA-mediated knockdown of TRIB1, followed by RT-qPCR and western 
blot for NLRC4 and MRPS21 gene and protein expression. Also, it would be useful to correlate 
the mRNA expression of TRIB1, NLRC4 and MRPS21 using different public transcriptomic 






















Chapter 6. miRNAs targeting TRIB1 in Prostate Cancer 
Declaration 
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biology of prostate cancer. Both the in silico and in vitro part of this chapter have been entirely 
performed by me. A huge thanks to Swapna Satam and Ziyanda Shologu for sending me RNA 
samples from prostate cancer cell lines and also to Dr Alessandra Iscaro for giving me prostate 
tissues from mice.  
Abstract 
Prostate cancer (PCa) is one of the most common male cancers in the western world with a 
poor long-term prognosis. Current treatment for PCa is based on a combination of endocrine 
therapy, radical prostatectomy, standard cycles of chemotherapy and radiotherapy. However, 
as the disease progresses the majority of patients experience relapse. Hence, the identification 
of new molecular targets and the development of new therapeutic strategies is critical. It is well 
established that microRNAs (miRNAs) have pivotal roles in PCa development and 
progression, as they are frequently silenced by epigenetic modifications, thus perturbing the 
expression of multiple genes. Recent studies have shown that the pseudo-kinase Tribbles-1 
(TRIB1) plays a crucial role in the proliferation and propagation of PCa. TRIB1 mRNA is 
overexpressed in PCa and regulates the ER chaperone GRP78, essential for prostate 
tumorigenesis. However, the mechanisms behind TRIB1 upregulation remain unclear. Here we 
investigate the potential association between TRIB1 overexpression and miRNA silencing in 
PCa, using both bioinformatics and experimental tools. Our results confirmed that TRIB1 is 
overexpressed in PCa cell lines, compared to cells derived from normal prostatic epithelium, 
as well as in a murine prostate cancer model. We identified 140 downregulated miRNAs in 
PCa and 21 of them are predicted to target the 3’UTR of TRIB1. We showed that miR-132-3p, 
an onco-suppressor miRNA, has two functional binding sites for the 3’UTR of TRIB1. miR-
132-3p was able to negatively modulate TRIB1 expression in vitro, inducing a gene expression 
profile that recapitulated the TRIB1 knockdown phenotype. The latter was associated with 
changes in the expression of pro-inflammatory cytokines and tumour-related genes. The 
overexpression of TRIB1 in PCa may be explained by the downregulation of endogenous 
miRNAs, thus offering an interesting, novel therapeutic target. Further work is needed to 




Prostate cancer (PCa) is one of the most common solid cancers in elderly males worldwide. 
Each year over 1,500,000 men are diagnosed with PCa and over 360,000 men die (Rawla et 
al., 2019). Established risk factors for PCa are age, genetics and family history, bad eating 
habits, sedentary life and lack of physical activity and also ethnicity. It has been reported that 
for African-American men both the incidence and mortality rates are higher compared to white 
men (Rawla et al., 2019). The causes of this are not fully understood, but likely due to genetic 
diversity (Huang et al., 2017). PCa is a slow-growing tumour: it starts in the prostate gland but 
over time it can spread throughout the body, most often in the bones and in lymph nodes. In 
patients affected by PCa, metastasis is the main cause of death (Rycaj et al., 2017). From a 
pathological point of view, the majority of PCa (>95%) consist of adenocarcinomas, which is 
a tumour developing in the gland cells (Alizadeh et al., 2014). Although the majority of cases 
are asymptomatic, patients suffering from PCa mainly experience urinary symptoms and sexual 
dysfunction (Merriel et al., 2018). Treatment of PCa usually depends on the stage of the 
disease. For years, androgen deprivation therapy (ADT), via both surgery and drugs, was the 
gold standard for the treatment of both early stages and advanced metastatic PCa and it has 
also been successfully combined with radiation therapy (Gomella et al., 2010). However, 
hormone suppression treatment inevitably leads to the development of castration-resistance 
within 18-36 months (Nakazawa et al., 2017) and recently this treatment has also been 
associated with the risk of developing dementia and Alzheimer disease (Jayadevappa et al., 
2019). Therefore, further treatments are needed. At the moment available options include 
chemotherapy, radiotherapy, immunotherapy, cryosurgery and high-intensity focused 
ultrasound therapy (HIFU) (Vieweg et al., 2007, Rodriguez et al., 2014, Chaussy et al., 2017, 
Nakazawa et al., 2017). Immunotherapy and vaccines-based therapies are particularly 
promising in the treatment of PCa, because it naturally progresses slowly and provides enough 
time to activate immune responses (Janiczek et al., 2017): for example, the vaccine Sipuleucel-
T (Provenge®) has been associated with an increased survival of patients with castration-
resistant PCa, reducing the risk of mortality by 22% (Kantoff et al., 2010). The vaccine targets 
the prostatic acid phosphatase (PAP) which is upregulated in PCa and correlates with a poor 
prognosis and survival (Kantoff et al.,2010, Kong et al., 2013, Janiczek et al., 2017).  
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Genetics of PCa 
PCa is one of the most heterogeneous cancers and no single gene is responsible for it (Yadav 
et al., 2018). However, numerous genetic aberrations have been associated with primary and 
metastatic tumours, including mutations in the genes coding for androgen receptor (AR), 
phosphatase and tensin homolog (PTEN), proto-oncogene Myc (MYC), erythroblast 
transformation specific (ETS)-transcription factor (ERG), Homeobox Protein NK-3 Homolog 
A (NKX3-1), adenomatous polyposis coli (APC), breast cancer susceptibility genes (BRCA1 
and BRCA2), ATM Serine/Threonine Kinase (ATM) and Speckle Type BTB/POZ Protein 
(SPOP) (Wang et al., 2018). It has been reported that the mutational burden in PCa is lower 
compared to other cancers. In fact, a recent genome cancer study showed that in PCa the 
median mutation frequency per megabase is lower (0.7) when compared to other malignancies 
(i.e. for bladder cancer is 7.1) (Lawrence et al., 2014). Besides genetic mutations, a large 
number of epigenetic modifications, including DNA and histone modifications, have been 
identified in PCa (Baumgart et al., 2017), as well as SNPs (Benafif et al., 2018). Interestingly, 
SNPs have been associated not only with the risk of developing PCa but also with cancer 
aggressiveness, survival and mortality (Sullivan et al., 2015, Benafif et al., 2018, Moya et al., 
2018).  
Downregulation of microRNAs in PCa 
Aberrant expression of microRNAs (miRNAs) has been implicated in the development and 
progression of many cancers, including PCa (Vanacore et al., 2017). miRNAs control the 
expression of genes involved in proliferation and apoptosis, thus acting as oncogenes and 
tumour suppressors (Zhang et al., 2007). However, in PCa the majority of miRNAs appear to 
be downregulated and most often silenced by epigenetic modifications (Ozen et al., 2007, 
Coppola et al., 2010, Ramassone et al., 2018). Formosa and colleagues observed that miR-18b, 
miR-132, miR-34b/c, miR-148a, miR-450a and miR-542-3p were downregulated in PCa 
specimens compared to control samples and this was associated with promoter CpG island 
methylation, unmasked by 5-aza-2′-deoxycytidine treatment (Formosa et al., 2013). In 
particular, miR-132-3p has been shown to simultaneously target the 3’UTR of heparin-binding 
epidermal growth factor (HB-EGF) and TALIN2, thus impairing cellular motility, adhesion 
and proliferation (Formosa et al., 2013). HB-EGF and TALIN2 are usually overexpressed in 
PCa supporting invasion and metastasis (Ongusaha et al., 2004, Desiniotis et al., 2011) 
Similarly, the miR-145 promoter region is methylated in both tumour samples and prostate 
cancer cell lines and its loss correlates with a poor survival of PCa patients (Zaman et al., 2010, 
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Avgeris et al., 2013). Other examples of silenced miRNAs in PCa are miR-338-5p and miR-
421, which have been shown to target the 3’UTR of SPINK1 (Serine Peptidase Inhibitor Kazal 
Type 1) (Bhatia et al., 2019), a gene usually upregulated in PCa and responsible for a more 
aggressive cancer subtype (Tomlins et al., 2008). The downregulation of miRNAs can be an 
important mechanism underlying the overexpression of genes involved in the prostate 
carcinogenesis, which are not necessarily altered by genetic mutations. Therefore, identifying 
and restoring the expression of de-regulated miRNAs could be a good approach to reduce the 
level of oncogenes and increase the expression of tumour suppressor genes. 
The potential role of TRIB1 in PCa 
As briefly explained in Chapter 1 (General Introduction), the TRIB1 gene has been implicated 
in PCa. To date only a few studies have been published covering this topic. Mashima and 
colleagues reported that TRIB1 was upregulated in prostate clinical tissues and in PCa cell line 
spheroid cultures (3D condition), compared to adherent cultures (2D condition). TRIB1 
knockdown was associated with a decrease in cell proliferation, while TRIB1 overexpression 
increased tumour cells growth; by employing a soft agar assay, they also showed that TRIB1 
knockdown impaired colony formation, while its overexpression significantly enhanced it. 
Moreover, overexpression of TRIB1 was linked to a significant reduction in the expression 
level of endoplasmic reticulum (ER) chaperones, including GRP78, GRP94 and GRP170 
(Mashima et al., 2014). These are well known to promote carcinogenesis (Gutiérrez et al., 
2014). Taken together these data suggest a fundamental role for TRIB1 in the growth and 
survival of PCa. However, no mutations in the gene have been described as causative of PCa 
and no mechanisms have been found responsible for its upregulation. However, a short tandem 
repeat (STR) was found in the 3’UTR of TRIB1 and it was significantly associated with 
prostate cancer risk and aggressiveness (Moya et al., 2018). The authors suggested that this 
STR could alter TRIB1 mRNA structure and stability, which in turn could affect TRIB1 
expression in an allelic-dependent manner and it could also be linked to miRNA activity (Moya 
et al., 2018). Other evidence supporting the role of TRIB1 in PCa comes from the work 
published by Lin and colleagues in 2014: they found that TRIB1 is a direct target of miR-224, 
a miRNA downregulated in PCa. By forcing the expression of miR-224 in PCa cell lines, they 
observed a decrease in cell proliferation, invasion and migration which was TRIB1-dependent 
(Lin et al., 2014).  
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6.2. Hypothesis and aim of the study  
The dysregulation of onco-suppressor miRNAs plays a central role in the development and 
progression of PCa. This is particularly true for miRNAs silenced by epigenetic modifications 
(i.e. promoter hypermethylation) that, in turn, cause the overexpression of their target genes. 
TRIB1 exerts an oncogenic role in PCa but the mechanisms underlying its upregulation are 
still unknown. Therefore, we hypothesize that the overexpression of TRIB1 gene in PCa is due 
to the downregulation of multiple microRNAs. The purpose of this study is to in silico identify 
and characterize downregulated miRNAs that potentially binds to the 3’UTR of TRIB1, post-
























6.3.1. Data mining of PCa datasets: cBioPortal for Cancer Genomics 
To understand the extent of TRIB1 contribution to PCa, we first carried out a data mining 
analysis using the cBioPortal for Cancer Genomics (https://www.cbioportal.org/). We 
investigated TRIB1 genomic alterations frequency, mRNA expression and overall survival in 
PCa patients, selecting 20 different studies for a total of 5051 patients and 5315 samples (details 
listed in Table 6.1.). 4952 of 5051 patients were profiled and TRIB1 alterations were found in 
383 patients and in 414 samples, thus accounting for the 8% of the integrated dataset (Figure 
6.1.). TRIB1 genomic alteration frequency was calculated in 15 of 20 datasets and ranged from 
40% (Neuroendrocrine Prostate Cancer, Multi-Institute, Nat Med 2016) to 1.75% (Prostate 
Adenocarcinoma, Broad/Cornell, Cell 2013) (Figure 6.2. A). When we filtered based on 
cancer type, TRIB1 was mostly mutated in castration-resistant PCa (41.43%) and 
neuroendrocrine PCa (31.48%) (Figure 6.2. B) However, in all cases the most abundant 
alteration was genomic amplification. Transcriptomic data were available for 3 of 20 selected 
studies, consisting of tumour/normal pairs (baseline, normal = 0) and showed overexpression 
of TRIB1 mRNA, even in the absence of genomic amplification (Figure 6.2. C). Finally, the 
overall survival (Kaplan-Meier estimate, calculated in 7 of 20 studies) showed a significant (p 
= 2.27e-13) decrease in the survival of TRIB1 positive patients, compared to TRIB1 negative 
















Table 6.1.  cBioPortal for Cancer genomics: selected studies 
Twenty published studies were selected from cBioPortal for Cancer Genomics (2012-2019), 
they include genomic, transcriptomic and clinical data obtained from metastatic prostate 
carcinoma, metastatic prostate adenocarcinoma, prostate adenocarcinoma-derived organoids 
















Combined Studies from cBioPortal for Cancer Genomics Number of Patients 
Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012) 119
Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019) 429
Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015) 150
Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016) 81
Prostate Adenocarcinoma (Broad/Cornell, Cell 2013) 82
Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012) 123
Prostate Adenocarcinoma (CPC-GENE, Nature 2017) 477
Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016) 63
Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) 238
Prostate Adenocarcinoma (MSKCC, PNAS 2014) 104
Prostate Adenocarcinoma (MSKCC/DFCI, Nature Genetics 2018) 1013
Prostate Adenocarcinoma (SMMU, Eur Urol 2017) 65
Prostate Adenocarcinoma (TCGA, Cell 2015) 334
Prostate Adenocarcinoma (TCGA, Firehose Legacy) 500
Prostate Adenocarcinoma (TCGA, PanCancer Atlas) 494
Prostate Adenocarcinoma Organoids (MSKCC, Cell 2014) 7
Prostate Cancer (DKFZ, Cancer Cell 2018) 292
Prostate Cancer (MSK, 2019) 10
Prostate Cancer (MSKCC, JCO Precis Oncol 2017) 451





Figure 6.1.  Screenshot of cBioPortal for Cancer Genomics showing the summary of 
TRIB1 alterations in PCa 
The figure is a screenshot taken from cBioPortal for Cancer Genomics: 4952 of 5051 patients 
were profiled for TRIB1 and alterations were found in 383 patients and in 414 samples (8%). 





Figure 6.2. Data mining of PCa datasets show TRIB1 gene amplification  
TRIB1 gene frequency alterations in 19 of 20 selected studies (A); TRIB1 gene frequency 
alterations filtered base on cancer types (4 of 5 categories shown) (B); TRIB1 RNA expression 
profile (RNA-seq) of 6 of 20 studies also showing the type of mutations (C). Graphs generated 
by cBioPortal for Cancer Genomics. CNA: copy number alterations; VUS: variance of 










Figure 6.3. Overall Survival Kaplan-Meier estimate 
Overall survival Kaplan-Meier estimate of prostate cancer cases with (red) and without (blue) 
TRIB1 alterations, calculated by cBioPortal for Cancer Genomics, shows a significant decrease 
in survival of patients between the two groups. However, the survival data of patients coming 
from different studies may have been defined by different criteria. Graph generated by 





















6.3.2. Assessment of TRIB1 gene expression in human and mouse models of 
PCa by RT-qPCR 
Next, we characterized the endogenous expression of TRIB1 mRNA in a panel of prostate 
cancer cell lines (described briefly in Table 6.2.) by using RT-qPCR. TRIB1 expression was 
significantly higher in PC3 (4-fold change, p < 0.0001), 22RV1 (3-fold change, p = 0.03) and 
LNCAP (2-fold change, p = 0.02) but not in DU145, which shows a TRIB1 expression similar 
to the controls (p > 0.9) (Figure 6.4. A) We also measured the level of murine Trib1 mRNA, 
isolated from prostate tumour of wild-type NU/J mice injected with either LNCAP cells or PBS 
as control (intra-prostatic injections). The cancer was allowed to grow for 30 days and prior to 
the RNA isolation, tumour development was assessed by gross examination. Despite LNCAP 
being human cells, Trib1 mRNA levels were significantly increased in LNCAP injected mice, 
compared to PBS control (p = 0.03) (Figure 6.4. B), suggesting that the tumour development 
and growth itself in the prostate gland may be responsible for upregulating Trib1 mRNA. We 
also checked the murine Trib1 RT-qPCR primers’ target specificity by using the web-based 
tool BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). As shown in Figure 6.5., 
Trib1 primers specifically amplified the Trib1 mouse gene and not the human one, which does 
not come up as “predicted” off-target. A predicted off target activity of the primers is for the 
transcript variant X7 of the human gene FER1L6, but with 4 nucleotides mis-matches in both 
the forward and the reverse strands, therefore this is unlikely to happen.  
 
Table 6.2. Overview of the human prostate cell lines used in the present study 
A total of seven cell lines has been used: three metastatic cancer cells (PC3, DU145 and 
LNCAP), one xenograft (22RV1) and three immortalised epithelial cells derived from normal 
prostatic tissue (PWRE1, RWPE1 and PNT1A). PC3, DU145 and PNT1A do not express or 
express at low levels the androgen receptor. LNCAP cells have also been used to generate a 




Cell line Characteristics Androgen Receptor
PC3 Human Prostatic Adenocarcinoma, Bone Metastasis -
DU145 Human Prostatic Adenocarcinoma, Brain Metastasis -
LNCAP Human Prostate Carcinoma, Lymph Nodes Metastasis +
22RV1 Human Prostate Carcinoma, Xenograft +
PWRE1 Human Prostatic Epithelial Cells, Normal +
RWPE1 Human Prostatic Epithelial Cells, Normal +
PNT1A Human Prostatic Epithelial Cells, Normal -
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Figure 6.4. Assessment of TRIB1 RNA expression in human and mouse models of PCa 
Relative level of TRIB1 RNA normalised to the housekeeping GAPDH in a panel of prostate 
cell lines (normal vs cancer) (mean ± SEM, Ordinary One Way Anova, n =3-6 , **** p<0.0001 
** p<0.002, * p<0.05, ns p>0.05) (A); relative level of murine Trib1 RNA normalised to the 
housekeeping Gapdh in prostate tissue from control mice and prostate tumour from mice 
injected with LNCAP cells (normal vs tumour) (mean ± SEM, unpaired t-test, n =4-11, * 
p<0.05) (B); schematic illustration of the prostate cancer mouse model, obtained by injecting 
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Figure 6.5. Assessment of murine Trib1 primers’ target specificity using BLAST Primers 
tool 
The figure is a screenshot taken from the BLAST Primers tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/), showing the specificity of murine Trib1 



















6.3.2. Identification of downregulated miRNAs potentially targeting TRIB1 
Once established that TRIB1 is amplified and overexpressed in different PCa datasets and 
upregulated at the RNA level in human and mouse models of PCa, we investigated whether 
miRNAs downregulated in PCa target the 3’UTR of TRIB1, causing its overexpression. We 
used miRCancer database (October 2019 release) (http://mircancer.ecu.edu/index.jsp) and 
found that a total of 168 distinct miRNAs are dysregulated in different models of PCa: 133 of 
168 are downregulated, while 51 are upregulated (complete list is in Chapter 8, Appendix V). 
However, 16 miRNAs are listed as either down or up-regulated, according to different studies. 
We focused on the downregulated miRNAs and among them we found 21 miRNAs predicted 
to target TRIB1 according to three different miRNA-target prediction tools (miRanda, 
TargetScan and StarBase), as explained in Chapter 2 (Figure 6.6.). Table 6.3. lists the 
candidate miRNAs targeting TRIB1 and relevant publications. To understand the potential 
biological impact of these miRNAs on TRIB1, we further analysed the output generated by 
TargetScan (version 7.2, released in March 2018), shown in Table 6.4. with a description of 
the scores and the main parameters of the algorithm in the table legend. All miRNAs are 
predicted to bind to the 3’UTR of TRIB1 and some of them have two different binding sites 
(let-7a-3p, miR-23a-3p, miR-101-3p, miR-130a-5p, miR-132-3p, miR-150-3p, miR-212-3p). 
They are characterized by a seed region pairing of 7-8 nucleotides (7-8mers) with different 
conformations (7mers 1A and M8). These two types of seed region strongly correlate with 
targeting efficiency and are selectively conserved (Friedman et al., 2009). The context++ and 
the weighted context++ scores, which are predictive of the efficicacy of the sites (Agarwal et 
al., 2015) are low, negative numbers, suggesting a great predicted activity for all miRNAs. In 
addition, all the miRNAs, expect for let-7a-3p, show a good context++ score percentile ranging 
from 62 to 99, suggesting that these sites on TRIB1 are more favourable than other sites of the 
same miRNA family. In fact, the context++ score percentile represents the percentile rank of 
each site compared to all sites of the same miRNA family: values between 50 and 100 indicates 
that that specific site is more favourable than most other sites of the same miRNA family. The 
context++ branch length, representing the site conservation, is also good, particularly for miR-
23a-3p, miR-23b-3p, miR-101-3p, let-7a-5p, let-7c-5p and miR-144-3p (threshold: 8mer >= 
1.8; 7mer-m8 >= 2.6; 7mer-1A >= 3.6). Finally, the PCT, calculated from the context++ branch 
length, indicates that some interactions are conserved due to their biological relevance. 
However, the algorithm calculates this only for highly conserved miRNA families. We 
previously have showed that miR-132-3p and miR-101-3p are able to modulate TRIB1 
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expression in both human and murine macrophages and miR-101/TRIB1 interaction was 
experimentally validated in our lab (see Chapter 3). Similarly, miR-224 was shown to modulate 
TRIB1 in a 3D model of PCa by Lin and colleagues (Lin et al., 2014). Therefore, we assessed 
the expression of these three miRNAs in prostate cancer cell lines by RT-qPCR. Consistent 
with published data, all the miRNAs were downregulated in cancer cells compared to control 
cells. miR-132-3p and miR-224-5p downregulation was the most robust in all cancer cell lines 
and miR-224-5p was not detected in PC3 and 22RV1 cell lines. miR-101 was significantly 
downregulated in PC3 (p = 0.04), but not in DU145, LNCAP and 22RV1 (p = 0.7, p = 0.10, p 





Figure 6.6. Identification of downregulated miRNAs targeting TRIB1 
miRCancer database was used to identify dysregulated miRNAs in PCa. A total of 162 
miRNAs was found to be altered: 133 of 168 are downregulated, 51 of 168 are upregulated and 
16 have been reported by several groups to be either down- or upregulated. Among the 
downregulated miRNAs, we found 21 potential regulators of TRIB1 gene, which have been 
previously associated with other targets in PCa. The miR-target prediction analysis was carried 
























Table 6.3. Candidate miRNAs downregulated in PCa and predicted to target the 3’UTR  
of TRIB1 
List of miRNAs downregulated in PCa, predicted to target TRIB1 according to three different 

















miRNAs Cancer Status Publications
hsa-let-7a Prostate Cancer Downregulated Dong et al., 2010, Tang et al., 2018
hsa-let-7c Prostate Cancer Downregulated Nadiminty et al., 2012
hsa-miR-101 Prostate Cancer Downregulated Hao et al., 2011, Chakravarthi et al., 2016, Huang et al., 2017
hsa-miR-10a Prostate Cancer Downregulated Mu et al., 2019
hsa-miR-129 Prostate Cancer Downregulated Xu et al., 2015, Xu et al., 2017
hsa-miR-130a Prostate Cancer Downregulated Ramalho-Carvalho et al., 2017
hsa-miR-132 Prostate Cancer Downregulated Formosa et al., 2013, Qu et al., 2016, Li et al., 2018
hsa-miR-144-3p Prostate Cancer Downregulated Zheng et al., 2018
hsa-miR-150 Prostate Cancer Downregulated Hong et al., 2019
hsa-miR-154 Prostate Cancer Downregulated Zhu et al., 2014
hsa-miR-212 Prostate Cancer Downregulated Borrego-Diaz et al., 2014, Ramalinga et al., 2015
hsa-miR-22 Prostate Cancer Downregulated Xin et al., 2016
hsa-miR-224 Prostate Cancer Downregulated Fu et al., 2015, Lin et al., 2014, Goto et al., 2014
hsa-miR-23a Prostate Cancer Downregulated Cai et al., 2015
hsa-miR-23b Prostate Cancer Downregulated Majid et al., 2012
hsa-miR-302a Prostate Cancer Downregulated Zhang et al., 2015
hsa-miR-330 Prostate Cancer Downregulated Lee et al., 2009, Mao et al., 2013
hsa-miR-3619-5p Prostate Cancer Downregulated Li et al., 2017
hsa-miR-372 Prostate Cancer Downregulated Kong et al., 2016
hsa-miR-373-3p Prostate Cancer Downregulated Qu et al., 2018
hsa-miR-382 Prostate Cancer Downregulated Zhang et al., 2016
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Table 6.4. TargetScan miRNA-TRIB1 analysis output 
TargetScan Human 7 output for candidate miRNAs targeting TRIB1 showing the binding site position 
on the 3’UTR, the seed region type, the context++ score (CS), the context++ score percentile (CSP), 
the weighted context++ score (WCS), the conserved branch length (CBL) and the probability of 
conserved targeting (PCT). The CS for a specific site is the sum of the contribution of 14 features, 
described by Agarwal et al., 2015: the lowest CS is the most favourable; the CSP is the percentile rank 
of each site compared to all sites of the same miRNA family: values between 50 and 100 indicates that 
that specific site is more favourable than most other sites of the same miRNA family. The WCS 
represents the predicted efficacy of the sites: scores with lower negative values indicated greater 
predicted activity (Nam et al., 2014). The CBL represents the site conservation (threshold: 8mer >= 1.8; 
7mer-m8 >= 2.6; 7mer-1A >= 3.6). The PCT, calculated only for the highly conserved miRNA families, 
ranges from 0 to 1 and it estimates that a site conserved to a particular branch length is conserved 
because of its targeting activity; it is then a measurement of the biological relevance of the interactions, 
as it correlates with the mean level of target destabilization, as reported by Friedman et al., 2009. The 




miRNA 3'UTR position Seed type CS CSP WCS CBL Pct 
hsa-let-7a-2-3p 1851-1857 7mer-m8 -0.14  86 -0.13 0.054 N/A 
hsa-let-7a-3p 1113-1119 7mer-1A -0.01  25 -0.01 0.054 N/A 
hsa-let-7a-5p 1518-1524 7mer-1A -0.22  78 -0.2 6.307 0.94
hsa-let-7c-3p 1538-1544 7mer-m8 -0.05  64 -0.05 1.01 N/A 
hsa-let-7c-5p 1518-1524 7mer-1A -0.22  78 -0.2 6.307 0.94
hsa-miR-101-3p.1 1526-1532 7mer-m8 -0.22  93 -0.21 4.444 0.84
hsa-miR-101-3p.1 1424-1430 7mer-1A -0.04  69 -0.04 3.274 0.22
hsa-miR-10a-5p 391-397 7mer-m8 -0.2  92 -0.2 1.351 < 0.1 
hsa-miR-129-1-3p 1467-1474 8mer -0.43  99 -0.41 3.64 0.49
hsa-miR-130a-3p 630-636 7mer-1A -0.12  82 -0.11 1.817 < 0.1 
hsa-miR-130a-5p 1662-1669 8mer -0.18  90 -0.17 6.643 0.63
hsa-miR-130a-5p 1869-1875 7mer-1A -0.08  74 -0.07 2.746 0.12
hsa-miR-132-3p 554-560 7mer-m8 -0.05  77 -0.05 1.369 < 0.1 
hsa-miR-132-3p 1763-1769 7mer-m8 -0.1  86 -0.09 1.264 < 0.1 
hsa-miR-144-3p 1423-1430 8mer -0.26  96 -0.24 3.196 0.28
hsa-miR-150-3p 79-85 7mer-1A -0.19  79 -0.19 0.054 N/A 
hsa-miR-150-5p 250-256 7mer-m8 -0.15  95 -0.15 0.154 < 0.1 
hsa-miR-150-5p 336-342 7mer-1A -0.2  97 -0.2 0.921 < 0.1 
hsa-miR-154-5p 1635-1641 7mer-m8 -0.06  65 -0.05 2.541 N/A 
hsa-miR-212-3p 554-560 7mer-m8 -0.03  67 -0.03 1.369 < 0.1 
hsa-miR-212-3p 1763-1769 7mer-m8 -0.1  86 -0.09 1.264 < 0.1 
hsa-miR-22-3p 458-464 7mer-m8 -0.13  78 -0.13 0 < 0.1 
hsa-miR-224-5p 157-163 7mer-m8 -0.19  94 -0.19 2.321 N/A 
hsa-miR-23a-3p 1662-1669 8mer -0.21  91 -0.19 6.643 0.63
hsa-miR-23a-3p 1869-1875 7mer-1A -0.07  70 -0.06 2.746 0.12
hsa-miR-23a-5p 221-227 7mer-m8 -0.29  96 -0.29 0 N/A 
hsa-miR-23b-3p 1662-1669 8mer -0.21  91 -0.19 6.643 0.63
hsa-miR-23b-5p 221-227 7mer-m8 -0.3  93 -0.3 0 N/A 
hsa-miR-302a-3p 680-687 8mer -0.18  91 -0.17 1.727 < 0.1 
hsa-miR-330-3p 947-954 8mer -0.03  65 -0.03 0.091 N/A 
hsa-miR-330-5p 1281-1287 7mer-1A -0.07  68 -0.06 2.089 N/A 
hsa-miR-3619-3p 1027-1033 7mer-m8 -0.1  81 -0.1 0 N/A 
hsa-miR-3619-5p 114-120 7mer-1A -0.09  78 -0.09 0.348 N/A 
hsa-miR-372-3p 680-687 8mer -0.2  93 -0.19 1.727 < 0.1 
hsa-miR-372-5p 169-175 7mer-m8 -0.02  63 -0.02 0.054 N/A 
hsa-miR-373-3p 680-687 8mer -0.13  91 -0.12 1.727 < 0.1 





Figure 6.7. Assessment of candidate miRNAs expression in prostate cancer cell lines by 
RT-qPCR 
Relative abundance of miR-132-3p (A), miR-224-5p (B) and miR-101-3p (C) normalised to 
the housekeeping U6 measured in a panel of prostate cancer cell lines by RT-qPCR (normal vs 
cancer) (mean ± SEM, Ordinary One Way Anova, n =3-6, **** p<0.0001, *** p<0.0002, * 
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6.3.3. Validation of miR-132-3p/TRIB1 interaction by gene reporter assay 
According to TargetScan analysis, miR-132-3p has two binding sites for the 3’UTR of TRIB1. 
Despite it not being well conserved (CBL is 1.3 for binding site 1 and 1.2 for binding site 2), 
miR-132-3p/TRIB1 interaction shows a good CS; moreover, miR-132-3p is an established 
onco-suppressor in PCa with multiple targets and it is normally silenced by promoter 
hypermethylation. Table 6.5. lists the experimentally validated targets of miR-132-3p in the 
context of PCa. To investigate whether miR-132-3p binds to the 3’UTR of TRIB1 we used a 
dual luciferase reporter assay. We transiently transfected TRIB1 3’UTR renilla reporter 
plasmid and a firefly reporter plasmid together with miR-132-3p mimic or miR-132-3p 
inhibitor in HEK293T cell line. We observed that in the presence of the mimic the gene reporter 
activity significantly decreased compared to the negative control (38% decrease, p=0.02) 
(Figure 6.8. A), suggesting that the overexpression on miR-132-3p is responsible for TRIB1 
3’UTR destabilization. Indeed, when miR-132-3p was inhibited there was a small increase of 
the luciferase activity (10% increase), meaning that the inhibition of the endogenous miR-132-
3p enhanced TRIB1 expression. However, this was not statistically significant (p=0.09) 
(Figure 6.8. B).  We did not perform miR-132-3p binding site mutagenesis, therefore we 


















Table 6.5. Experimentally validated targets of miR-132-3p and their effect on PCa 
The table lists miR-132-3p target genes which have been experimentally validated, along with 
their biological effect in the context of PCa.  
 
miR-132-3p target gene Downstream effect Reference 
TALIN2 Impairment of cellular adhesion, cell death Formosa et al., 2013 
HB-EGF Impairment of cellular adhesion, cell death Formosa et al., 2013 
E2F5 Reduction of cancer cells viability, increase in apoptosis Li et al., 2018 
GLUT1 Reduction of glycolysis and proliferation Qu et al., 2016 
 
              
 
 
Figure 6.8. miR-132-3p/TRIB1 experimental validation 
Relative luciferase activity measured in HEK293T cell line following 24 hours co-transfection 
of TRIB1 3’UTR-renilla reporter, firefly reporter and miR-132-3p mimic (50nM) (A) and 
inhibitor (25nM) (B) Total DNA transfected was 100ng/well (renilla/firefly readings, mean ± 



























































































6.3.4. Impact of miR-132-3p and TRIB1 on PC3 gene expression  
To evaluate the impact of miR-132-3p on PCa, we transiently overexpressed the miRNA in 
PC3 cell line by using a mimic and in parallel we knocked-down TRIB1 by using a siRNA. 
Figure 6.9. shows the TRIB1 mRNA level following miR-132 overexpression (Figure 6.9. A) 
and siRNA-mediated TRIB1 knockdown in PC3 cell line (Figure 6.9. B), which was reduced 
by 60% (p=0.03) and 80% (p<0.0001), respectively. We then used the same RNA samples to 
investigate the gene expression profile induced by either miR-132-3p mimic and TRIB1 
knockdown and we found similar signatures. The genes we investigated are listed in Table 
6.6.; all of them have been previously implicated in PCa biology, although the literature 
presents opposing and controversial data. We chose IL-1, IL-6 and IL-8 to evaluate the 
inflammatory status and PDL1, SPAR-C and VEGF as cancer-related genes for 
immunoregulation, metastasis and angiogenesis. We observed that the mRNA levels of pro-
inflammatory cytokines IL-1, IL-6 and IL-8 increased in both conditions (Figure 6.10.). 
Specifically, IL-1  significantly increased (1.4-fold change, p=0.004) in TRIB1 knockdown 
cells and in PC3 overexpressing miR-132-3p (1.2-fold change, p=0.04) (Figure 6.10. A, D). 
Both IL-6 and IL-8 mRNA expression was enhanced in TRIB1 knockdown samples (2.4-fold 
change, p=0.001, 1.6-fold change, p=0.008, respectively) (Figure 6.10. E, F). This is in line 
with what we have previously shown in macrophages in Chapter 3: TRIB1 manipulation 
affected IL-6 and IL-8 expression and secretion. Similarly, in PC3 treated with miR-132-3p 
mimic, IL-8 mRNA levels also increased (1.8-fold change, p=0.03), while the changes in IL-6 
were not statistically significant (p=0.2). When we analysed the cancer genes, we also observed 
similar signatures: the expression of SPAR-C was significantly increased in TRIB1 knockdown 
cells by 1.6-fold change (p=0.01), but not in PC3 overexpressing miR-132-3p (p=0.5) (Figure 
6.11. A, D); the expression of PD-L1 was significantly increased in both conditions 
(knockdown 1.9-fold change, p=0.02; mimic 2-fold change, p=0.02) (Figure 6.11. B, E). 






Figure 6.9. Assessment of TRIB1 RNA expression by RT-qPCR after miR-132-3p 
overexpression and TRIB1 knockdown in PC3 cell line 
Relative TRIB1 RNA expression normalised to the housekeeping GAPDH, after 48 hours 
overexpression of miR-132-3p (50 nM) (A) and 48 hours TRIB1 knockdown (50 nM) (B) in 
PC3 cell line. Data are presented as mean  SEM (n = 3-4, unpaired t-test, * p<0.05, **** p < 
0.0001).  
 
Table 6.6. List of genes analysed in transfected PC3 cell line 
The table lists the genes we analysed in transfected PC3 cell line along with their expression 
and function in PCa, according to published literature.  
 
Gene Expression 
in PCa  
Role in PCa Reference 
IL-1, Interleukin 1 +++ Pro-inflammatory, tumorigenic, pro-
metastatic  
Liu et al., 2013,  
Shahriari et al., 2017 
IL-6, Interleukin 6 +++ Pro-inflammatory, multifunctional Culig et al., 2005, Nguyen 
et al., 2014 
IL-8, Interleukin 8 +++ Pro-inflammatory, tumorigenic and 
pro-angiogenic 
Kim et al., 2001, Guo et al., 
2017 
SPAR-C, Secreted 
Protein Acidic and 
Cysteine Rich 
Variable Controversial, inhibition/promotion of 
metastasis 
Thomas et al., 2000, 
DeRosa et al., 2012, Ma et 
al., 2017, Liu et al., 2018 
PD-L1, Programmed 
death-ligand 1 
+++ Immunoregulatory, inhibition of anti-
tumour immunity 










































































Figure 6.10. Impact of miR-132-3p and TRIB1 on pro-inflammatory cytokines in PC3 
cell line 
Relative RNA expression of pro-inflammatory cytokines IL-1, IL-6 and IL-8 normalised to 
the housekeeping GAPDH, after 48 hours overexpression of miR-132-3p (50 nM) (A, B, C) 
and 48 hours TRIB1 knockdown (50 nM) (D, E, F) in PC3 cell line. Data are presented as 






























































































































































































Figure 6.11. Impact of miR-132-3p and TRIB1 on cancer-related genes in PC3 cell line 
Relative RNA expression of SPAR-C, PD-L1 and VEGF normalised to the housekeeping 
GAPDH, after 48 hours overexpression of miR-132-3p (50 nM) (A, B, C) and 48 hours TRIB1 
knockdown (50 nM) (D, E, F) in PC3 cell line. Data are presented as mean  SEM (n = 4, 












































































































































































































Considering the high rates of incidence and mortality of PCa, the identification of new 
molecular targets and therapeutic strategies appears critical (Rawla et al., 2019). A growing 
number of cancer studies highlight the potential of miRNAs: given their ability to 
simultaneously control the expression of multiple genes in virtually all animal tissues, miRNAs 
represent attractive candidates through which we can modulate the expression of oncogenes 
and tumour suppressor genes (Shah et al., 2016). It has been shown that in PCa the majority of 
miRNAs are downregulated and often silenced by epigenetic modifications (Ozen et al., 2007, 
Coppola et al., 2010, Ramassone et al., 2018). As a consequence, the expression of their target 
genes increases. Here, we showed that TRIB1, an established oncogene in acute myeloid 
leukemia (Röthlisberger et al., 2007) and in hepatocellular carcinoma (Ye et al., 2017), is 
overexpressed in PCa and is a direct target of multiple downregulated/silenced miRNAs. 
Previous work showed that TRIB1 is upregulated in PCa both in vitro and in vivo and it 
supports prostate tumorigenesis via regulating ER chaperones (Lin et al., 2014, Mashima et al., 
2014, Moya et al., 2018). A short tandem repeat (STR) found in the 3’UTR of TRIB1 has also 
been linked to PCa risk, aggressiveness and survival (Moya et al., 2018). Still, what is upstream 
of TRIB1 overexpression in PCa remains unclear. In this study, we hypothesised that the 
overexpression of TRIB1 in PCa can be explained by the downregulation of endogenous 
miRNAs. Our bioinformatics analysis of published cancer datasets showed that the most 
frequent alteration in TRIB1 is in genomic amplification; however, the gene is upregulated 
even in the absence of amplification. This was consistent with what was observed by Mashima 
and colleagues (Mashima et al., 2014). We showed that TRIB1 mRNA is overexpressed in 
PC3, LNCAP and 22RV1 cancer cell lines, but not in DU145, compared to non-tumour 
controls (PWRE1, RWPE1 and PNT1A); interestingly, we also found that murine Trib1 mRNA 
tends to increase in mice injected with LNCAP cells, compared to control mice. LNCAP is a 
human derived cell line and this suggests that there might be intrinsic, environmental factors 
in the developed prostate tumour that, in turn, increase Trib1 transcription. However, this 
should be investigated further, using different models and also by looking at Trib1 protein 
levels. By using the miRCancer database and TargetScan prediction algorithm, we identified 
21 downregulated miRNAs, predicted to target the 3’UTR of TRIB1 gene. The majority of 
predicted interactions are characterized by good score alignment, free energy and phylogenetic 
conservation, suggesting a potential biological relevance. We confirmed the downregulation 
of two candidate miRNAs (miR-132-3p and miR-224-5p) in a panel of PCa cell lines and 
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controls by using RT-qPCR and we further substantiated the interaction between miR-132-3p 
and TRIB1 through a luciferase gene reporter assay. We selected miR-132-3p as its expression 
was significantly downregulated in all cancer cell lines and we previously showed that it is able 
to modulate TRIB1 expression in human and murine macrophages (see Chapter 3). Moreover, 
miR-132-3p is well appreciated to be a tumour suppressor miRNA and several targets in PCa 
have already been experimentally validated (see Table 6.5). The gene reporter assay confirmed 
that miR-132-3p mimic exerts a negative effect on the 3’UTR of TRIB1. However, inhibiting 
miR-132-3p had no significant effect on gene reporter activity. This may be explained by the 
variability of transfection efficiency and the low number of biological replicates (n = 3). 
Although our in- silico prediction and luciferase assay data strongly suggest that miR-132-3p 
binds to the 3’UTR of the pseudo-kinase, we cannot conclude that the 2 binding sites are 
functional, due to the lack of mutagenesis experiment. Last, we evaluated the effect of both 
miR-132-3p overexpression and TRIB1 knockdown on PC3 gene expression profile and 
observed similar signatures. Specifically, the mRNA expression of IL-1, IL-6, IL-8, PD-L1 
and SPAR-C is enhanced, suggesting that these genes might specifically respond to TRIB1 
changes. We previously showed that overexpressing TRIB1 in human macrophages results in 
the reduction of IL-6 and IL-8 and we observed the opposite effect in cells treated with miR-
101-3p mimic, regulator of TRIB1 (see Chapter 3). Furthermore, miR-132-3p has been already 
shown to increase IL-8 expression, via directly targeting SirT1 (nicotinamide adenine 
dinucleotide-dependent deacetylase) and modulating nuclear factor  (NF) in adipocytes 
(Strum et al., 2009). The expression of IL-1, IL-6, IL-8 is usually upregulated in PCa patients 
and it has been associated with poor prognosis of PCa and tumorigenic activity (Kim et al., 
2001, Culig et al., 2005, Liu et al., 2013, Nguyen et al., 2014, Guo et al., 2017, Shahriari et 
al., 2017). The immunoregulatory protein PD-L1 is also highly expressed in prostate cancer, 
enabling the tumour to escape the immune system surveillance (Gevensleben et al., 2015), 
while the role of SPAR-C appears to be controversial. In fact, SPAR-C has been implicated in 
PCa and breast cancer bone metastasis with opposite effects: in PCa high expression of SPAR-
C is correlated with a bad prognosis and predicts metastasis progression (Thomas et al., 2000, 
Derosa et al., 2012); in breast cancer it has been shown to inhibit migration and invasion (Ma 
et al., 2017). Interestingly, Liu and colleague observed that SPAR-C is downregulated in PCa 
by promoter hypermethylation and lower levels of SPAR-C mRNA and protein correlate with 
a poorer prognosis (Liu et al., 2018).  
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In conclusion, we demonstrated that TRIB1 is a target of multiple downregulated miRNAs in 
PCa that might represent the mechanisms behind TRIB1 overexpression. We experimentally 
demonstrated that miR-132-3p is able to negatively modulate TRIB1 expression. Although we 
observed similar transcriptional changes induced by miR-132-3p overexpression and TRIB1 
knockdown, further experimental validation is needed to understand whether modulating 
TRIB1 can be beneficial or detrimental for the biology of PCa. In fact, the genes we analysed 
are considered “bad” for patient outcomes, despite the existence of controversial data (Said et 
al., 2009, Kapinas et al., 2012, Shin et al., 2013). Considering the context-dependent function 
of Tribbles proteins (see Chapter 1, section 1.3.3.) we do not exclude the possibility of a dual 
role for TRIB1, as well as “stage” dependent function. Therefore, in vivo experiments are also 
needed.   
 
6.5. Limitations of the study  
The work presented in this Chapter has some limitations. First of all, we have only tested miR-
132-3p, but it would be interesting to investigate the activity of additional miRNAs targeting 
TRIB1, which are downregulated and/or silenced in PCa. This study was focussed on gene 
expression and RNA, but in future it should be also supported with protein data. The interaction 
between miR-132-3p and TRIB1 should be fully validated by involving the use of binding sites 
mutants, as well as a target-site blocker. In addition, the impact of miR-132-3p and TRIB1 
manipulation on gene expression should be tested in animal models to see whether it changes 
in in vivo environments. More relevant genes should be included, as well as in vitro-based 
assay (proliferation, invasion, metastasis) to investigate the influence of miRNAs and TRIB1 












Chapter 7. General discussion and conclusions 
The work described in this thesis explored, for the first time, the post-transcriptional regulation 
of TRIB1 by miRNAs, with the main focus on macrophage and prostate cancer. By taking 
advantage of bioinformatics and miRNA-target prediction tools, we identified multiple 
miRNAs that could potentially target the 3’UTR of TRIB1, thus contributing to its variable 
expression in different tissues, as well as its short half-life and context-dependent function.  
Below we discuss the main findings of this research and their potential biological impact. 
However, further work should be performed in the future, focussing on more mechanistic 
investigations and in vivo models.  
 
TRIB1 is recognised to play a major role in polarising macrophages, by regulating the 
activation of the MAPK cascade and modulating the induction of inflammatory genes (Satoh 
et al., 2013, Arndt et al., 2018). More recently, the pseudo-kinase has been associated with the 
development and progression of prostate cancer (Lin et al., 2014, Mashima et al., 2014, Moya 
et al., 2018, Liu et al., 2019). In fact, TRIB1 is highly expressed in prostate cancer, compared 
to other types of malignancies (Su et al., 2001, Ramaswamy et al., 2003). It has been suggested 
that the mechanism by which TRIB1 affects prostate tumorigenesis involves the regulation of 
endoplasmic reticulum chaperone expression (Mashima et al., 2014). Nevertheless, whilst the 
downstream effectors of TRIB1 are well characterised, the molecular mechanisms by which 
TRIB1 expression itself is regulated are still largely unknown. TRIB1 mRNA has an unusually 
long 3’UTR and has previously been reported to be highly unstable, having a half-life shorter 
than 1 hour (Sharova et al., 2009, Soubeyrand et al., 2016). Therefore, we carried out a 
systematic analysis and experimental validation of the concept that TRIB1 expression is 
regulated via multiple miRNAs and that this, in turn, controls the expression of inflammatory 
genes. We have focussed our research on macrophages and prostate cancer models. We have 
shown that both human and murine TRIB1 are negatively regulated by miR-101-3p and miR-
132-3p. To address the biological impact of these miRNAs, we performed an enrichment 
pathway analysis, using their predicted target genes. Among the top 10 enriched terms for miR-
101-3p target genes we observed MAPK and chemokines mediated signalling pathways; for 
the genes targeted by miR-132-3p one of the most enriched term was prostate cancer. In fact, 
miR-132-3p is a well-established onco-suppressor miRNA and in prostate cancer has been 
shown to be silenced by DNA methylation (Formosa et al., 2013). Similarly, miR-101-3p has 
been documented to play important roles in macrophages, for example by direct interaction 
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with ABCA1 (Zhang et al., 2015) and DUSP1 (Wei et al.  2015), thus controlling metabolic 
and inflammatory responses. Both miRNAs have not been associated with the TRIB1 gene 
before. We demonstrated that, via regulating TRIB1 expression, miR-101-3p and miR-132-3p 
affect inflammatory gene induction in both cellular systems. Specifically, miR-101-3p caused 
a significant increase in the expression of M1 macrophage markers, such as IL-6, IL-8, CD80 
and CD86. However, it did not alter the levels of M2 polarisation markers. This suggests that 
the negative effect of miR-101-3p on TRIB1 is enough to drive an inflammatory phenotype, 
but not to switch off the genetic signatures typical of alternatively-activated macrophages. In 
fact, it is believed that the knockdown effect exerted by miRNAs on their target genes is small 
and seed region dependent (Liu et al., 2019). On the contrary, the experimental overexpression 
of TRIB1 led to a robust increase of M2 macrophage markers, including CD163 and MSR-1. 
On one hand this confirms the crucial transcriptional role of the pseudo-kinase in M2 
polarisation; on the other hand, low levels of TRIB1 promote the induction of M1 genes. 
Similarly, in PC3 cell line, forced expression of miR-132-3p led to an increase of pro-
inflammatory genes, including IL-8 and the cancer related gene PD-L1. We confirmed that this 
was TRIB1-dependent, as the same directional changes were observed in cells treated with a 
TRIB1 siRNA. It has already been shown that TRIB1 overexpression affects the immune 
microenvironment of prostate cancer, promoting the infiltration of CD163+ macrophages (Liu 
et al., 2019), but it has never been linked to the activity of PD-L1, which enables the tumour 
to escape the immune system surveillance (Gevensleben et al., 2015). Therefore, our 
preliminary findings should be validated in the future to address whether TRIB1 has a role in 
influencing the immune escape, which is a well-known obstacle in cancer treatment.  
Overall, the most consistent and robust effect of miRNAs regulating TRIB1 expression was 
the upregulation of IL-8, assessed in both cellular systems. Previously, Kiss-Toth and 
colleagues observed that TRIB1 was able to regulate the activity of the IL-8 promoter in a gene 
reporter assay, but this was not explored further (Kiss-Toth et al., 2006). Similar to TRIB1, the 
IL-8 gene is a key player in numerous inflammatory diseases and cancers (Russo et al., 2014, 
Alfaro et al., 2017). Finding a link between the regulation of TRIB1 and IL-8 might be 











Figure 7.1. miRNAs targeting TRIB1 in macrophages and prostate cancer 
The figure summarises the main findings described in this thesis. The 3’UTR of TRIB1 is 
enriched in miRNAs binding sites, detected by a systematic miRNA-target prediction analysis 
(1); miR-101-3p, miR-132-3p and miR-214-3p regulate TRIB1 expression and function in 
macrophages, thus altering the levels of pro-inflammatory cytokines (2); the onco-suppressor 
miR-132-3p regulates TRIB1 expression and function in prostate cancer, altering the levels of 





A short research was conducted to investigate the impact of TRIB1 non-coding variants on 
miRNA-binding sites. TRIB1 variants have been associated with plasma triglycerides and 
cardiovascular disease risk by numerous independent studies (Kathiresan et al., 2008, Willer 
et al., 2008, Teslovich et al., 2010, Deloukas et al., 2013, Nikpay et al., 2015, van der Harst et 
al., 2018). However, nothing is known about the role of TRIB1 non-coding variants. The 
majority of SNPs in the GWAS catalogue are located in non-coding regions of the genome 
(Tak et al., 2015) and have been reported to be regulators of gene expression at the post-
transcriptional level (Hudson et al., 2003). It has been demonstrated that non-coding SNPs can 
alter miRNA-mRNA interaction, by creating, abolishing or modifying their binding sites 
(Moszyńska et al., 2017). This has been often linked to human diseases or traits, such as prostate 
cancer (Stageman et al., 2015), coronary heart disease (Hu et al., 2016) and type 2 diabetes 
(Goda et al., 2015). Here we reported that multiple SNPs located in the 3’UTR of TRIB1 are 
predicted to alter miRNAs sites. By using a reporter assay, we demonstrated that 2 minor 
alleles, rs62521034 C>T and rs56395423 A>C, have a significant negative impact on TRIB1 
mRNA stability, thus potentially acting as cis-eQTLs for the TRIB1 gene. In fact, rs62521034 
and rs56395423 are predicted to create novel binding sites for 10 miRNAs, which have not 
been predicted to bind to the reference alleles. We validated as functional the interaction 
between rs62521034 C>T and miR-29a/b. This could have a biological impact in the 
pathogenesis and progression of multiple cancers, including acute myeloid leukaemia. In acute 
myeloid leukaemia, TRIB1 acts as an oncogene by promoting the degradation of C/EBPα 
(Dedhia et al., 2010). On the contrary, miR-29a/b is dysregulated and has been reported to 
have an onco-suppressor role, targeting apoptosis, cell cycle and proliferation (Garzon et al., 
2009).  Due to the lack of tools enabling the correlation between miRNAs and their targets in 
a given tissue/disease using pre-existing data, we could not investigate whether a correlation 
between TRIB1/rs62521034 and miR-29a/b exists and if it could have an impact in acute 
myeloid leukaemia or in other types of cancer. Therefore, further investigations are needed.  
In addition, by using the RNA microarray data produced by the Cardiogenics Consortium, we 
identified two potential TRIB1 trans-eQTLs: rs3201475 (5’UTR) and rs62521034 (3’UTR) 
were significantly associated with a small reduction in distant genes: NLRC4, activator of the 
inflammasome and MRPS21, a mitochondrial ribosomal protein. So far, there is no association 
between TRIB1 and these genes. However, considering the role of TRIB1 in inflammation 
(Johnston et al., 2015) and mitochondrial dysfunction (Soubeyrand et al., 2013), this should 
be further explored in the future.  
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Lastly, as a collaborative work, we performed a comprehensive, simultaneous analysis of 
miRNAs and mRNAs in human polarised macrophages by using multiple RNA sequencing 
experiments and downstream bioinformatics analysis. In fact, it is well established that 
miRNAs are master regulators of macrophage polarisation and inflammatory responses, 
controlling hundreds of key genes at the same time (Essandoh et al., 2010). However, the extent 
of miRNA-mRNA networks in macrophage polarisation have not been explored in a 
systematic, integrative manner. Here we have focussed on pro-inflammatory M1-like 
macrophage transcriptomic signatures, looking at both miRNAs and mRNAs. First, by using a 
small RNA seq, we detected 73 differentially expressed miRNAs between M0 and M1 
macrophages, of which 47 were downregulated and 26 were upregulated. Among the 
upregulated miRNA we observed miR-155-5p, which has been previously reported to play a 
major role in regulating M1 macrophage polarisation (Jablonski et al., 2016). After identifying 
candidate miRNAs differentially expressed between M0 and M1 macrophages, we performed 
a target prediction analysis by using TargetScan. We filtered the list of target genes, selecting 
only those expressed by macrophages, using an RNA seq previously generated in our group. 
Interestingly, we found that 1573 genes upregulated in M1 polarised cells were predicted 
targets of 44 miRNAs, which were rather downregulated. Similarly, 1790 downregulated genes 
were predicted to be targeted by 26 upregulated miRNAs. This suggests that miRNAs 
contribute to the dysregulation of more than half of the genes differentially expressed between 
M0 and M1 polarised macrophages. Our pathway enrichment analysis indicated that the target 
genes of downregulated miRNAs participate to cytokine and chemokine signalling pathways, 
antigen presentation, T cell receptor signalling pathway, apoptosis, MAPK signalling pathway. 
On the contrary, the target genes of miRNAs upregulated in M1 cells are involved in DNA 
replication, cell cycle and metabolic pathways. Therefore, miRNAs control the two major 
events of the M1 macrophage activation: immune response and cell cycle. This was also 
consistent with a murine model of macrophage polarisation (Jiang et al., 2017), suggesting that 
the target genes of the differentially expressed miRNAs are conserved between human and 
mouse. In addition, our systematic approach allowed us to identify 9 miRNAs targeting more 
than 500 genes, which we named “super regulators”. None of them have been associated with 
this number of targets before. Therefore, we explored the effect of the experimental 
overexpression of two “super regulators” (miR-125a-3p and miR-186-5p), including miR-155-
5p as a positive control, followed by an RNA-seq experiment. This was carried out on 
unpolarised macrophage and compared to the differential expression analysis previously done 
between M0 and M1 polarised cells. Although we did not observe many statistically significant 
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changes in gene expression, we did find gene overlapping and same directional changes. Gene 
Ontology analysis confirmed that the genes downregulated in response to “super regulators” 
miRNAs take part to the regulation of cell cycle and chromatin segregation. Taken together, 
our results indicate the existence of a macrophage-specific targetome that underlie many of the 
critical biological pathways involved in inflammation and in the classical activation of 
macrophages. Future work will focus on the experimental validation of these findings. This 
could certainly have an impact on the discovery and development of new strategies in the 
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Chapter 8, Supporting Information  
Appendix I, Chapter 2, General Materials and Methods 
A1.1. List of reagents and kits 
Reagent/Kit Company Cat. No 
iScript cDNA Synthesis Kit Biorad 1708891 
miRCURY LNA RT Kit Qiagen 339340 
miRCURY LNA SYBR Green PCR Kit Qiagen 339345 
miRNeasy Mini Kit Qiagen 217004 
RNase-Free DNase Set Qiagen 79256 
Precision Plus 2x qPCR Master Mix with SYBR 
Green 
Primer Design PPLUS-SY-20ML 
GenElute™ HP Plasmid Midiprep Kit Sigma-Aldrich NA0200-1KT 
GenElute™ HP Plasmid Miniprep Kit Sigma-Aldrich NA0160 
Dual Luciferase Reporter Assay Kit Promega E1910 
Human IL-8 DuoSet ELISA R & D DY208 
RealTime-Glo™ MT Cell Viability Assay Promega G9711 
QuikChange II-Site-directed mutagenesis Agilent  200521 
pENTR/D-TOPO directional cloning Invitrogen K240020 
Gateway LR Clonase II enzyme mix Invitrogen 11791020 
E.Coli C2987H NEB  C2987I 
Human Recombinant M-CSF PrepoTech 300-25 
Human Recombinant IL-4 PrepoTech 200-04 
Human Recombinant IL-10 PrepoTech 200-10 
Human Recombinant IFN-γ PrepoTech 300-02 
Human Recombinant M-CSF ImmunoTools 11343117 
E.Coli Lipopolysaccaride Enzo Life Sciences  ALX-581-007-L001 
miR-101-3p mimic Horizon Discovery C-300518-07-0005 
miR-132-3p mimic Horizon Discovery C-300599-06-0005 
miR-214-5p mimic Horizon Discovery C-301153-01-0005 
miR-101-3p inhibitor Horizon Discovery IH-300518-08-0005 
miR-132-3p inhibitor Horizon Discovery IH-300599-05-0005 
Mimic Negative Control Horizon Discovery CN-001000-01-05 
Inhibitor Negative Control Horizon Discovery IN-001005-01-05 
miR-155-5p primer mix Qiagen 339306 
miR-125a-3p primer mix Qiagen 339306 
miR-186-5p primer mix Qiagen 339306 
miR-149-5p primer mix Qiagen 339306 
miR-766-3p primer mix Qiagen 339306 
miR-1343-3p primer mix Qiagen 339306 
TRIB1 siRNA Horizon Discovery L-003633-00-0005 
DICER1 siRNA Horizon Discovery L-003483-00-0005 
AGO2 siRNA Horizon Discovery L-004639-00-0005 
siRNA negative control (scramble) Horizon Discovery D-001810-01-05 
siGLO Green Transfection Indicator Horizon Discovery D-001630 
MIR-101/TRIB1 Target Site Blocker Qiagen 339199 
Negative Control Target Site Blocker Qiagen  339199 
Viromer Green Cambridge Bioscience VG-01LB-01 
Viromer Blue Cambridge Bioscience VG-01LB-01 
Dharmafect DUO Horizon Discovery T-2010-03 
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Lipofectamine 3000 Reagent Invitrogen L3000008, 
L3000015 
Ficoll Paque Plus GE Healthcare 171440-02 
DMEM media Gibco 11885084 
RMPI 1640 media Gibco 21875034 
Keratinocyte SF media Gibco 17005042 
NEAA Gibco 11140050 
Sodium Pyruvate Gibco 11360070 
Penicillin/Streptomycin Gibco 15070-063 
L-glutamine Gibco 17-605E 
Trypsin Lonza BE02-007E 
Low-endotoxin heat inactivated FBS PAN Biotech  P40-37500 
Bovine Serum Albumin Sigma-Aldrich A7906 
Bovine Serum Albumin, fatty acid free Sigma-Aldrich A8806 
Protease Inhibitor Cocktail Sigma-Aldrich P8340 
RIPA Lysis Buffer Sigma-Aldrich R0278 
Pierce BCA Protein Assay Thermo Fisher 
Scientific 
23225 
Tris Buffered Saline pH 8.0, powder Sigma-Aldrich T6664-10PAK 
MOPS SDS Running Buffer (20X) Invitrogen NP0001 
MES SDS Running Buffer (20X) Invitrogen NP0002 
NuPAGE 4-12% Bis-Tris Protein Gels 
10 wells, 15 wells 
Invitrogen NP0323PK2, 
NP0335PK2 
NuPAGE Antioxidant Invitrogen NP0005 
Protein Ladder  Invitrogen  LC5925 
Re-blot stripping solution Merck 2504 
TopFluor Cholesterol Avanti Polar Lipids 810255 
CD14+ microbeads Miltenyi Biotech 130-050-201 
High Density Lipoprotein Biorad 5685-2004 


















A1.2. List of machines and equipment 
Machine/Equipment Company 
Nanodrop Spectrophotometer Thermo Fisher Scientific 
Flow Cytometer, LSR II BD Bioscience 
CFX384 C1000 Touch Thermal Cycler Biorad 
ChemiDoc TM XRS+ Biorad 
C-DiGit ® Blot Scanner, LI-COR LI-COR Biosciences 
Microplate Reader, Varioskan Flash Thermo Fisher Scientific 
Transilluminator UV InGenius3 Syngene 
 
A1.3. List of antibodies used in western blot and immunofluorescence 
Antibody Company and Cat. Number Working Dilution 
Trib1 Millipore, 09-126 1:1000 WB, 1:200 IF 
Alpha-tubulin Santa Cruz Biotech, sc-5286 1:5000 WB, 1:500 IF 
Heat Shock Protein 90 Abcam, ab13495 1:5000 WB 
Mouse IgG, Isotype Control Invitrogen, 10400C 1:500 IF 
Rabbit IgG, Isotype Control Invitrogen, 10500C 1:500 IF 
Anti-Mouse Dako, P0447 1:5000 WB, 1:1000 IF 
Anti-Rabbit Dako, P0448 1:5000 WB, 1:1000 IF 
























A1.4. Plasmids maps 
Plasmids were generated in our lab, as described in Chapter 2. Entry plasmids and destination 





A1.4.1. Firefly reporter plasmid map 
Firefly reporter plasmid used in the dual luciferase reporter assay, as internal control, for data 




A1.4.2. Renilla reporter plasmid map 
Renilla reporter plasmid used in the dual luciferase reporter assay, as “NO UTR” control. Map 




















A1.4.3. TRIB1 3’UTR renilla reporter plasmid map  
TRIB1 3’UTR renilla reporter plasmid used in the dual luciferase reporter assay, as test 
plasmid. The same plasmid was used to generate miRNA-binding site mutant and SNPs. Map 





A1.4.4. Plasmids used for overexpression experiment   
Expression plasmid used for overexpressing GFP (left) and TRIB1 (right) in MDMs by 




TRIB1 3’UTR Renilla Reporter plasmid
TRIB1 3’UTR Full length 
Renilla luciferase gene
pEFBOS promoter
GFP overexpression plasmid hTRIB1 overexpression plasmid
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A1.5. List of RT-qPCR primers 
Gene Forward primer Reverse primer 
hTRIB1 CTCCACGGAGGAGAGAACCC GACAAAGCATCATCTTCCCCC 
hGAPDH ATTGCCCTCAACGACCACTTT CCCTGTTGCTGTAGCCAAATTC 
hIL-4 TCCGATTCCTGAAACGGCTC TGGTTGGCTTCCTTCACAGG 
hIL-6 ACCCCCAGGAGAAGATTCCA GATGCCGTCGAGGATGTACC 
hIL-8 TGCCAAGGAGTGCTAAAG CTCCACAACCCTCTGCAC 





hCD163 AGGAGAGAACTTAGTCCACCA TCAGAATGGCCTCCTTTTCCA 
hSPAR-C TGATGGTGCAGAGGAAACCG TGTTCTCATCCAGCTCGCAC 
hPD-L1 AGGGCATTCCAGAAAGATGAGG GGTCCTTGGGAACCGTGAC 
hVEGF ATGCGGATCAAACCTCACCA GCTCTATCTTTCTTTGGTCTGC 
hTNF- CCTGCTGCACTTTGGAGTGA CTTGTCACTCGGGGTTCGAG  
hCD80 TGCCTGACCTACTGCTTTGC GGCGTACACTTTCCCTTCTCA 




hDICER1 ACCAATCTCAACCAGCCACT TCAAAAGGCAGTGAAGGCGA 
hAGO2 GTCACCAAACATTCCCGCTG GTGTTTCTGCTCCTGTCCGA 
hABCA1 TACATCTCCCTTCCCGAGCA GGGCCAGAGTCCCAAGACTA 
hDUSP1 CCCCACTCTACGATCAGGGT CCTTGCGGGAAGCGTGATA 
mTrib1 CTTACATCCAGCTGCCGTCC GTAGGCCTTGCTCTCACCAA 























A1.6.1. Forward and reverse primers used for site-directed mutagenesis of miR-101-3p 
binding site 
Mutagenesis primers used for deleting miR-101-3p binding site in the 3’UTR of TRIB1 

























A1.6.2. Forward and reverse primers used to generate SNPs in the 3’UTR of TRIB1 
Mutagenesis primers used for generating rs62521034(A) and rs56395423 (B, C) in 3’UTR of 











Appendix II, Supplementary data for Chapter 3 
This section contains supporting data for Chapter 3, miR-101-3p negatively regulates Tribbles-
1 expression in primary human macrophages. 
 
A2.1. Assessment of CD14+ monocyte purity: flow cytometry 
The specificity of the PBMCs isolation protocol was previously confirmed in our group by 
using Flow Cytometry (LSR II flow cytometer, BD Bioscience). Monocytes were stained for 
both purity and activation by Dr Yang Li (PhD thesis submitted in 2019). More than 90% of 
monocytes were detected in total CD14+ PBMCs fraction with minor proportions of cell debris, 
lymphocytes and monocyte doublets. Figure 8.2.1. shows the proportion of CD14+ monocytes 
(>90%) isolated by myself from two different donors.  
 
 
A2.1. Assessment of CD14+ monocyte population purity 
Flow Cytometry was performed after the positive selection of CD14+ monocytes (human 
CD14+ beads- conjugated antibody) to assess the purity of the isolated population (> 90 %). 
The figures show two representative experiments. Gating was performed using the intrinsic 
parameters of cell size and granularity (SSC and FSC), according to previous gating generated 






A2.2. Immunofluorescence: isotype controls 
For each condition tested in the immunofluorescence we included isotype controls that did not 
show any strong signal. Below images taken from a representative sample, the same showed 




A2.2. Immunofluorescence isotype controls 
Representative immunofluorescence images for Donor B showing polarised MDMs stained for 



































A2.3. Assessment of co-transfection efficiency 
Transfection efficiency was assessed for the DNA/RNA co-transfection in HEK293T cell line 
(Dharmafect DUO kit) by using Flow Cytometry and evaluating fluorescence signal. To this 
aim, we used GFP and an empty plasmid (pcDNA3.1) and a fluorescent RNA (siGLO) and its 
negative control. Transfection was carried out for 24 hours (2 biological experiments, 3 
technical replicates each). Cells were washed in PBS, removed from tissue culture plate and 
resuspended in MACs buffer (500-1000uL). Figure 8.2.3.1-4 show representative flow 
cytometry images, while Figure 8.2.3.5. shows the quantification as percentage and mean 
fluorescent intensity (MFI). The percentage of live/dead cells and GFP positive/negative is 
specified in each figure legend. The percentage of efficiency, measured through fluorescence, 
was approximately 30% (GFP + siGLO). We believe that this is due to cell death occurring 
during the collection and the preparation of the samples, prior to the flow cytometry analysis. 
The transfection of both DNA and RNA was successful. Transient transfections using 
Lipofectamine 3000 and Viromer kits were previously optimised in our lab by other PhD 





A2.3.1. Flow cytometry: non-transfected HEK293T cells  
The graphs show the main cell population in dot plots (SSC/FSC) (left) and blue emission as 






A2.3.2. Flow cytometry: DNA transfection in HEK293T cells  
Histogram and dot plot for GFP (left) and an empty plasmid vector pcDNA3.1 (right). GFP 




A2.3.3. Flow cytometry: DNA and RNA co-transfection in HEK293T cells  
Histogram and dot plot for GFP and RNA negative control (left) and an empty plasmid vector 
pcDNA3.1 and RNA negative control (right). GFP positive cells were 20%. No blue emission 
























A2.3.4. Flow cytometry: DNA and RNA siGLO co-transfection in HEK293T cells  
Histogram and dot plot for GFP and RNA siGLO (left) and an empty plasmid vector pcDNA3.1 
and RNA siGLO (right). GFP/siGLO positive cells were 30%; pcDNA3.1/siGLO positive cells 




A2.3.5. Flow cytometry: fluorescence percentage and MFI 
The graphs show the % of the fluorescence (left) and the mean fluorescence intensity (right) 






































































































































Appendix III, Supplementary data for Chapter 4 
This section contains supporting data for Chapter 4, Integrated transcriptome analysis of small 
non-coding RNAs and mRNAs in pro-inflammatory macrophages. 
 
A3.1. RNA quality and concentration: representative samples 
Prior to RNA-seq experiments, RNA was checked for quality and concentration by the 
company Novogene, using agarose gel electrophoresis, nanodrop and the bioanalyser Agilent 




A3.1.1. RNA agarose gel electrophoresis: RNA quality assessment 
Agarose gel electrophoresis of RNA samples isolated from MDMs and sent for small non-
coding RNA sequencing experiment (GelConc:1%; Voltage:180v; Run Time:16min). The 18S 





A3.1.2. Agilent 2100 bioanalyser: RNA quality assessment 
RNA quality assessment of a representative sample sent for small non-coding RNA sequencing 
experiment: the plot, generated by Agilent 2100 bioanalyser, shows two distinct peaks 
corresponding to the S18 and S28 ribosomal subunits. The small peak between 20s and 25s 
represents the marker. The RNA Integrity Number (RIN) is 9.5 and indicates that the sample 











A3.2. miRNA-seq: overrepresented sequence 
As mentioned in Chapter 4, before analysing the small RNA seq, we removed an 
overrepresented sequence, corresponding to miR-21. The plot below, generated during the 




A3.2. MultiQC report: overrepresented sequences 
MultiQC report plot showing overrepresented sequences in small RNA sequencing experiment. 









A3.3. List of differentially expressed small RNAs 
The tables below list small RNAs differentially expressed between M0 and M1 macrophages, 
including miRNAs, sorted according the adjusted p values (>0.05).  
BaseMean is the average of the normalised count values; log2FoldChange represents the effect 
size estimate: how much the expression of a gene changed due to the treatment (M0 vs M1); 
lfcSE is the standard error estimate for the log2FoldChange; stat represents the wald statistics; 
pvalue is attained by the wald test; padj is the pvalue corrected for multiple testing using the 
Benjamini and Hochberg method. 
 
A3.3.1. List of small RNAs upregulated in M1 macrophages 
RNACentral ID baseMean log2FoldChange lfcSE stat pvalue padj 
URS0000287398 87.07 1.01 0.26 3.81 1.42E-04 2.05E-03 
URS00005E1F00 137.17 1.01 0.24 4.12 3.74E-05 7.05E-04 
URS00000C18F2 477.18 1.01 0.24 4.28 1.91E-05 4.09E-04 
URS0000386F92 423.37 1.01 0.22 4.51 6.54E-06 1.75E-04 
URS0000EC0861 25.55 1.01 0.31 3.21 1.35E-03 1.32E-02 
URS0000682FB0 717.09 1.01 0.23 4.42 9.81E-06 2.37E-04 
URS00006C8EDF 97.24 1.01 0.25 3.97 7.31E-05 1.22E-03 
URS0000624312 1048.65 1.01 0.21 4.77 1.88E-06 5.96E-05 
URS00006FCBA3 47.56 1.01 0.32 3.21 1.34E-03 1.32E-02 
URS00002D40C8 486.68 1.01 0.24 4.18 2.88E-05 5.75E-04 
URS00006CF521 86.93 1.02 0.29 3.50 4.62E-04 5.54E-03 
URS0000A8472C 1036.60 1.02 0.21 4.76 1.96E-06 6.15E-05 
URS0000EC0779 10.35 1.02 0.36 2.83 4.72E-03 3.49E-02 
URS000043D1A9 93.87 1.03 0.27 3.84 1.23E-04 1.82E-03 
URS00005A0236 26.99 1.04 0.31 3.34 8.45E-04 9.35E-03 
URS000067843B 318.62 1.04 0.23 4.46 8.26E-06 2.08E-04 
URS000072BBEB 72.89 1.04 0.34 3.03 2.46E-03 2.11E-02 
URS0000728B3E 25.49 1.04 0.36 2.88 3.99E-03 3.05E-02 
URS00001672F3 103.12 1.05 0.20 5.17 2.39E-07 1.04E-05 
URS0000635FFC 43.61 1.05 0.37 2.88 3.99E-03 3.05E-02 
URS0000640661 711.17 1.05 0.23 4.61 3.98E-06 1.17E-04 
URS0000EA616E 22.62 1.05 0.28 3.74 1.84E-04 2.53E-03 
URS00006C2A6C 660.71 1.06 0.23 4.57 4.78E-06 1.33E-04 
URS00006F59B4 45.68 1.06 0.23 4.68 2.86E-06 8.52E-05 
URS000072540A 468.42 1.06 0.22 4.93 8.27E-07 3.18E-05 
URS0000D588F3 23.51 1.06 0.39 2.70 6.90E-03 4.66E-02 
URS00006744D5 454.29 1.06 0.24 4.33 1.51E-05 3.41E-04 
URS00002154C2 240.85 1.06 0.24 4.33 1.50E-05 3.41E-04 
URS00000FC8EB 1694.09 1.06 0.22 4.84 1.32E-06 4.60E-05 
 264 
URS000015A6F8 483.64 1.06 0.25 4.18 2.97E-05 5.89E-04 
URS0000521091 497.31 1.07 0.23 4.57 4.77E-06 1.33E-04 
URS0000685E74 43.95 1.07 0.27 4.01 6.08E-05 1.06E-03 
URS000064074C 84.35 1.08 0.33 3.27 1.08E-03 1.14E-02 
URS0000739B5B 81.70 1.08 0.32 3.38 7.29E-04 8.22E-03 
URS000020CB8F 473.69 1.08 0.25 4.35 1.33E-05 3.11E-04 
URS00006100A0 30.79 1.08 0.33 3.23 1.23E-03 1.23E-02 
URS000069A1F2 26.78 1.09 0.30 3.66 2.52E-04 3.32E-03 
URS00001AD596 762.43 1.09 0.37 2.94 3.32E-03 2.63E-02 
URS000062AA63 30.47 1.10 0.38 2.86 4.25E-03 3.21E-02 
URS0000EC1AE8 21.81 1.11 0.39 2.88 3.93E-03 3.02E-02 
URS0000659544 397.57 1.11 0.29 3.79 1.53E-04 2.18E-03 
URS0000AA94DC 8.77 1.12 0.38 2.94 3.27E-03 2.59E-02 
URS0000E82BA2 586.88 1.12 0.29 3.84 1.21E-04 1.80E-03 
URS00006F4537 48.47 1.13 0.23 4.83 1.40E-06 4.64E-05 
URS000061B694 12821.77 1.13 0.19 5.86 4.72E-09 3.13E-07 
URS00006E7A67 36.36 1.13 0.27 4.16 3.24E-05 6.34E-04 
URS00002F039B 123.40 1.13 0.41 2.78 5.44E-03 3.88E-02 
URS0000311FB0 78.60 1.14 0.23 4.92 8.60E-07 3.26E-05 
URS000029EF95 559.55 1.14 0.27 4.21 2.53E-05 5.10E-04 
URS00000A8253 123.43 1.14 0.42 2.69 7.12E-03 4.77E-02 
URS00006F58F8 27.10 1.14 0.37 3.10 1.94E-03 1.74E-02 
URS000022B8AA 557.92 1.14 0.25 4.48 7.35E-06 1.88E-04 
URS000065EBC0 32.18 1.14 0.36 3.17 1.50E-03 1.43E-02 
URS0000D5EDDD 13.50 1.15 0.35 3.26 1.13E-03 1.17E-02 
URS00008B5862 34.04 1.15 0.38 3.03 2.46E-03 2.11E-02 
URS00006174C2 167.42 1.15 0.35 3.33 8.70E-04 9.54E-03 
URS00004F5239 90.36 1.16 0.30 3.79 1.50E-04 2.15E-03 
URS00004A2461 588.86 1.17 0.27 4.29 1.80E-05 3.89E-04 
URS0000D5C559 988.23 1.17 0.26 4.54 5.69E-06 1.55E-04 
URS000005A7A9 21.94 1.18 0.33 3.62 2.99E-04 3.87E-03 
URS00005F7694 770.70 1.18 0.37 3.15 1.62E-03 1.52E-02 
URS000045533A 125.06 1.18 0.43 2.74 6.15E-03 4.26E-02 
URS000044BAE3 842.59 1.18 0.31 3.78 1.59E-04 2.23E-03 
URS0000EA7AA7 248.63 1.18 0.23 5.07 3.89E-07 1.64E-05 
URS00000FB60D 171.46 1.18 0.25 4.70 2.56E-06 7.70E-05 
URS00004DC6D6 874.55 1.19 0.31 3.87 1.10E-04 1.66E-03 
URS0000EBEE05 903.19 1.19 0.33 3.61 3.10E-04 3.98E-03 
URS00002F2AEC 896.33 1.19 0.31 3.87 1.09E-04 1.66E-03 
URS000006E1E3 906.31 1.20 0.33 3.69 2.28E-04 3.08E-03 
URS0000527A9F 238.06 1.21 0.27 4.49 7.24E-06 1.87E-04 
URS00006D74B2 106.96 1.21 0.38 3.18 1.49E-03 1.43E-02 
URS0000815951 119.39 1.21 0.42 2.86 4.26E-03 3.22E-02 
 265 
URS00003177B8 125.08 1.22 0.40 3.08 2.04E-03 1.81E-02 
URS0000DC002B 118.26 1.22 0.45 2.74 6.09E-03 4.24E-02 
URS00006C58BC 472.72 1.23 0.34 3.64 2.70E-04 3.52E-03 
URS00003E8921 120.23 1.23 0.46 2.70 7.02E-03 4.71E-02 
URS000069B369 963.37 1.25 0.29 4.32 1.57E-05 3.48E-04 
URS00000A7517 113.71 1.25 0.45 2.75 5.98E-03 4.20E-02 
URS000001A289 451.63 1.25 0.32 3.91 9.09E-05 1.45E-03 
URS000065BD15 408.85 1.25 0.21 5.89 3.94E-09 2.76E-07 
URS00004F76B3 30.79 1.25 0.46 2.74 6.16E-03 4.26E-02 
URS0000AEC348 119.35 1.26 0.44 2.86 4.20E-03 3.18E-02 
URS000064FAB6 12.52 1.26 0.37 3.40 6.74E-04 7.71E-03 
URS000029D0D3 113.47 1.26 0.43 2.95 3.21E-03 2.57E-02 
URS0000E53B55 119.19 1.27 0.45 2.79 5.32E-03 3.84E-02 
URS00004B70B9 114.28 1.27 0.44 2.87 4.04E-03 3.08E-02 
URS000062C4DE 124.52 1.27 0.28 4.57 4.80E-06 1.33E-04 
URS00001C308D 1258.45 1.28 0.29 4.34 1.44E-05 3.30E-04 
URS00006B2647 21.86 1.28 0.38 3.38 7.27E-04 8.22E-03 
URS00005C3DDD 119.56 1.29 0.42 3.09 1.98E-03 1.77E-02 
URS00003ECA54 106.19 1.29 0.38 3.40 6.64E-04 7.63E-03 
URS00006C8412 10.30 1.29 0.40 3.25 1.17E-03 1.21E-02 
URS00006C721A 36.46 1.30 0.36 3.59 3.29E-04 4.15E-03 
URS00006C06E6 33.15 1.30 0.40 3.24 1.19E-03 1.21E-02 
URS00006914B1 7.58 1.31 0.48 2.71 6.80E-03 4.61E-02 
URS0000DC92B6 121.89 1.32 0.44 2.96 3.07E-03 2.49E-02 
URS00006A9AE8 128.39 1.33 0.28 4.73 2.22E-06 6.89E-05 
URS000064A807 20.27 1.33 0.48 2.81 4.99E-03 3.64E-02 
URS0000EBF1EC 998.21 1.34 0.21 6.26 3.95E-10 2.95E-08 
URS000066C003 478.34 1.34 0.23 5.73 1.02E-08 6.21E-07 
URS0000677B31 16.23 1.34 0.33 4.02 5.90E-05 1.04E-03 
URS0000190FE5 275.18 1.35 0.26 5.24 1.59E-07 7.62E-06 
URS000074CBFD 760.51 1.36 0.21 6.41 1.48E-10 1.17E-08 
URS00006D1B55 32.18 1.36 0.40 3.38 7.37E-04 8.27E-03 
URS000040DCFF 1826.38 1.36 0.17 8.09 6.10E-16 1.11E-13 
URS000068668E 21.52 1.36 0.36 3.83 1.29E-04 1.90E-03 
URS000042F13F 169.74 1.37 0.24 5.69 1.28E-08 7.61E-07 
URS0000B01320 114.06 1.38 0.44 3.13 1.72E-03 1.59E-02 
URS00000AA464 22.03 1.39 0.40 3.50 4.59E-04 5.53E-03 
URS00003361F9 21.05 1.39 0.52 2.69 7.14E-03 4.77E-02 
URS000063FB43 2232.93 1.40 0.52 2.71 6.68E-03 4.57E-02 
URS00005EA0AD 137.27 1.41 0.29 4.83 1.36E-06 4.61E-05 
URS00001123BD 24.72 1.41 0.33 4.24 2.20E-05 4.59E-04 
URS0000147B41 24.96 1.42 0.30 4.72 2.39E-06 7.26E-05 
URS0000AC252C 107.78 1.43 0.45 3.14 1.67E-03 1.55E-02 
 266 
URS0000591950 298.69 1.44 0.21 6.80 1.07E-11 1.08E-09 
URS00003496BE 71.05 1.44 0.25 5.82 5.88E-09 3.81E-07 
URS00006E357A 31.67 1.45 0.36 4.05 5.18E-05 9.40E-04 
URS0000A9690B 8.42 1.46 0.46 3.17 1.51E-03 1.43E-02 
URS0000158189 7.96 1.46 0.49 2.99 2.78E-03 2.32E-02 
URS00007362AD 32.78 1.46 0.32 4.55 5.36E-06 1.48E-04 
URS00007063CB 7.55 1.46 0.49 2.98 2.86E-03 2.35E-02 
URS00006A9C77 15.10 1.47 0.35 4.23 2.29E-05 4.67E-04 
URS0000244A71 5.05 1.47 0.55 2.67 7.57E-03 4.97E-02 
URS0000757938 33.15 1.47 0.38 3.83 1.31E-04 1.91E-03 
URS00004B1671 1602.06 1.48 0.31 4.83 1.34E-06 4.61E-05 
URS0000E13005 60.86 1.49 0.51 2.93 3.39E-03 2.66E-02 
URS00006B6C08 5.28 1.51 0.52 2.91 3.61E-03 2.80E-02 
URS00006CFACA 32.52 1.51 0.46 3.27 1.07E-03 1.13E-02 
URS000013899F 122.72 1.53 0.30 5.05 4.36E-07 1.77E-05 
URS0000758A62 26.41 1.55 0.40 3.90 9.43E-05 1.48E-03 
URS0000648E1F 27.93 1.56 0.38 4.08 4.54E-05 8.28E-04 
URS0000DEEC0E 16.29 1.58 0.52 3.02 2.54E-03 2.15E-02 
URS000068FD04 697.14 1.60 0.28 5.63 1.79E-08 1.02E-06 
URS00004208C5 1644.39 1.60 0.18 8.89 5.88E-19 1.77E-16 
URS000038D768 14.98 1.60 0.41 3.90 9.81E-05 1.51E-03 
URS000073124E 82.23 1.61 0.29 5.63 1.82E-08 1.02E-06 
URS0000697465 79.61 1.61 0.28 5.78 7.31E-09 4.64E-07 
URS000069E2A5 4.75 1.62 0.60 2.69 7.17E-03 4.78E-02 
URS000047C79B 15.64 1.62 0.34 4.81 1.53E-06 4.97E-05 
URS000068C733 7.54 1.63 0.51 3.17 1.51E-03 1.43E-02 
URS000071ED2F 32.58 1.65 0.44 3.75 1.74E-04 2.42E-03 
URS00004F0321 6947.27 1.67 0.39 4.24 2.19E-05 4.59E-04 
URS00005402A5 14.84 1.67 0.63 2.67 7.54E-03 4.95E-02 
URS000011CFE8 5919.12 1.67 0.45 3.70 2.18E-04 2.97E-03 
URS0000635088 6939.36 1.69 0.39 4.31 1.66E-05 3.61E-04 
URS0000593537 178.13 1.70 0.26 6.48 9.34E-11 7.58E-09 
URS0000282AB2 17.19 1.70 0.40 4.24 2.27E-05 4.67E-04 
URS00001B460B 13.16 1.72 0.43 3.99 6.67E-05 1.14E-03 
URS000037F5E2 14.04 1.73 0.38 4.51 6.39E-06 1.73E-04 
URS0000D6E1B0 13.80 1.74 0.47 3.71 2.11E-04 2.87E-03 
URS00007F742E 17.76 1.76 0.65 2.70 6.89E-03 4.66E-02 
URS00007EC19C 15.95 1.77 0.66 2.69 7.23E-03 4.81E-02 
URS000057E781 11.63 1.78 0.63 2.83 4.69E-03 3.47E-02 
URS0000DE23D7 20.05 1.81 0.67 2.70 6.91E-03 4.66E-02 
URS0000381B86 5.17 1.82 0.60 3.05 2.32E-03 2.02E-02 
URS000038C474 12.65 1.85 0.45 4.14 3.41E-05 6.60E-04 
URS0000804A0D 17.53 1.86 0.69 2.71 6.76E-03 4.60E-02 
 267 
URS000031B6ED 8.28 1.87 0.45 4.13 3.58E-05 6.78E-04 
URS0000807EA6 15.59 1.89 0.61 3.10 1.93E-03 1.74E-02 
URS00004AC6E6 12.04 1.92 0.64 3.02 2.56E-03 2.16E-02 
URS00004AA2F0 16.02 1.92 0.66 2.91 3.61E-03 2.80E-02 
URS00003130BD 257.42 1.93 0.42 4.60 4.25E-06 1.23E-04 
URS0000DDA3BB 18.37 1.93 0.64 3.01 2.64E-03 2.21E-02 
URS000042B8BF 8.61 1.94 0.48 4.03 5.55E-05 9.88E-04 
URS0000DC3018 15.45 1.97 0.72 2.75 5.90E-03 4.15E-02 
URS00007E8E68 16.95 2.01 0.65 3.10 1.91E-03 1.73E-02 
URS00006D3DD2 13.22 2.03 0.45 4.50 6.89E-06 1.83E-04 
URS000034E9D0_63221 17.02 2.08 0.65 3.19 1.42E-03 1.38E-02 
URS0000DE2957 15.57 2.09 0.65 3.23 1.26E-03 1.25E-02 
URS000075BEBE 35.93 2.09 0.37 5.64 1.75E-08 1.02E-06 
URS0000E339B7 232.38 2.09 0.41 5.11 3.31E-07 1.42E-05 
URS000048FEBE 16.21 2.16 0.58 3.75 1.80E-04 2.48E-03 
URS00001F5B39 15.61 2.16 0.42 5.18 2.17E-07 9.59E-06 
URS00008EE2B1 9.42 2.20 0.68 3.24 1.21E-03 1.22E-02 
URS000070BF11 7.11 2.27 0.56 4.03 5.51E-05 9.88E-04 
URS00001F0C23 55.30 2.32 0.35 6.70 2.05E-11 1.93E-09 
URS00006E19EA 397.35 2.33 0.30 7.85 4.14E-15 6.72E-13 
URS0000424278 300.29 2.37 0.32 7.37 1.69E-13 2.15E-11 
URS000023FB43 6.16 2.45 0.72 3.42 6.19E-04 7.17E-03 
URS0000338542 35900.61 2.52 0.22 11.34 8.78E-30 8.54E-27 
URS000019676E 23.14 2.83 0.42 6.72 1.88E-11 1.83E-09 
URS0000D54CAD 211862.08 2.83 0.23 12.05 1.89E-33 2.76E-30 
URS00002198F3 16.15 2.95 0.45 6.58 4.59E-11 3.83E-09 
URS0000199B53 6.45 2.95 0.90 3.27 1.08E-03 1.14E-02 
URS00006E0DAF 5.89 3.11 0.68 4.60 4.20E-06 1.23E-04 
URS0000688DD3 32.64 3.13 0.43 7.29 3.17E-13 3.70E-11 
URS0000CFBCCA 6.30 3.16 0.64 4.93 8.17E-07 3.18E-05 
URS00006BACE4 33.42 3.24 0.36 8.92 4.66E-19 1.70E-16 
URS000034309A 8.34 3.31 0.87 3.79 1.54E-04 2.18E-03 
URS00003D4175 66.96 3.59 0.44 8.17 3.01E-16 5.87E-14 
URS0000054224 69.14 3.77 0.45 8.30 1.06E-16 2.21E-14 
URS0000EBB7A5 4.98 3.90 0.95 4.10 4.20E-05 7.81E-04 
URS000001C659 7.14 4.50 0.93 4.83 1.40E-06 4.64E-05 
URS00002DABEA 13.47 4.97 0.74 6.67 2.56E-11 2.27E-09 






A3.3.2. List of small RNAs downregulated in M1 macrophages 
RNACentral ID baseMean log2FoldChange lfcSE stat pvalue padj 
URS00002B2B5C 15.60 -4.75 0.61 -7.85 4.02E-15 6.72E-13 
URS000002103A 11.92 -4.60 0.63 -7.33 2.22E-13 2.70E-11 
URS00000DA3DF 8.82 -4.13 0.79 -5.24 1.65E-07 7.75E-06 
URS000056B04E 240.87 -3.61 0.30 
-
12.13 7.05E-34 2.06E-30 
URS00006E0B8F 14.77 -3.30 0.55 -5.95 2.64E-09 1.93E-07 
URS00004FCB5F 6.12 -3.24 0.72 -4.48 7.60E-06 1.93E-04 
URS00001C770D 15.83 -3.04 0.41 -7.47 8.12E-14 1.08E-11 
URS000075E96D 35.02 -2.97 0.39 -7.62 2.60E-14 3.62E-12 
URS00006E020B 15.90 -2.86 0.45 -6.36 2.00E-10 1.54E-08 
URS000007ACA1 6.30 -2.71 0.69 -3.91 9.36E-05 1.48E-03 
URS000064426B 5.29 -2.62 0.62 -4.24 2.27E-05 4.67E-04 
URS0000237FB8 64.70 -2.52 0.28 -9.01 2.06E-19 8.58E-17 
URS00008B5FCF 5.79 -2.40 0.76 -3.15 1.61E-03 1.51E-02 
URS000003ABC4 22.32 -2.37 0.55 -4.32 1.56E-05 3.47E-04 
URS0000E9F36E 6.20 -2.32 0.62 -3.78 1.60E-04 2.23E-03 
URS00006F9520 5.46 -2.25 0.65 -3.44 5.79E-04 6.82E-03 
URS000005D4F5 407.73 -2.21 0.24 -9.16 5.00E-20 2.43E-17 
URS00001597DC 11.68 -2.18 0.39 -5.57 2.56E-08 1.41E-06 
URS000067E5FF 5.14 -2.17 0.64 -3.38 7.23E-04 8.21E-03 
URS0000CB6503 11.29 -2.16 0.51 -4.25 2.16E-05 4.58E-04 
URS00006C0B51 371.11 -2.13 0.23 -9.24 2.44E-20 1.43E-17 
URS0000CA62EF 12.80 -2.00 0.38 -5.32 1.07E-07 5.27E-06 
URS000075AEBC 5.52 -1.99 0.60 -3.32 9.02E-04 9.76E-03 
URS0000564C39 76.06 -1.93 0.20 -9.55 1.33E-21 9.70E-19 
URS00002CBC6D 280.84 -1.87 0.21 -8.72 2.78E-18 7.38E-16 
URS00006E4867 9.68 -1.85 0.63 -2.95 3.19E-03 2.57E-02 
URS00003FFA6C 20.68 -1.84 0.33 -5.51 3.51E-08 1.90E-06 
URS0000045DBD 163.60 -1.80 0.20 -8.89 6.07E-19 1.77E-16 
URS0000D55DFB 14.74 -1.73 0.52 -3.33 8.53E-04 9.40E-03 
URS000075C34D 288.28 -1.71 0.29 -5.89 3.97E-09 2.76E-07 
URS00004E57E7 65.82 -1.66 0.23 -7.11 1.16E-12 1.28E-10 
URS0000BB15D5 18.11 -1.66 0.39 -4.25 2.12E-05 4.52E-04 
URS0000241987 172.07 -1.65 0.29 -5.76 8.52E-09 5.29E-07 
URS00006DF24F 39564.84 -1.64 0.25 -6.67 2.57E-11 2.27E-09 
URS0000080D0A 809.22 -1.63 0.20 -8.32 8.94E-17 2.01E-14 
URS00002F8148 9.54 -1.62 0.45 -3.58 3.43E-04 4.29E-03 
URS0000384021 23.54 -1.60 0.29 -5.45 5.04E-08 2.67E-06 
URS00005092C2 8.62 -1.59 0.41 -3.86 1.12E-04 1.69E-03 
URS00001012BC 58.79 -1.56 0.22 -7.11 1.19E-12 1.28E-10 
URS0000EA6322 11.91 -1.56 0.43 -3.64 2.75E-04 3.57E-03 
 269 
URS0000065D58 18.51 -1.52 0.42 -3.60 3.18E-04 4.05E-03 
URS00006CE6B7 10.59 -1.50 0.42 -3.55 3.88E-04 4.78E-03 
URS000052AB63 14.50 -1.49 0.38 -3.90 9.82E-05 1.51E-03 
URS0000EBB075 6.86 -1.47 0.50 -2.93 3.35E-03 2.64E-02 
URS000075C652 7.78 -1.46 0.49 -2.99 2.79E-03 2.32E-02 
URS00006AFF4E 8.22 -1.43 0.46 -3.10 1.96E-03 1.76E-02 
URS000008230A 7.19 -1.40 0.51 -2.75 6.05E-03 4.22E-02 
URS000015D23B 22.22 -1.39 0.31 -4.50 6.96E-06 1.83E-04 
URS00004B2A47 49.73 -1.37 0.29 -4.81 1.51E-06 4.96E-05 
URS0000079D48 196.05 -1.36 0.28 -4.90 9.73E-07 3.55E-05 
URS000066288D 8.32 -1.36 0.43 -3.14 1.67E-03 1.55E-02 
URS0000662807 466.45 -1.33 0.15 -8.64 5.50E-18 1.34E-15 
URS00000BD1DE 24.48 -1.30 0.36 -3.66 2.54E-04 3.33E-03 
URS00001C85C7 12.23 -1.29 0.42 -3.04 2.34E-03 2.02E-02 
URS00004C9052 100.63 -1.26 0.28 -4.45 8.43E-06 2.09E-04 
URS000023BE29 154.63 -1.26 0.30 -4.14 3.41E-05 6.60E-04 
URS000044EF2B 29.80 -1.25 0.42 -2.96 3.05E-03 2.48E-02 
URS0000424D74 25.17 -1.24 0.25 -4.89 1.01E-06 3.65E-05 
URS000060AABB 428.54 -1.22 0.16 -7.63 2.36E-14 3.45E-12 
URS00000CF1D2 827.74 -1.22 0.18 -6.63 3.38E-11 2.90E-09 
URS0000EABDD4 23.02 -1.21 0.30 -4.03 5.59E-05 9.88E-04 
URS000062982B 12.85 -1.18 0.42 -2.83 4.63E-03 3.44E-02 
URS0000383E7F 9.07 -1.18 0.44 -2.68 7.44E-03 4.91E-02 
URS00003E16E5 140.82 -1.15 0.23 -5.07 4.08E-07 1.68E-05 
URS0000246356 23.42 -1.14 0.34 -3.32 8.91E-04 9.70E-03 
URS0000554A4F 33.16 -1.09 0.28 -3.93 8.49E-05 1.38E-03 
URS00002CDFCA 32.60 -1.08 0.30 -3.59 3.34E-04 4.21E-03 
URS000023133F 31.81 -1.08 0.34 -3.16 1.58E-03 1.49E-02 
URS000003F252 1081.27 -1.07 0.20 -5.35 8.95E-08 4.58E-06 
URS000071E3CB 24.12 -1.06 0.33 -3.24 1.20E-03 1.22E-02 
URS00000451A1 131428.28 -1.05 0.21 -5.07 3.93E-07 1.64E-05 
URS0000679788 220.26 -1.04 0.24 -4.31 1.63E-05 3.58E-04 
URS0000156390 43.49 -1.04 0.35 -2.99 2.80E-03 2.32E-02 
URS0000629ECF 14.16 -1.03 0.37 -2.74 6.18E-03 4.27E-02 
URS0000259CF4 116.17 -1.02 0.21 -4.90 9.60E-07 3.55E-05 
URS000050E4BA 1798.91 -1.00 0.19 -5.22 1.81E-07 8.37E-06 






A3.4. List of differentially expressed genes 
The tables below list the genes differentially expressed in response to miRNAs overexpression, 
sorted according to the adjusted p values (>0.05).  
LogFC represents the log2 fold change, AveExpr is the average expression over all samples 
(CPM values); stat represents the wald statistics; pvalue is attained by the wald test; padj is the 
pvalue corrected for multiple testing using the Benjamini and Hochberg method. 
 
A3.4.1. List of genes significantly downregulated in miR-155-5p overexpressing 
macrophages 
Gene logFC AveExpr stat P.Value adj.P.Val 
SLC1A3 -1.02 8.12 -11.97 1.47E-10 4.62E-07 
ARHGAP18 -1.14 6.22 -10.84 8.33E-10 9.56E-07 
CSF1R -1.20 7.47 -10.61 1.19E-09 1.19E-06 
MOCS2 -1.34 4.19 -10.50 1.44E-09 1.27E-06 
MPEG1 -2.30 6.53 -10.48 1.47E-09 1.27E-06 
MARCHF1 -1.62 6.33 -9.63 6.07E-09 3.35E-06 
PICALM -1.13 8.00 -9.16 1.39E-08 5.73E-06 
ANXA2 -0.81 11.04 -9.01 1.83E-08 6.60E-06 
PTPN22 -1.64 4.00 -8.71 3.15E-08 9.17E-06 
SPRED1 -1.65 4.28 -8.71 3.11E-08 9.17E-06 
GATM -1.51 4.00 -8.19 8.32E-08 1.75E-05 
TBC1D14 -1.19 5.54 -8.00 1.20E-07 2.22E-05 
MARVELD1 -1.32 3.46 -7.97 1.26E-07 2.27E-05 
NRP1 -1.12 7.36 -7.90 1.44E-07 2.48E-05 
CSE1L -0.65 5.42 -7.90 1.45E-07 2.48E-05 
NME4 -0.95 3.70 -7.83 1.66E-07 2.68E-05 
IKBIP -1.23 3.72 -7.79 1.78E-07 2.76E-05 
ABHD6 -1.31 4.13 -7.68 2.22E-07 2.98E-05 
MRPS27 -0.75 4.73 -7.64 2.42E-07 3.13E-05 
MEX3B -1.29 1.98 -7.58 2.69E-07 3.38E-05 
TM6SF1 -1.32 5.12 -7.46 3.43E-07 3.93E-05 
TGFBR1 -1.30 5.53 -7.36 4.17E-07 4.54E-05 
OPRL1 -1.79 0.28 -7.24 5.36E-07 5.31E-05 
FMNL2 -0.46 7.31 -6.97 9.21E-07 7.88E-05 
S1PR3 -2.86 -2.86 -6.95 9.68E-07 8.14E-05 
POLE3 -0.63 5.17 -6.90 1.08E-06 8.87E-05 
SLC25A43 -0.70 4.58 -6.84 1.22E-06 9.39E-05 
RCBTB2 -0.57 6.46 -6.78 1.38E-06 1.03E-04 
CD36 -1.08 9.03 -6.66 1.79E-06 1.26E-04 
BACH1 -0.86 6.54 -6.59 2.05E-06 1.36E-04 
FGD5 -2.51 2.00 -6.54 2.30E-06 1.48E-04 
AGTRAP -0.71 6.09 -6.35 3.43E-06 1.93E-04 
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RAB6A -0.35 6.98 -6.29 3.92E-06 2.11E-04 
AP1B1 -0.49 7.30 -6.28 3.99E-06 2.13E-04 
NBPF1 -0.83 5.37 -6.19 4.88E-06 2.44E-04 
GPD1L -1.28 2.67 -5.98 7.72E-06 3.31E-04 
CDC25A -2.83 -0.45 -5.93 8.46E-06 3.53E-04 
UROS -0.65 5.05 -5.94 8.46E-06 3.53E-04 
FITM2 -0.97 1.99 -5.92 8.69E-06 3.58E-04 
E2F2 -2.53 -1.26 -5.75 1.27E-05 4.70E-04 
IL16 -1.82 3.25 -5.74 1.31E-05 4.80E-04 
PFKFB2 -0.87 3.48 -5.73 1.33E-05 4.86E-04 
RXRA -0.74 6.21 -5.67 1.52E-05 5.37E-04 
RGS18 -2.53 -0.16 -5.65 1.60E-05 5.56E-04 
CIAO1 -0.53 6.12 -5.63 1.66E-05 5.72E-04 
DUSP10 -0.56 5.23 -5.63 1.66E-05 5.72E-04 
VWA8 -0.58 4.86 -5.62 1.70E-05 5.78E-04 
TGFBR2 -0.84 6.01 -5.59 1.81E-05 6.05E-04 
NDUFV3 -0.58 4.76 -5.57 1.91E-05 6.28E-04 
LGI2 -3.03 -1.97 -5.54 2.04E-05 6.54E-04 
CLINT1 -0.47 5.94 -5.51 2.17E-05 6.88E-04 
PARVB -0.75 5.99 -5.46 2.41E-05 7.40E-04 
HMGCR -0.92 5.67 -5.37 2.98E-05 8.57E-04 
PCCA -1.11 3.30 -5.37 2.99E-05 8.59E-04 
MYO1D -0.80 4.96 -5.36 3.05E-05 8.71E-04 
BRI3BP -0.87 4.38 -5.34 3.16E-05 8.95E-04 
SORL1 -1.34 3.76 -5.34 3.20E-05 9.03E-04 
DIS3L -0.91 3.88 -5.34 3.22E-05 9.07E-04 
INPP5A -1.02 2.34 -5.30 3.46E-05 9.59E-04 
PTDSS1 -0.34 6.63 -5.27 3.72E-05 1.01E-03 
PRKDC -1.01 6.51 -5.22 4.18E-05 1.09E-03 
SPARC -1.12 8.18 -5.20 4.42E-05 1.13E-03 
HSPA5 -0.61 9.61 -5.19 4.46E-05 1.14E-03 
SGK3 -0.71 6.76 -5.15 4.94E-05 1.23E-03 
SGK3 -0.71 6.76 -5.15 4.94E-05 1.23E-03 
ANKH -1.17 3.96 -5.11 5.36E-05 1.30E-03 
FXN -0.98 2.36 -5.11 5.44E-05 1.32E-03 
RNF166 -1.08 4.28 -5.10 5.47E-05 1.32E-03 
RAB11FIP2 -0.62 4.19 -5.09 5.60E-05 1.34E-03 
MXI1 -0.62 3.76 -5.04 6.25E-05 1.46E-03 
RRM2 -2.21 1.69 -5.04 6.35E-05 1.47E-03 
USP31 -0.68 3.16 -4.99 7.09E-05 1.58E-03 
SFXN2 -1.84 1.13 -4.92 8.38E-05 1.78E-03 
MRS2 -0.54 5.27 -4.90 8.71E-05 1.84E-03 
SNX29 -0.58 5.18 -4.81 1.06E-04 2.10E-03 
TP53INP1 -0.54 4.76 -4.78 1.14E-04 2.21E-03 
MBNL3 -0.93 3.51 -4.75 1.23E-04 2.32E-03 
HACD1 -1.12 0.95 -4.64 1.58E-04 2.80E-03 
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SLC26A11 -0.51 8.52 -4.63 1.64E-04 2.87E-03 
LRP12 -0.77 5.14 -4.60 1.75E-04 3.02E-03 
HLTF -1.09 3.20 -4.59 1.77E-04 3.04E-03 
EEPD1 -0.99 4.98 -4.57 1.88E-04 3.17E-03 
CCT2 -0.35 6.55 -4.56 1.92E-04 3.22E-03 
MMD -1.09 3.38 -4.51 2.13E-04 3.48E-03 
RBFA -0.63 2.75 -4.48 2.30E-04 3.64E-03 
FASTKD1 -0.56 4.84 -4.48 2.31E-04 3.65E-03 
EEFSEC -0.61 3.64 -4.47 2.35E-04 3.70E-03 
OTULINL -1.20 2.89 -4.36 3.06E-04 4.49E-03 
SLC7A11 -0.88 7.33 -4.34 3.23E-04 4.68E-03 
DOK2 -1.20 2.82 -4.33 3.26E-04 4.72E-03 
TM7SF3 -0.53 5.89 -4.31 3.42E-04 4.90E-03 
CYP7B1 -1.93 -2.26 -4.23 4.10E-04 5.67E-03 
DENND2B -1.55 1.89 -4.23 4.12E-04 5.70E-03 
OXA1L -0.39 6.66 -4.23 4.14E-04 5.72E-03 
STRN3 -0.55 4.22 -4.23 4.15E-04 5.73E-03 
NOLC1 -0.38 5.26 -4.22 4.23E-04 5.82E-03 
RAB32 -0.65 4.78 -4.21 4.31E-04 5.89E-03 
EPAS1 -0.69 7.17 -4.20 4.45E-04 6.01E-03 
CMTM4 -0.88 2.81 -4.20 4.48E-04 6.04E-03 
SYT1 -2.77 -1.98 -4.15 4.96E-04 6.53E-03 
LIN7A -3.05 -0.96 -4.15 5.02E-04 6.59E-03 
CRHBP -1.53 -1.27 -4.13 5.17E-04 6.72E-03 
AMIGO1 -1.70 -0.05 -4.10 5.64E-04 7.17E-03 
ACVR1 -0.39 4.81 -4.08 5.87E-04 7.39E-03 
EBPL -0.79 1.32 -4.06 6.19E-04 7.70E-03 
ARFGAP3 -0.33 6.40 -4.05 6.23E-04 7.74E-03 
MPI -0.75 3.59 -4.05 6.31E-04 7.82E-03 
TMED3 -0.56 6.39 -4.03 6.63E-04 8.09E-03 
ELL2 -0.50 6.26 -3.98 7.44E-04 8.81E-03 
HIF1A -0.32 7.18 -3.96 7.68E-04 9.04E-03 
TRIM32 -0.59 2.20 -3.94 8.05E-04 9.35E-03 
ABHD2 -0.74 7.87 -3.86 9.80E-04 1.08E-02 
ABAT -0.82 2.52 -3.83 1.05E-03 1.13E-02 
TMEM218 -0.53 3.96 -3.79 1.17E-03 1.23E-02 
CD84 -0.67 9.68 -3.78 1.17E-03 1.23E-02 
CHAF1A -0.67 3.63 -3.77 1.21E-03 1.26E-02 
GRHPR -0.43 5.04 -3.74 1.29E-03 1.33E-02 
RNF26 -0.34 4.42 -3.74 1.30E-03 1.33E-02 
DTNA -1.02 1.70 -3.66 1.55E-03 1.52E-02 
PCLAF -1.60 -0.42 -3.65 1.58E-03 1.55E-02 
KDM5B -0.52 4.98 -3.63 1.66E-03 1.60E-02 
SLC2A9 -0.60 3.54 -3.63 1.67E-03 1.61E-02 
CLCN4 -1.85 -1.36 -3.58 1.89E-03 1.78E-02 
ANTXR1 -2.26 -2.39 -3.56 1.98E-03 1.84E-02 
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DUSP7 -0.86 4.56 -3.54 2.05E-03 1.89E-02 
PSMG1 -0.46 3.84 -3.51 2.23E-03 2.01E-02 
KCNJ1 -0.71 3.96 -3.46 2.49E-03 2.17E-02 
KLHL32 -1.58 0.01 -3.42 2.70E-03 2.31E-02 
MEGF6 -0.95 1.94 -3.39 2.90E-03 2.44E-02 
GMNN -0.62 2.85 -3.39 2.92E-03 2.45E-02 
METRN -0.65 2.24 -3.37 3.07E-03 2.54E-02 
ZHX3 -1.12 3.40 -3.36 3.15E-03 2.59E-02 
ATP5F1A -0.45 8.59 -3.35 3.20E-03 2.62E-02 
CTDSPL -0.79 3.32 -3.32 3.46E-03 2.78E-02 
TNIK -0.39 6.21 -3.31 3.50E-03 2.81E-02 
CDCA3 -1.45 -0.95 -3.31 3.53E-03 2.83E-02 
GATB -0.37 4.60 -3.29 3.64E-03 2.89E-02 
TMEM236 -1.47 -0.75 -3.29 3.65E-03 2.90E-02 
PPP5C -0.28 5.17 -3.22 4.33E-03 3.30E-02 
NME2 -0.40 7.37 -3.21 4.36E-03 3.31E-02 
ITGAV -0.52 6.69 -3.21 4.42E-03 3.34E-02 
PLXDC2 -0.45 7.19 -3.20 4.52E-03 3.40E-02 
RAPH1 -0.62 3.64 -3.17 4.87E-03 3.60E-02 
NDUFAF6 -0.60 2.91 -3.14 5.20E-03 3.79E-02 
RASSF8 -0.72 2.43 -3.13 5.28E-03 3.83E-02 
VKORC1L1 -0.24 5.36 -3.12 5.40E-03 3.89E-02 
TRIP13 -1.25 0.30 -3.10 5.60E-03 4.00E-02 
OTUB2 -0.66 2.90 -3.10 5.66E-03 4.04E-02 
GOLGA3 -0.42 6.13 -3.09 5.81E-03 4.11E-02 
GFPT1 -0.47 5.76 -3.07 6.09E-03 4.27E-02 
PLD1 -0.43 5.61 -3.05 6.32E-03 4.40E-02 
DHFR -0.64 3.04 -3.02 6.76E-03 4.63E-02 
METAP1 -0.27 5.14 -3.00 7.02E-03 4.77E-02 
MECR -0.52 2.74 -3.00 7.04E-03 4.78E-02 
LGALSL -0.69 2.52 -2.99 7.18E-03 4.85E-02 
PDHX -0.24 4.90 -2.98 7.46E-03 4.99E-02 
MMP8 -1.79 -2.61 -2.98 7.47E-03 4.99E-02 










A3.4.2. List of genes significantly downregulated in miR-125a-3p overexpressing 
macrophages 
Gene logFC AveExpr stat P.Value adj.P.Val 
DTX4 -0.57 6.31 -5.51 2.20E-05 1.77E-02 
DUSP1 -0.80 5.64 -5.39 2.84E-05 2.10E-02 
INF2 -0.29 6.69 -5.05 6.23E-05 3.60E-02 
EHD1 -0.81 5.84 -4.92 8.38E-05 3.99E-02 
 
A3.4.3. List of genes significantly downregulated in miR-186-5p overexpressing 
macrophages 
Gene logFC AveExpr stat P.Value adj.P.Val 



















Appendix IV, Supplementary data for Chapter 5 
This section contains supporting data for Chapter 5, miRNAs targeting TRIB1 non-coding 
variants and identification of two novel eQTLs.  
A4.1. TRIB1 non-coding variants  
TRIB1 non-coding variants affecting the 3’UTR were downloaded from 
https://www.ncbi.nlm.nih.gov/snp. Table A4.1.1. lists the ID of the 90 SNPs/INDELs analysed 
in Chapter 5. We selected the following parameters: 
 annotations: nucleotide;  
 functional class: 3’UTR;  
 validation status: by frequency. 
 
A4.1. List of TRIB1 non-coding variants 
rs544226392 rs17405319 rs762994344 rs564442600 rs145010344 rs777776886 
rs546022723 rs56395423 rs764331355 rs566209806 rs145449131 rs780519373 
rs546479447 rs62521034 rs764779399 rs568362286 rs149107463 rs777112667 
rs546842228 rs72647345 rs765360657 rs568453644 rs367637074 rs575452977 
rs548263380 rs72647346 rs766250927 rs568845890 rs372324007 rs372022826 
rs548386397 rs72647347 rs767431696 rs570838123 rs375565353 rs144434073 
rs550925842 rs72647348 rs768403240 rs573109640 rs529150647 rs756175087 
rs550939781 rs72647349 rs770137661 rs575121683 rs529289692 rs756397904 
rs552692797 rs73704997 rs771645792 rs575198443 rs530681133 rs757344260 
rs554138846 rs74486799 rs772580999 rs577356981 rs530790403 rs757466992 
rs554972862 rs80023284 rs775715767 rs751789944 rs533208547 rs758576660 
rs555208281 rs138055464 rs775724040 rs754065243 rs536284997 rs758819773 
rs555485182 rs140611687 rs776325924 rs755860381 rs537301973 rs759347835 
rs557685029 rs140952648 rs776449618 rs540547779 rs539767360 rs761444485 









A4.2. SNPs analysis with miRanda algorithm: workflow and scripts  
I. Input files pre-processing scripts  
miRanda algorithm works with sequences printed in one line. Alignment of FASTA sequences 
(TRIB1 3’UTR, reference sequence) was performed using the following command: 
 
awk '!/^>/ { printf "%s", $0; n = "\n" } /^>/ { print n $0; n = "" }END { printf "%s", n }' 
input_file.txt > output_file.txt 
 
SNPs sequences were pre-processed using the Python scripts. These scripts require Biopython 
as extension (http://biopython.org/wiki/Download). Pre-processing was performed in order to 
generate sequences of the same length as the reference sequence. As mentioned in Chapter 5, 
SNPs were downloaded as short sequences containing IUPAC ambiguity codes. The first script 
uses the TRIB1 3’UTR reference sequence to complete the regions flanking the polymorphism; 
warning messages will alert the user that the flanking region (upstream or downstream or both) 











The third script reads the header of each sequence (the header contains information about the 
SNP/INDEL) and replaces the IUPAC letters with the correspondent nucleotides. The 




    
II. Output file post-processing script 
After generating the input files, we run miRanda algorithm, following default settings. The 
output generated contains all the information about the target-prediction scan, but it does not 




For this reason, we post-processed the original output to organise the data in a table, using the 


















After applying the script, miRanda output looks like a table that can be exported in different 
formal, including .xlsx, .txt and .csv. It contains the miRNA name (column 1), the target region 
(column 2), the start and the end of the alignment (column 3, 4), the sequence aligned with the 




III. Output analysis: mySQL  
Post-processed outputs from miRanda algorithm were imported as tables in mySQL and 
analysed by SELECT, INTERSECT, EXCEPT and UNION functions. These allow the users 
to select distinct interactions using desired parameters (score, energy etc..) and intersect data 
from different datasets (different tables), for example intersection of miRNAs targeting the 
reference allele and miRNAs targeting SNPs to find shared interactions. Below a screenshot of 




Appendix V, Supplementary data for Chapter 6 
This section contains supporting data for Chapter 6, miRNAs targeting TRIB1 in Prostate 
Cancer.  
A5.1. miRCancer database output 
The output of miRCancer database can be accessed at this link 
http://mircancer.ecu.edu/search.jsp?mirId=&logic=&condition=Or&cancerName=prostate+c
ancer&buttonSearch. The tables below list the dysregulated miRNAs in PCa, based on 
published literature (downregulated miRNAs are shown in red, upregulated in green). Some 
miRNAs have been identified as either down- or upregulated in different studies. The number 
of distinct miRNAs is 168.  
 






hsa-miR-3619-5p hsa-let-7a-3p hsa-miR-218 hsa-miR-628-5p hsa-miR-615 hsa-miR-125b hsa-miR-21
hsa-miR-486-5p hsa-let-7c hsa-miR-221 hsa-miR-642a-5p hsa-miR-1246 hsa-miR-1301 hsa-miR-210-3p
hsa-miR-382 hsa-miR-100 hsa-miR-222 hsa-miR-7 hsa-miR-493-3p hsa-miR-1301-3p hsa-miR-22
hsa-miR-1297 hsa-miR-101 hsa-miR-224 hsa-miR-765 hsa-miR-132 hsa-miR-1307 hsa-miR-221
hsa-miR-372 hsa-miR-105 hsa-miR-23a hsa-miR-940 hsa-miR-491-5p hsa-miR-141 hsa-miR-222
hsa-miR-186 hsa-miR-124 hsa-miR-23b hsa-miR-223 hsa-miR-185-5p hsa-miR-141-3p hsa-miR-223-3p
hsa-miR-27a hsa-miR-128 hsa-miR-25 hsa-miR-125b hsa-miR-1266-5p hsa-miR-146b hsa-miR-301a
hsa-miR-509-5p hsa-miR-1296 hsa-miR-26a hsa-miR-573 hsa-miR-126 hsa-miR-150 hsa-miR-301b
hsa-miR-802 hsa-miR-130b hsa-miR-26b hsa-miR-340 hsa-miR-1 hsa-miR-152-3p hsa-miR-30d
hsa-miR-466 hsa-miR-133b hsa-miR-29b hsa-miR-378 hsa-miR-152 hsa-miR-153 hsa-miR-30e*
hsa-miR-141 hsa-miR-135a hsa-miR-302a hsa-miR-135b hsa-miR-29c hsa-miR-155 hsa-miR-31
hsa-miR-34b-3p hsa-miR-143 hsa-miR-30a hsa-miR-24 hsa-miR-17 hsa-miR-181a hsa-miR-323
hsa-miR-130a hsa-miR-145 hsa-miR-30b hsa-miR-421 hsa-miR-452-5p hsa-miR-181b hsa-miR-429
hsa-miR-194 hsa-miR-146a hsa-miR-30d hsa-miR-103 hsa-miR-206 hsa-miR-181c hsa-miR-454
hsa-miR-1271 hsa-miR-154 hsa-miR-30e hsa-miR-613 hsa-miR-1180 hsa-miR-181d hsa-miR-483-5p
hsa-miR-501-3p hsa-miR-15a hsa-miR-31 hsa-miR-335 hsa-miR-211 hsa-miR-182 hsa-miR-486-5p
hsa-miR-196a-5p hsa-miR-15b hsa-miR-323 hsa-miR-543 hsa-miR-144-3p hsa-miR-182-5p hsa-miR-500
hsa-miR-33a hsa-miR-16 hsa-miR-330 hsa-miR-146b hsa-miR-202 hsa-miR-183 hsa-miR-543
hsa-miR-618 hsa-miR-187 hsa-miR-331-3p hsa-miR-129 hsa-miR-133a-3p hsa-miR-18a hsa-miR-588
hsa-miR-30c hsa-miR-188-5p hsa-miR-345 hsa-miR-138 hsa-miR-99a hsa-miR-191 hsa-miR-590-3p
hsa-let-7a hsa-miR-195 hsa-miR-34a hsa-miR-204-5p hsa-miR-410-3p hsa-miR-192 hsa-miR-652
hsa-miR-199a hsa-miR-199b hsa-miR-34b hsa-miR-26a-5p hsa-miR-139-5p hsa-miR-194 hsa-miR-671
hsa-miR-141-3p hsa-miR-200b hsa-miR-34c hsa-miR-204 hsa-miR-519d hsa-miR-204
hsa-miR-205-5p hsa-miR-203 hsa-miR-374b hsa-miR-22 hsa-miR-150 hsa-miR-206
hsa-miR-193a-3p hsa-miR-205 hsa-miR-449a hsa-miR-154-5p hsa-miR-373-3p hsa-miR-20a
hsa-miR-493-5p hsa-miR-212 hsa-miR-4723-5p hsa-miR-452 hsa-miR-744 hsa-miR-20b
hsa-miR-539 hsa-miR-497 hsa-miR-503 hsa-miR-10a hsa-miR-93 hsa-miR-96
